|
Australian Clinical Labs Limited is a provider of pathology diagnostic services in Australia. The company operates a national network of NATA-accredited laboratories and collection centres, delivering community and hospital pathology services to clinicians, patients, hospitals, and corporate clients. Its business includes general pathology, molecular testing, and specialised diagnostics such as oncological genomics, reproductive health testing, and skin cancer clinics. The company serves markets in Victoria, New South Wales, Western Australia, South Australia, Queensland, the Northern Territory, and the Australian Capital Territory. It is a primary pathology provider to major private hospital groups and offers services through brands including SunDoctors, SouthernSun Pathology, Specialised Trials, BeFunctional Labs, and Gribbles Veterinary Pathology. The company utilizes a single national Laboratory Information System to support operational efficiency and digital billing initiatives. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Health Care Equipment & Services | Homepage clinicallabs.com.au |
| Sector Healthcare | IR page investors.clinicallabs.com.au | |
|
Tags
pathology, diagnostic services, molecular testing, genomics, skin cancer clinics, hospital pathology, community pathology, veterinary pathology, clinical trials, reproductive health, SunDoctors, SouthernSun Pathology, Specialised Trials, BeFunctional Labs, Gribbles Veterinary Pathology
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 604.322M |
| Market cap (USD) | $ 410.089M |
| P/E | 25.86 |
| PEG | — |
| P/BV | 3.45 |
| P/S | 0.82 |
| P/OCF | 3.70 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 14.9% |
| ROI | 11.3% |
| ROIC | 11.3% |
| Profit margin | 3.3% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -12.7% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | 41.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 5.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Announcement Summary
Entity name AUSTRALIAN CLINICAL LABS LIMITED Date of this announcement Thursday November 05, 2026 The +securities the subject of this notification are: Unquoted options that have been exercised or other unquoted +convertible securities that have been converted Total number of +securities to be issued/transferred
ASX +security code
Security description
ACL
ORDINARY FULLY PAID
Total number of +securities to be issued/transferred
Issue date
31,368
20/11/2021
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1/5
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 1 - Entity and announcement details
1.1 Name of entity AUSTRALIAN CLINICAL LABS LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type
Registration number
ABN
94645711128
1.3 ASX issuer code ACL 1.4 The announcement is New announcement 1.5 Date of this announcement 5/11/2026
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2/5
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 2 - Issue details
2.1 The +securities the subject of this notification are: Unquoted options that have been exercised or other unquoted +convertible securities that have been converted 2.2b The +securities being issued, transferred or re-classified as a result of the options being exercised or other +convertible securities being converted are: securities that have already been quoted on ASX ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3/5
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by: A transfer of existing +securities The underlying securities being received by the holder are: Already quoted by ASX Existing +securities converting into an existing class FROM (Existing Class) ASX +Security code and description ACLAD : SERVICE RIGHTS
TO (Existing Class) ASX +Security code and description ACL : ORDINARY FULLY PAID Please state the number of options that were exercised or other +convertible securities that were converted
The first date the options were exercised or other +convertible securities were converted
The last date the options were exercised or other +convertible securities were converted
29/10/2026
4/11/2026
31,368 Is this all of the options or other +convertible securities on issue of that type? No Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme? Yes Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate? No Date the +securities the subject of this notification were issued/transferred 20/11/2021 Any other information the entity wishes to provide about the +securities the subject of this notification
Issue details
Number of +securities 31,368
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4/5
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description
Total number of +securities on issue
ACL : ORDINARY FULLY PAID
186,518,985
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description ACLAD : SERVICE RIGHTS ACLAL : PERFORMANCE RIGHTS
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
Total number of +securities on issue 2,674,811 721,943
5/5
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To Company Name/Scheme
Australian Clinical Labs Limited
ACN/ARSN/ABN
645 711 128
- Details of substantial holder (1) Name
Allan Gray Australia Pty Ltd (Allan Gray Australia) and its related bodies corporate as set out in Table 1 of Annexure A (together the Group), as investment manager for the funds or investment mandates listed at Table 2 of Annexure A
ACN/ARSN (if applicable)
112 316 168 (ACN of Allan Gray Australia)
There was a change in the interests of the substantial holder on
28 October 2026
The previous notice was given to the company on
16 March 2026
The previous notice was dated
16 March 2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Previous notice
Present notice
Class of securities (4)
Person's votes
Voting power (5)
Person's votes
Voting power (5)
Ordinary shares
33,867,789
17.80%
31,158,062
16.71%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
Person whose relevant interest changed
Nature of change (6)
Consideration given in relation to change (7)
Class and number of securities affected
Person’s votes affected
See Annexure A, Tables 2 and 3 4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
See Annexure A, Tables 2 and 4 5. Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable) See Annexure A, Tables 1 and 2
Nature of association
Person’s votes
- Addresses The addresses of persons named in this form are as follows: Name
Address
The Group
C/- Allan Gray Australia, Level 2 Challis House, 4 Martin Place Sydney , NSW 2000
Signature print name
Elizabeth Lee
sign here
Company Secretary
Date: 30 October 2026
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of “associate” in section 9 of the Corporations Act 2001.
(3)
See the definition of “relevant interest” in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person’s votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of “relevant agreement” in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg if the relevant interest arises because of an option) write “unknown”.
(9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
Australian Clinical Labs Limited THIS IS ANNEXURE A OF 2 PAGES REFERRED TO IN THE ABOVE FORM 604 Print name
Elizabeth Lee
Company Secretary
Sign here
Date: 30 October 2026
Table 1 – Related bodies corporate The following entities are associates of Allan Gray Australia Pty Ltd (AGA) and each other by virtue of being related bodies corporate. Allan & Gill Gray Foundation (Guernsey)
Orbis Holdings Limited
Allan Gray (Holdings) Pty Ltd
Orbis Investment Advisory Pty Limited
EmCap Limited (Jersey)
Orbis Investment Management (U.S.), L.P.
SecCap Limited (Jersey)
Orbis Portfolio Management (Europe) LLP
Orbis Administration Limited
Orbis Investment Management (Hong Kong) Limited
Orbis Allan Gray Limited
Orbis Investment Management (Luxembourg) S.A
Orbis Asset Management Limited (OAML)
Orbis Investment Management Limited (OIML)
Orbis Holdings (UK) Limited
Orbis Investments (Canada) Limited
Table 2 - Funds An entity within the Group acts as investment manager for some or all of the assets in the following funds. No
Fund name
Registered holder / Persons entitled to be registered holder
1
Allan Gray Australia Equity Fund
Citibank N.A., Sydney Branch
2
Allan Gray Australia Balanced Fund
Citibank N.A., Sydney Branch
3
Allan Gray Australia Stable Fund
Citibank N.A., Sydney Branch
4
AMP Capital Specialist Australian Share Fund
BNP Paribas Fund Services Australasia Pty Ltd
5
AMP Super Fund
BNP Paribas Fund Services Australasia Pty Ltd
6
Morningstar Australian Shares High Alpha Fund
JP Morgan Chase Bank
7
Construction and Building Unions Superannuation Fund
JP Morgan Chase Bank
8
HESTA Superannuation Fund
JP Morgan Chase Bank
9
AustralianSuper
JP Morgan Chase Bank
10
Accident Compensation Corporation
JP Morgan Chase Bank
11
Hostplus Pooled Superannuation Trust
Citibank N.A., Sydney Branch
12
Equipsuper
Northern Trust Corporation
13
Non-Government Schools Superannuation Fund
State Street Australia Ltd
14
Orbis Global Equity Fund (Australia Registered)
Citibank N.A.
15
Orbis Emerging Markets Equity Fund (Australia Registered)
Citibank N.A.
16
Orbis Global Equity LE Fund (Australia Registered)
Citibank N.A.
17
Orbis Global Real Return Fund
Citibank N.A.
18
Orbis Global Equity Fund Limited
Citibank N.A.
19
Orbis Optimal SA Fund Limited
Citibank N.A.
20
Institutional Global Equity Fund
Citibank N.A.
21
Orbis Optimal LP
Citibank N.A.
22
Orbis International Equity LP
Citibank N.A.
23
Orbis Institutional Global Equity LP
Citibank N.A.
24
Orbis Institutional International Equity LP
Citibank N.A.
No
Fund name
Registered holder / Persons entitled to be registered holder
25
Orbis Institutional U.S. Equity LP
Citibank N.A.
26
Orbis Institutional Emerging Markets Equity LP
Citibank N.A.
27
Orbis SICAV - Global Equity Fund
Citibank N.A.
28
Orbis SICAV - Emerging Markets Fund
Citibank N.A.
29
Orbis SICAV - Global Balanced Fund
Citibank N.A.
30
Orbis SICAV - International Equity
Citibank N.A.
31
Orbis OEIC Global Equity Fund
Citibank N.A.
32
Orbis Institutional Global Equity (OFO)
Citibank N.A.
33
OEIC Global Balanced Fund
Citibank N.A.
34
OEIC Global Cautious Fund
Citibank N.A.
35
Orbis SICAV Global Cautious Fund
Citibank N.A.
Table 3 – Change in relevant interest Ordinary shares Person whose relevant interest Nature of Number of Date of change changed change securities Consideration 13 Mar 2026 to 28 Oct AGA and its associates listed in 2026 Table 1 Buys 1,072,167 2,146,299 13 Mar 2026 to 28 Oct AGA and its associates listed in 2026 Table 1 Sells 3,781,894 10,312,353 All trades occur on market, via in-specie, under a dividend reinvestment plan, or pursuant to a capital raising (as applicable). Table 4 – Present relevant interest Ordinary shares Holder of relevant interest AGA and its associates listed in Table 1 AGA and its associates listed in Table 1 AGA and its associates listed in Table 1 AGA and its associates listed in Table 1 AGA and its associates listed in Table 1
Registered holder of securities / Person entitled to be registered as holder
Currency AUD AUD
Number of securities held
BNP Paribas Fund Services Australasia Pty Ltd
1,950,179
Citibank N.A., Sydney Branch
16,691,042
JP Morgan Chase Bank
9,842,109
Northern Trust Corporation
1,901,685
State Street Australia Ltd
773,047
Total 31,158,062 An entity within the Group acts as investment manager for the funds set out in Table 2 and the above registered holders hold all or some of the assets within those funds.
Docusign Envelope ID: BB29E570-E981-8FB6-82FC-64FE07FAEF4A
Form 604
Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To Company Name/Scheme
Australian Clinical Labs Limited
ACN/ARSN
645 711 128
- Details of substantial holder Name
Comet Asia Holdings II Pte. Ltd., Comet Asia Holdings I Pte. Ltd., KKR Asia III Fund Investments Pte. Ltd. and KKR Asian Fund III L.P. (each a KKR Entity and collectively the KKR Entities)
ACN/ARSN (if applicable)
N/A
There was a change in the interests of the substantial holder on
27/10/2026
The previous notice was given to the company on 21/05/2026 The previous notice was dated 20/05/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate had a relevant interest in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities
Person’s votes
Fully Paid Ordinary Shares
Previous notice Voting power
15,391,016
8.21%
Present notice Person’s votes Voting power 13,428,481
7.20%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change
Person whose relevant interest changed
Various
Each KKR Entity
Nature of change
Consideration given in relation to change
Class and number of securities affected
Person’s votes affected
See Form 604 lodged by Superannuation and Investments HoldCo Pty Ltd dated 28 October 2026.
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Each KKR Entity
Registered holder of securities
Person entitled to be registered as holder
Nature of relevant interest
Class and number of securities
Person’s votes
See Form 604 lodged by Superannuation and Investments HoldCo Pty Ltd dated 28 October 2026.
Docusign Envelope ID: BB29E570-E981-8FB6-82FC-64FE07FAEF4A
- Changes in association The persons who have become associates of, ceased to be associates of, or have changed the nature of their association with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
N/A
N/A
- Addresses The addresses of persons named in this form are as follows: Name
Address
Comet Asia Holdings II Pte. Ltd.
12 Marina View, #11-01 Asia Square Tower 2, Singapore 018961
Comet Asia Holdings I Pte. Ltd.
12 Marina View, #11-01 Asia Square Tower 2, Singapore 018961
KKR Asia III Fund Investments Pte. Ltd.
12 Marina View, #11-01 Asia Square Tower 2, Singapore 018961
KKR Asian Fund III L.P.
30 Hudson Yards, Suite 7500, New York, NY 10001
Signature
print name sign here
Tan Yong Yi
capacity date
Authorised Signatory
October 28, 2026 | 5:52:49
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To: Company Name/Scheme:
Australian Clinical Labs Limited
ACN/ARSN
645 711 128
- Details of substantial holder Name
Superannuation and Investments HoldCo Pty Ltd ACN 644 660 882 and its related bodies corporate listed in annexure A
There was a change in the interests of the substantial holder on The previous notice was given to the company on The previous notice was dated
27/10/2026
20/05/2026 18/05/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate had a relevant interest in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities
Previous notice
Present notice
Person’s votes Fully Paid Ordinary Shares
Voting power (%) 60,646
Person’s votes 0.03%
Voting power (%)
59,446
0.03%
For the Securities (if any) listed below see NOTE 1 at the end of this form
Class of securities
Previous notice
Present notice
Person’s votes Fully Paid Ordinary Shares
Class of securities
Voting power (%) 15,330,370
Previous notice
Voting power (%)
13,369,035
7.17%
Present notice
Person’s votes GRAND TOTAL
Person’s votes 8.18%
Voting power (%) 15,391,016
Person’s votes 8.21%
13,428,481
Voting power (%) 7.20%
1
PUBLIC
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change
Person whose relevant interest changed
Consideration given in relation to change
Nature of change
Class and number of securities affected
Person's votes affected
See annexure B to this notice
2
PUBLIC
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder
Nature of relevant interest
Class and number of securities
Person's votes
Avanteos Investments Limited ACN 096 259 979
Citicorp Nominees Pty Limited
Relevant interest under paragraph 608(1)(b) and 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a superannuation trustee. In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being an accelerated relevant interest held in the same capacity.
59,446 Fully Paid Ordinary Shares
59,446
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citibank N A Hong Kong
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
11,777,012 Fully Paid Ordinary Shares
11,777,012
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citicorp Nominees Pty Limited (Australia)
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
588,640 Fully Paid Ordinary Shares
588,640
3
PUBLIC
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citigroup Prime Broker
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
503,352 Fully Paid Ordinary Shares (including 503,352 borrowed from Citigroup Global Markets Limited (Agreement 5), see Annexure C)
503,352
Colonial First State Investments Limited (Note 1) ACN 002 348 352
UBS Nominees Pty Ltd
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
500,031 Fully Paid Ordinary Shares
500,031
Colonial First State Investments Limited ACN 002 348 352
Citicorp Nominees Pty Limited
Relevant interest under paragraph 608(1)(a) and/or 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from being either (a) the registered holder of the relevant securities in its capacity as a custodian and/or (b) the registered holder of the relevant securities and in its capacity as administrator of managed accounts and/or (c) the registered holder of the relevant securities, having the power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is managed by Colonial First Statement Investments Limited). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being an accelerated relevant interest held in the same capacity.
59,446 Fully Paid Ordinary Shares
59,446
4
PUBLIC
- Changes in association The persons who have become associates of, ceased to be associates of, or have changed the nature of their association with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
5
PUBLIC
- Addresses The addresses of persons named in this form are as follows: Name
Address
Avanteos Investments Limited ACN 096 259 979 Colonial First State Investments Limited (Note 1)
Level 15, 400 George Street, Sydney, NSW, 2000, Australia ACN 002 348 352
Level 15, 400 George Street, Sydney, NSW, 2000, Australia
6
PUBLIC
Signature NOTE 1--(This note is relevant to section 2,3,4 and 5) The relevant interests in these securities: are/were held by Colonial First State Investments Limited (CFS) as responsible entity of the specified registered managed investment schemes and relate(d) to holdings in connection with the Colonial First State First Choice product range. Decisions to buy/sell those securities and exercise voting rights in relation to those securities are made by managers to whom CFS has outsourced those functions. By instrument dated 29 October 2001 the Australian Securities and Investments Commission (“ASIC”) has granted certain relief to CFS and its related bodies corporate for these holdings from the applicable provisions of Chapter 6 of the Corporations Act in relation to the acquisition of or increase in voting power of such securities (the Manager Relief). These managers are not associates of, other than by virtue of an agreement in accordance with the terms of the Manager Relief, the Commonwealth Bank of Australia group.
7
PUBLIC
Annexure A
This is annexure A referred to in Form 604, Notice of change of interest of substantial holder
Superannuation and Investments HoldCo Pty Ltd ACN 644 660 882
Dated the 28/10/2026
SCHEDULE Avanteos Investments Limited Colonial First State Investments Limited Superannuation And Investments US LLC Superannuation and Investments FinCo Pty Ltd Superannuation and Investments HoldCo Pty Ltd Superannuation and Investments Management Pty Ltd Superannuation and Investments MidCo Pty Ltd Superannuation and Investments Services Pty Ltd
8
PUBLIC
Annexure B
This is annexure B referred to in Form 604, Notice of change of interest of substantial holder
Superannuation and Investments HoldCo Pty Ltd ACN 644 660 882
Date of change 18/05/2026 18/05/2026
19/05/2026
20/05/2026 20/05/2026 20/05/2026 25/05/2026 26/05/2026 28/05/2026 04/06/2026 11/06/2026
10/06/2026
10/06/2026 17/06/2026 16/06/2026 17/06/2026 17/06/2026 22/06/2026 22/06/2026 25/06/2026 24/06/2026 30/06/2026 26/06/2026 26/06/2026 01/07/2026 01/07/2026 02/07/2026 01/07/2026 03/07/2026 03/07/2026 03/07/2026 06/07/2026 07/07/2026 08/07/2026 09/07/2026 10/07/2026
Person whose relevant interest changed Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Nature of change
Consideration Class and number of securities given in relation to affected change
Purchase
35,724.94
Purchase
73,793.20
Borrow Increase
N/A
Purchase
18,312.41
Purchase
145,836.72
Purchase
22,776.74
Purchase
71,652.54
Purchase
53,897.86
Purchase
454,827.49
Sale
19,524.00
Sale
320,445.33
Borrow Increase
N/A
Purchase
81,291.58
Sale
21,601.02
Purchase
38,195.28
Purchase
21,048.47
Purchase
16,909.86
Sale
126,184.21
Sale
19,893.21
Sale
12,535.56
Purchase
44,995.71
Sale
29,635.40
Purchase
11,000.10
Purchase
61,935.39
Sale
8,143.61
Sale
7,814.25
Sale
4,066.12
Purchase
31,622.20
Purchase
28,803.35
Purchase
21,327.04
Sale
172,866.37
Sale
18,553.25
Sale
106,185.10
Sale
137,111.43
Sale
109,893.38
Sale
337,458.21
PUBLIC
Dated the 28/10/2026
19,316 Fully Paid Ordinary Shares 39,899 Fully Paid Ordinary Shares Fully Paid Ordinary Shares (borrowed from 31,760 Citigroup Global Markets Limited (Agreement 5), see Annexure C) 9,508 Fully Paid Ordinary Shares 75,720 Fully Paid Ordinary Shares 11,829 Fully Paid Ordinary Shares 36,370 Fully Paid Ordinary Shares 26,694 Fully Paid Ordinary Shares 229,063 Fully Paid Ordinary Shares 9,662 Fully Paid Ordinary Shares 155,247 Fully Paid Ordinary Shares Fully Paid Ordinary Shares (borrowed from 16,895 Citigroup Global Markets Limited (Agreement 5), see Annexure C) 38,786 Fully Paid Ordinary Shares 9,906 Fully Paid Ordinary Shares 17,151 Fully Paid Ordinary Shares 9,288 Fully Paid Ordinary Shares 7,471 Fully Paid Ordinary Shares 57,422 Fully Paid Ordinary Shares 8,985 Fully Paid Ordinary Shares 5,724 Fully Paid Ordinary Shares 20,978 Fully Paid Ordinary Shares 13,268 Fully Paid Ordinary Shares 4,955 Fully Paid Ordinary Shares 27,765 Fully Paid Ordinary Shares 3,637 Fully Paid Ordinary Shares 3,473 Fully Paid Ordinary Shares 1,801 Fully Paid Ordinary Shares 13,944 Fully Paid Ordinary Shares 12,834 Fully Paid Ordinary Shares 9,521 Fully Paid Ordinary Shares 76,598 Fully Paid Ordinary Shares 8,258 Fully Paid Ordinary Shares 47,366 Fully Paid Ordinary Shares 59,984 Fully Paid Ordinary Shares 48,220 Fully Paid Ordinary Shares 152,063 Fully Paid Ordinary Shares
Person's votes affected 19,316 39,899
31,760
9,508 75,720 11,829 36,370 26,694 229,063 9,662 155,247
16,895
38,786 9,906 17,151 9,288 7,471 57,422 8,985 5,724 20,978 13,268 4,955 27,765 3,637 3,473 1,801 13,944 12,834 9,521 76,598 8,258 47,366 59,984 48,220 152,063
9
08/07/2026 13/07/2026 09/07/2026 14/07/2026 13/07/2026 13/07/2026 13/07/2026 13/07/2026 13/07/2026 13/07/2026 15/07/2026 15/07/2026 16/07/2026 16/07/2026 17/07/2026 15/07/2026 15/07/2026 20/07/2026 21/07/2026 22/07/2026 27/07/2026 27/07/2026 28/07/2026 28/07/2026 28/07/2026 29/07/2026 30/07/2026 31/07/2026 06/08/2026
07/08/2026
10/08/2026 12/08/2026 14/08/2026 19/08/2026 20/08/2026 20/08/2026 21/08/2026 21/08/2026 21/08/2026 21/08/2026 19/08/2026 19/08/2026 24/08/2026 24/08/2026 21/08/2026 24/08/2026 27/08/2026 27/08/2026 28/08/2026 26/08/2026
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Purchase
27,460.93
Sale
475,880.42
Purchase
26,700.57
Sale
679,620.70
Purchase
14,647.91
Purchase
6,051.09
Purchase
12,735.29
Purchase
154,209.59
Purchase
67,466.14
Purchase
140,368.04
Sale
140,368.04
Sale
56,774.28
Sale
221,182.33
Sale
83,938.13
Sale
380,575.17
Purchase
92,305.85
Purchase
34,179.37
Sale
276,459.04
Sale
11,611.20
Purchase
199,092.03
Purchase
136,732.07
Purchase
78,666.36
Purchase
573,379.41
Purchase
64,745.18
Purchase
21,720.00
Purchase
32,010.27
Purchase
166,069.27
Purchase
48,168.24
Purchase
139,665.31
Borrow Increase
N/A
Purchase
121,685.51
Purchase
56,381.04
Sale
15,189.04
Sale
2,246,411.90
Sale
564,260.00
Sale
96,260.30
Sale
534,926.00
Sale
10,693.01
Sale
23,362.71
Sale
37,819.86
Purchase
148,445.87
Purchase
28,675.50
Sale
31,122.64
Sale
28,132.79
Purchase
121,618.34
Purchase
30,526.88
Sale
10,005.93
Sale
35,948.30
Sale
30,923.85
Purchase
44,207.57
PUBLIC
12,391 Fully Paid Ordinary Shares 212,960 Fully Paid Ordinary Shares 11,896 Fully Paid Ordinary Shares 307,855 Fully Paid Ordinary Shares 6,594 Fully Paid Ordinary Shares 2,724 Fully Paid Ordinary Shares 5,733 Fully Paid Ordinary Shares 69,420 Fully Paid Ordinary Shares 30,371 Fully Paid Ordinary Shares 63,189 Fully Paid Ordinary Shares 63,189 Fully Paid Ordinary Shares 25,574 Fully Paid Ordinary Shares 97,223 Fully Paid Ordinary Shares 37,725 Fully Paid Ordinary Shares 168,106 Fully Paid Ordinary Shares 40,624 Fully Paid Ordinary Shares 15,055 Fully Paid Ordinary Shares 116,674 Fully Paid Ordinary Shares 4,920 Fully Paid Ordinary Shares 85,749 Fully Paid Ordinary Shares 58,440 Fully Paid Ordinary Shares 33,495 Fully Paid Ordinary Shares 240,855 Fully Paid Ordinary Shares 27,197 Fully Paid Ordinary Shares 9,050 Fully Paid Ordinary Shares 13,180 Fully Paid Ordinary Shares 69,184 Fully Paid Ordinary Shares 20,112 Fully Paid Ordinary Shares 57,651 Fully Paid Ordinary Shares Fully Paid Ordinary Shares (borrowed from 21,516 Citigroup Global Markets Limited (Agreement 5), see Annexure C) 51,457 Fully Paid Ordinary Shares 24,078 Fully Paid Ordinary Shares 6,547 Fully Paid Ordinary Shares 832,251 Fully Paid Ordinary Shares 200,000 Fully Paid Ordinary Shares 34,066 Fully Paid Ordinary Shares 190,000 Fully Paid Ordinary Shares 3,758 Fully Paid Ordinary Shares 8,292 Fully Paid Ordinary Shares 13,354 Fully Paid Ordinary Shares 52,674 Fully Paid Ordinary Shares 10,178 Fully Paid Ordinary Shares 11,056 Fully Paid Ordinary Shares 9,936 Fully Paid Ordinary Shares 41,319 Fully Paid Ordinary Shares 10,178 Fully Paid Ordinary Shares 3,369 Fully Paid Ordinary Shares 12,114 Fully Paid Ordinary Shares 10,782 Fully Paid Ordinary Shares 15,413 Fully Paid Ordinary Shares
12,391 212,960 11,896 307,855 6,594 2,724 5,733 69,420 30,371 63,189 63,189 25,574 97,223 37,725 168,106 40,624 15,055 116,674 4,920 85,749 58,440 33,495 240,855 27,197 9,050 13,180 69,184 20,112 57,651
21,516
51,457 24,078 6,547 832,251 200,000 34,066 190,000 3,758 8,292 13,354 52,674 10,178 11,056 9,936 41,319 10,178 3,369 12,114 10,782 15,413
10
26/08/2026 31/08/2026 01/09/2026 01/09/2026 02/09/2026 03/09/2026 03/09/2026 07/09/2026 08/09/2026 09/09/2026 09/09/2026 09/09/2026 14/09/2026 18/09/2026 21/09/2026 22/09/2026 17/09/2026 21/09/2026 24/09/2026 22/09/2026 25/09/2026 25/09/2026 24/09/2026 25/09/2026 02/10/2026 30/09/2026 08/10/2026 09/10/2026 07/10/2026 07/10/2026 08/10/2026 13/10/2026 13/10/2026 09/10/2026 12/10/2026 15/10/2026 13/10/2026 19/10/2026 22/10/2026 26/10/2026 27/10/2026 23/10/2026 26/10/2026 23/10/2026
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Avanteos Investments Limited ACN 096 259 979 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Purchase
51,202.17
Sale
66,888.13
Sale
6,669.60
Sale
32,266.18
Sale
39,327.67
Sale
740.89
Purchase
56,390.91
Purchase
192,656.75
Purchase
73,850.71
Purchase
177,458.58
Purchase
48,600.26
Purchase
29,401.18
Sale
5,522.76
Sale
4,945.96
Sale
86,172.00
Sale
315,304.00
Purchase
38,793.73
Purchase
55,420.65
Sale
115,016.00
Purchase
59,797.46
Sale
183,447.42
Sale
4,968.62
Purchase
60,493.45
Purchase
45,849.83
Sale
525,777.86
Purchase
43,090.46
Sale
25,928.04
Sale
12,626.80
Purchase
18,314.62
Purchase
21,436.02
Purchase
419,499.63
Sale
228,392.85
Sale
11,672.24
Purchase
129,501.60
Purchase
49,916.31
Sale
230,194.57
Purchase
153,558.01
Sale
3,360.00
Sale
409,734.17
Sale
194,191.68
Sale
1,277,219.37
Purchase
20,878.27
Sale
795,149.26
Purchase
795,149.26
17,866 Fully Paid Ordinary Shares 23,668 Fully Paid Ordinary Shares 2,382 Fully Paid Ordinary Shares 11,555 Fully Paid Ordinary Shares 14,138 Fully Paid Ordinary Shares 266 Fully Paid Ordinary Shares 20,735 Fully Paid Ordinary Shares 69,614 Fully Paid Ordinary Shares 26,742 Fully Paid Ordinary Shares 63,202 Fully Paid Ordinary Shares 17,397 Fully Paid Ordinary Shares 10,529 Fully Paid Ordinary Shares 2,001 Fully Paid Ordinary Shares 1,757 Fully Paid Ordinary Shares 30,000 Fully Paid Ordinary Shares 110,000 Fully Paid Ordinary Shares 13,478 Fully Paid Ordinary Shares 19,133 Fully Paid Ordinary Shares 40,000 Fully Paid Ordinary Shares 20,679 Fully Paid Ordinary Shares 64,363 Fully Paid Ordinary Shares 1,751 Fully Paid Ordinary Shares 21,083 Fully Paid Ordinary Shares 16,488 Fully Paid Ordinary Shares 184,083 Fully Paid Ordinary Shares 15,084 Fully Paid Ordinary Shares 9,211 Fully Paid Ordinary Shares 4,476 Fully Paid Ordinary Shares 6,501 Fully Paid Ordinary Shares 7,599 Fully Paid Ordinary Shares 149,453 Fully Paid Ordinary Shares 77,682 Fully Paid Ordinary Shares 4,114 Fully Paid Ordinary Shares 45,428 Fully Paid Ordinary Shares 17,131 Fully Paid Ordinary Shares 79,219 Fully Paid Ordinary Shares 52,869 Fully Paid Ordinary Shares 1,200 Fully Paid Ordinary Shares 141,517 Fully Paid Ordinary Shares 66,504 Fully Paid Ordinary Shares 438,907 Fully Paid Ordinary Shares 7,143 Fully Paid Ordinary Shares 271,382 Fully Paid Ordinary Shares 271,382 Fully Paid Ordinary Shares
17,866 23,668 2,382 11,555 14,138 266 20,735 69,614 26,742 63,202 17,397 10,529 2,001 1,757 30,000 110,000 13,478 19,133 40,000 20,679 64,363 1,751 21,083 16,488 184,083 15,084 9,211 4,476 6,501 7,599 149,453 77,682 4,114 45,428 17,131 79,219 52,869 1,200 141,517 66,504 438,907 7,143 271,382 271,382
11
PUBLIC
Annexure C
This is annexure C referred to in Form 604, Notice of change of interest of substantial holder
Superannuation and Investments HoldCo Pty Ltd ACN 644 660 882
Dated the 28/10/2026
Superannuation and Investments HoldCo Pty Ltd will, if requested by the company or responsible entity to whom this form must be given or by the Australian Securities and Investments Commission (ASIC), give a copy of one or more of the following agreements to the company, responsible entity or ASIC (as appropriate). Citigroup Global Markets Limited (Agreement 5) Type of agreement: Parties to agreement: Can the parties exercise voting rights attaching to the securities? If yes, in what circumstances? Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date): Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date): Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances? Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No] If yes, in which circumstances? Are there circumstances in which the borrower will not be required to return the securities on settlement? [Yes/No] If yes, in which circumstances?
Australian Master Securities Lending Agreement (1) Citigroup Global Markets Limited; and (2) Colonial First State Investments Limited No N/A The dates indicated in Annexure B on which securities were borrowed. Any particular day. Yes At any time subject to giving notice. Yes At any time subject to giving notice. No N/A
12
PUBLIC
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
Wednesday, 28 October 2026 AUSTRALIAN CLINICAL LABS LIMITED – ANNUAL GENERAL MEETING 2026 Australian Clinical Labs Limited (ACL or Company) provides a copy to the market of the addresses to shareholders for its 2026 Annual General Meeting, which will be held today at 2pm AEDT.
– ENDS – This announcement was authorised for release to ASX by the Company Secretary of ACL.
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To: Company Name/Scheme:
Australian Clinical Labs Limited
ACN/ARSN
645 711 128
- Details of substantial holder Name
Commonwealth Bank of Australia ACN 123 123 124 (CBA) and its related bodies corporate listed in annexure A
There was a change in the interests of the substantial holder on
27/10/2026
The previous notice was given to the company on
25/05/2026
The previous notice was dated
22/05/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate had a relevant interest in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities
Previous notice
Present notice
Person’s votes Fully Paid Ordinary Shares
Voting power (%) 60,646
Person’s votes 0.03%
Voting power (%)
59,446
0.03%
For the Securities (if any) listed below see NOTE 1 at the end of this form
Class of securities
Previous notice
Present notice
Person’s votes Fully Paid Ordinary Shares
Class of securities
Voting power (%) 15,518,402
Previous notice
Voting power (%)
13,369,035
7.17%
Present notice
Person’s votes GRAND TOTAL
Person’s votes 8.28%
Voting power (%) 15,579,048
Person’s votes 8.31%
13,428,481
Voting power (%) 7.20%
1
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change
Person whose relevant interest changed
Nature of change
Consideration given in relation to change
Class and number of securities affected
Person's votes affected
See annexure B to this notice
2
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder
Nature of relevant interest
Class and number of securities
Person's votes
CBA and its related bodies corporate listed in Annexure A
Various as set out below
Relevant interest under paragraph 608(3)(a) of the Corporations Act 2001 (Cth), being a relevant interest arising as a result of CBA and its related bodies corporate listed in Annexure A having voting power in Avanteos Investments Limited and Colonial First State Investments Limited above 20%,and therefore having the relevant interests in any securities that either of Avanteos or Colonial First State has. As neither CBA nor any of its related bodies corporate are entitled to be registered as the holder of those securities, their ability to vote and dispose of those securities is qualified accordingly.
13,428,481 Fully Paid Ordinary Shares
13,428,481
Avanteos Investments Limited ACN 096 259 979
Citicorp Nominees Pty Limited
Relevant interest under paragraph 608(1)(b) and 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a superannuation trustee. In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being an accelerated relevant interest held in the same capacity.
59,446 Fully Paid Ordinary Shares
59,446
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citibank Global Markets Limited (Citi PB)
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
503,352 Fully Paid Ordinary Shares (including 503,352 borrowed from Citigroup Global Markets Limited (Agreement 5), see Annexure C)
503,352
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citibank N A Hong Kong
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
11,777,012 Fully Paid Ordinary Shares
11,777,012
3
Colonial First State Investments Limited (Note 1) ACN 002 348 352
Citicorp Nominees Pty Limited (Australia)
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
588,640 Fully Paid Ordinary Shares
588,640
Colonial First State Investments Limited (Note 1) ACN 002 348 352
UBS Nominees Pty Ltd
Relevant interest under paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from having the residual power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is not managed by either Colonial First State Investments Limited or a related body corporate). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being a residual accelerated relevant interest held in the same capacity. Colonial First State Investments Limited has authorised the manager of each such managed investment scheme to exercise the powers referred to in paragraph 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth) in relation to those securities managed by the manager to the exclusion of Colonial First State Investments Limited except for provisions allowing Colonial First State Investments Limited to terminate the agreement with the manager or to exercise those powers where the agreement is terminated.
500,031 Fully Paid Ordinary Shares
500,031
Colonial First State Investments Limited ACN 002 348 352
Citicorp Nominees Pty Limited
Relevant interest under paragraph 608(1)(a) and/or 608(1)(b) and/or 608(1)(c) of the Corporations Act 2001 (Cth), being a relevant interest arising from being either (a) the registered holder of the relevant securities in its capacity as a custodian and/or (b) the registered holder of the relevant securities and in its capacity as administrator of managed accounts and/or (c) the registered holder of the relevant securities, having the power to control the exercise of the right to vote attached to securities and/or to control the exercise of the power to dispose of securities in its capacity as a responsible entity of a managed investment scheme (which managed investment scheme is managed by Colonial First Statement Investments Limited). In addition, if any OTC derivatives, warrants or other securities (other than ordinary shares or ordinary units (as applicable)) are referred to below in this row, the relevant interest in respect of those securities arises under subsection 608(8) being an accelerated relevant interest held in the same capacity.
59,446 Fully Paid Ordinary Shares
59,446
4
- Changes in association The persons who have become associates of, ceased to be associates of, or have changed the nature of their association with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
5
- Addresses The addresses of persons named in this form are as follows: Name
Address
Avanteos Investments Limited ACN 096 259 979 Colonial First State Investments Limited (Note 1)
Level 15, 400 George Street, Sydney, NSW, 2000, Australia ACN 002 348 352
Level 15, 400 George Street, Sydney, NSW, 2000, Australia
6
Signature NOTE 1--(This note is relevant to section 2,3,4 and 5) The relevant interests in these securities: are/were held by Colonial First State Investments Limited (CFS) as responsible entity of the specified registered managed investment schemes and relate(d) to holdings in connection with the Colonial First State First Choice product range. Decisions to buy/sell those securities and exercise voting rights in relation to those securities are made by managers to whom CFS has outsourced those functions. By instrument dated 29 October 2001 the Australian Securities and Investments Commission (“ASIC”) has granted certain relief to CFS and its related bodies corporate for these holdings from the applicable provisions of Chapter 6 of the Corporations Act in relation to the acquisition of or increase in voting power of such securities (the Manager Relief). These managers are not associates of, other than by virtue of an agreement in accordance with the terms of the Manager Relief, the Commonwealth Bank of Australia group.
Dated the 28 day of October 2026 Vicki Clarkson - Company Secretary
7
Annexure A
This is annexure A referred to in Form 604, Notice of change of interest of substantial holder
Vicki Clarkson
Company Secretary
Commonwealth Bank of Australia ACN 123 123 124
Dated the 28/10/2026
SCHEDULE ASB BANK LIMITED ASB GROUP INVESTMENTS LIMITED ASB HOLDINGS LIMITED ASB NOMINEES LIMITED ASB SECURITIES LIMITED ASKLEPIOS PTY LIMITED BWA GROUP SERVICES PTY LTD BWA INTELLECTUAL PROPERTY HOLDINGS PTY LIMITED CAPITAL 121 PTY LIMITED CBA A320 6749 PTY LIMITED CBA A330 1561 PTY LTD CBA AIRCRAFT LEASING 2 PTY LTD CBA CAPTIVE INSURANCE PTE. LTD CBA CORPORATE SERVICES (NSW) PTY LIMITED CBA CORPORATE SERVICES (VIC) PTY LIMITED CBA ES BUSINESS SERVICES PTY LTD CBA EUROPE LIMITED CBA FUNDING (NZ) LIMITED CBA GROUP PTY LIMITED CBA INVESTMENTS (NO.4) LIMITED CBA NEW DIGITAL BUSINESSES PTY LTD CBA REGISTERED AGENT PTY LTD CBA SAF HOLDING PTY LIMITED CBA SAF UK LIMITED CBA SERVICES INTERNATIONAL LIMITED CBA SERVICES PRIVATE LIMITED CBA SPECIALISED FINANCING PTY LIMITED CBFC LEASING PTY. LIMITED CBFC PTY LIMITED COLONIAL HOLDING COMPANY PTY LIMITED COLONIAL SERVICES PTY LIMITED COMMBANK STAFF FOUNDATION LIMITED COMMONWEALTH AUSTRALIA SECURITIES LLC COMMONWEALTH BANK OF AUSTRALIA COMMONWEALTH BANK OF AUSTRALIA (EUROPE) N.V. COMMONWEALTH BANK OFFICERS SUPERANNUATION CORPORATION PTY LIMITED COMMONWEALTH FINANCIAL PLANNING LIMITED COMMONWEALTH INSURANCE HOLDINGS PTY LIMITED COMMONWEALTH INVESTMENTS PTY LIMITED COMMONWEALTH PRIVATE LIMITED COMMONWEALTH SECURITIES LIMITED COMMSEC CUSTODIAL NOMINEES PTY LIMITED COMMWEALTH INTERNATIONAL HOLDINGS PTY LIMITED COMSEC NOMINEES PTY LIMITED CPM TRANSFORM HOLDCO PTY LIMITED CTB AUSTRALIA LIMITED DOSHII CONNECT PTY LTD FINANCIAL WISDOM LIMITED FUNDING NO.1 PTY LIMITED INVERLOCH LEASING PTY LIMITED IPSI GROUP PTY LTD IPSI PTY LTD IPSI TECHNOLOGY PTY LTD IWL BROKING SOLUTIONS PTY LIMITED MILAN HOLDCO PTY LTD PREMIUM CUSTODY SERVICES PTY LTD RESIDENTIAL MORTGAGE GROUP PTY LTD SAF CORPORATE SERVICES PTY LTD SAFE NO4 PTY LIMITED SAFE USD HOLDINGS PTY LTD SECURITISATION ADVISORY SERVICES PTY. LIMITED SECURITISATION MANAGEMENT SERVICES LIMITED
8
SHARE DIRECT NOMINEES PTY LIMITED SHARE INVESTMENTS PTY LIMITED STATE NOMINEES LTD STICHTING CBA CARBON CUSTODY SERVICES THE COLONIAL MUTUAL LIFE ASSURANCE SOCIETY PTY LIMITED WADDLE (AUSTRALIA) HOLDINGS PTY LIMITED WADDLE HOLDINGS PTY LTD WADDLE IP PTY LTD WADDLE SERVICING PTY LTD WHITECOAT HOLDINGS PTY LTD WHITECOAT OPERATING PTY LTD
9
Annexure B
This is annexure B referred to in Form 604, Notice of change of interest of substantial holder
Vicki Clarkson
Date of change
25/05/2026 26/05/2026 28/05/2026 04/06/2026 11/06/2026
10/06/2026
10/06/2026 17/06/2026 16/06/2026 17/06/2026 17/06/2026 22/06/2026 22/06/2026 25/06/2026 24/06/2026 30/06/2026 26/06/2026 26/06/2026 01/07/2026 01/07/2026 02/07/2026 01/07/2026 03/07/2026 03/07/2026 03/07/2026 06/07/2026 07/07/2026 08/07/2026 09/07/2026 10/07/2026 08/07/2026 13/07/2026 09/07/2026 14/07/2026 13/07/2026 13/07/2026 13/07/2026
Company Secretary
Commonwealth Bank of Australia ACN 123 123 124
Person whose relevant interest changed Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Nature of change
Consideration Class and number of securities given in relation affected to change
Purchase
71,652.54
Purchase
53,897.86
Purchase
454,827.49
Sale
19,524.00
Sale
320,445.33
Borrow Increase
Dated the 28/10/2026
N/A
Purchase
81,291.58
Sale
21,601.02
Purchase
38,195.28
Purchase
21,048.47
Purchase
16,909.86
Sale
126,184.21
Sale
19,893.21
Sale
12,535.56
Purchase
44,995.71
Sale
29,635.40
Purchase
11,000.10
Purchase
61,935.39
Sale
8,143.61
Sale
7,814.25
Sale
4,066.12
Purchase
31,622.20
Purchase
28,803.35
Purchase
21,327.04
Sale
172,866.37
Sale
18,553.25
Sale
106,185.10
Sale
137,111.43
Sale
109,893.38
Sale
337,458.21
Purchase
27,460.93
Sale
475,880.42
Purchase
26,700.57
Sale
679,620.70
Purchase
14,647.91
Purchase
6,051.09
Purchase
12,735.29
36,370 Fully Paid Ordinary Shares 26,694 Fully Paid Ordinary Shares 229,063 Fully Paid Ordinary Shares 9,662 Fully Paid Ordinary Shares 155,247 Fully Paid Ordinary Shares Fully Paid Ordinary Shares (borrowed from 16,895 Citigroup Global Markets Limited (Agreement 5), see Annexure C) 38,786 Fully Paid Ordinary Shares 9,906 Fully Paid Ordinary Shares 17,151 Fully Paid Ordinary Shares 9,288 Fully Paid Ordinary Shares 7,471 Fully Paid Ordinary Shares 57,422 Fully Paid Ordinary Shares 8,985 Fully Paid Ordinary Shares 5,724 Fully Paid Ordinary Shares 20,978 Fully Paid Ordinary Shares 13,268 Fully Paid Ordinary Shares 4,955 Fully Paid Ordinary Shares 27,765 Fully Paid Ordinary Shares 3,637 Fully Paid Ordinary Shares 3,473 Fully Paid Ordinary Shares 1,801 Fully Paid Ordinary Shares 13,944 Fully Paid Ordinary Shares 12,834 Fully Paid Ordinary Shares 9,521 Fully Paid Ordinary Shares 76,598 Fully Paid Ordinary Shares 8,258 Fully Paid Ordinary Shares 47,366 Fully Paid Ordinary Shares 59,984 Fully Paid Ordinary Shares 48,220 Fully Paid Ordinary Shares 152,063 Fully Paid Ordinary Shares 12,391 Fully Paid Ordinary Shares 212,960 Fully Paid Ordinary Shares 11,896 Fully Paid Ordinary Shares 307,855 Fully Paid Ordinary Shares 6,594 Fully Paid Ordinary Shares 2,724 Fully Paid Ordinary Shares 5,733 Fully Paid Ordinary Shares
Person's votes affected 36,370 26,694 229,063 9,662 155,247
16,895
38,786 9,906 17,151 9,288 7,471 57,422 8,985 5,724 20,978 13,268 4,955 27,765 3,637 3,473 1,801 13,944 12,834 9,521 76,598 8,258 47,366 59,984 48,220 152,063 12,391 212,960 11,896 307,855 6,594 2,724 5,733
10
13/07/2026 13/07/2026 13/07/2026 15/07/2026 15/07/2026 16/07/2026 16/07/2026 17/07/2026 15/07/2026 15/07/2026 20/07/2026 21/07/2026 22/07/2026 27/07/2026 27/07/2026 28/07/2026 28/07/2026 28/07/2026 29/07/2026 30/07/2026 31/07/2026 06/08/2026
07/08/2026
10/08/2026 12/08/2026 14/08/2026 19/08/2026 20/08/2026 20/08/2026 21/08/2026 21/08/2026 21/08/2026 21/08/2026 19/08/2026 19/08/2026 24/08/2026 24/08/2026 21/08/2026 24/08/2026 27/08/2026 27/08/2026 28/08/2026 26/08/2026 26/08/2026 31/08/2026 01/09/2026 01/09/2026 02/09/2026
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Purchase
154,209.59
Purchase
67,466.14
Purchase
140,368.04
Sale
140,368.04
Sale
56,774.28
Sale
221,182.33
Sale
83,938.13
Sale
380,575.17
Purchase
92,305.85
Purchase
34,179.37
Sale
276,459.04
Sale
11,611.20
Purchase
199,092.03
Purchase
136,732.07
Purchase
78,666.36
Purchase
573,379.41
Purchase
64,745.18
Purchase
21,720.00
Purchase
32,010.27
Purchase
166,069.27
Purchase
48,168.24
Purchase
139,665.31
Borrow Increase
N/A
Purchase
121,685.51
Purchase
56,381.04
Sale
15,189.04
Sale
2,246,411.90
Sale
564,260.00
Sale
96,260.30
Sale
534,926.00
Sale
10,693.01
Sale
23,362.71
Sale
37,819.86
Purchase
148,445.87
Purchase
28,675.50
Sale
31,122.64
Sale
28,132.79
Purchase
121,618.34
Purchase
30,526.88
Sale
10,005.93
Sale
35,948.30
Sale
30,923.85
Purchase
44,207.57
Purchase
51,202.17
Sale
66,888.13
Sale
6,669.60
Sale
32,266.18
Sale
39,327.67
69,420 Fully Paid Ordinary Shares 30,371 Fully Paid Ordinary Shares 63,189 Fully Paid Ordinary Shares 63,189 Fully Paid Ordinary Shares 25,574 Fully Paid Ordinary Shares 97,223 Fully Paid Ordinary Shares 37,725 Fully Paid Ordinary Shares 168,106 Fully Paid Ordinary Shares 40,624 Fully Paid Ordinary Shares 15,055 Fully Paid Ordinary Shares 116,674 Fully Paid Ordinary Shares 4,920 Fully Paid Ordinary Shares 85,749 Fully Paid Ordinary Shares 58,440 Fully Paid Ordinary Shares 33,495 Fully Paid Ordinary Shares 240,855 Fully Paid Ordinary Shares 27,197 Fully Paid Ordinary Shares 9,050 Fully Paid Ordinary Shares 13,180 Fully Paid Ordinary Shares 69,184 Fully Paid Ordinary Shares 20,112 Fully Paid Ordinary Shares 57,651 Fully Paid Ordinary Shares Fully Paid Ordinary Shares (borrowed from 21,516 Citigroup Global Markets Limited (Agreement 5), see Annexure C) 51,457 Fully Paid Ordinary Shares Fully Paid 24,078 Ordinary Shares 6,547 Fully Paid Ordinary Shares 832,251 Fully Paid Ordinary Shares 200,000 Fully Paid Ordinary Shares 34,066 Fully Paid Ordinary Shares 190,000 Fully Paid Ordinary Shares 3,758 Fully Paid Ordinary Shares 8,292 Fully Paid Ordinary Shares 13,354 Fully Paid Ordinary Shares 52,674 Fully Paid Ordinary Shares 10,178 Fully Paid Ordinary Shares 11,056 Fully Paid Ordinary Shares 9,936 Fully Paid Ordinary Shares 41,319 Fully Paid Ordinary Shares 10,178 Fully Paid Ordinary Shares 3,369 Fully Paid Ordinary Shares 12,114 Fully Paid Ordinary Shares 10,782 Fully Paid Ordinary Shares 15,413 Fully Paid Ordinary Shares 17,866 Fully Paid Ordinary Shares 23,668 Fully Paid Ordinary Shares 2,382 Fully Paid Ordinary Shares 11,555 Fully Paid Ordinary Shares 14,138 Fully Paid Ordinary Shares
69,420 30,371 63,189 63,189 25,574 97,223 37,725 168,106 40,624 15,055 116,674 4,920 85,749 58,440 33,495 240,855 27,197 9,050 13,180 69,184 20,112 57,651
21,516
51,457 24,078 6,547 832,251 200,000 34,066 190,000 3,758 8,292 13,354 52,674 10,178 11,056 9,936 41,319 10,178 3,369 12,114 10,782 15,413 17,866 23,668 2,382 11,555 14,138
11
03/09/2026 03/09/2026 07/09/2026 08/09/2026 09/09/2026 09/09/2026 09/09/2026 14/09/2026 18/09/2026 21/09/2026 22/09/2026 17/09/2026 21/09/2026 24/09/2026 22/09/2026 25/09/2026 25/09/2026 24/09/2026 25/09/2026 02/10/2026 30/09/2026 08/10/2026 09/10/2026 07/10/2026 07/10/2026 08/10/2026 13/10/2026 13/10/2026 09/10/2026 12/10/2026 15/10/2026 13/10/2026 19/10/2026 22/10/2026 26/10/2026 27/10/2026 23/10/2026
Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Avanteos Investments Limited ACN 096 259 979 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352 Colonial First State Investments Limited (Note
- ACN 002 348 352
Sale
740.89
Purchase
56,390.91
Purchase
192,656.75
Purchase
73,850.71
Purchase
177,458.58
Purchase
48,600.26
Purchase
29,401.18
Sale
5,522.76
Sale
4,945.96
Sale
86,172.00
Sale
315,304.00
Purchase
38,793.73
Purchase
55,420.65
Sale
115,016.00
Purchase
59,797.46
Sale
183,447.42
Sale
4,968.62
Purchase
60,493.45
Purchase
45,849.83
Sale
525,777.86
Purchase
43,090.46
Sale
25,928.04
Sale
12,626.80
Purchase
18,314.62
Purchase
21,436.02
Purchase
419,499.63
Sale
228,392.85
Sale
11,672.24
Purchase
129,501.60
Purchase
49,916.31
Sale
230,194.57
Purchase
153,558.01
Sale
3,360.00
Sale
409,734.17
Sale
194,191.68
Sale
1,277,219.37
Purchase
20,878.27
266 Fully Paid Ordinary Shares 20,735 Fully Paid Ordinary Shares 69,614 Fully Paid Ordinary Shares 26,742 Fully Paid Ordinary Shares 63,202 Fully Paid Ordinary Shares 17,397 Fully Paid Ordinary Shares 10,529 Fully Paid Ordinary Shares 2,001 Fully Paid Ordinary Shares 1,757 Fully Paid Ordinary Shares 30,000 Fully Paid Ordinary Shares 110,000 Fully Paid Ordinary Shares 13,478 Fully Paid Ordinary Shares 19,133 Fully Paid Ordinary Shares 40,000 Fully Paid Ordinary Shares 20,679 Fully Paid Ordinary Shares 64,363 Fully Paid Ordinary Shares 1,751 Fully Paid Ordinary Shares 21,083 Fully Paid Ordinary Shares 16,488 Fully Paid Ordinary Shares 184,083 Fully Paid Ordinary Shares 15,084 Fully Paid Ordinary Shares 9,211 Fully Paid Ordinary Shares 4,476 Fully Paid Ordinary Shares 6,501 Fully Paid Ordinary Shares 7,599 Fully Paid Ordinary Shares 149,453 Fully Paid Ordinary Shares 77,682 Fully Paid Ordinary Shares 4,114 Fully Paid Ordinary Shares 45,428 Fully Paid Ordinary Shares 17,131 Fully Paid Ordinary Shares 79,219 Fully Paid Ordinary Shares 52,869 Fully Paid Ordinary Shares 1,200 Fully Paid Ordinary Shares 141,517 Fully Paid Ordinary Shares 66,504 Fully Paid Ordinary Shares 438,907 Fully Paid Ordinary Shares 7,143 Fully Paid Ordinary Shares
266 20,735 69,614 26,742 63,202 17,397 10,529 2,001 1,757 30,000 110,000 13,478 19,133 40,000 20,679 64,363 1,751 21,083 16,488 184,083 15,084 9,211 4,476 6,501 7,599 149,453 77,682 4,114 45,428 17,131 79,219 52,869 1,200 141,517 66,504 438,907 7,143
12
Annexure C
This is annexure C referred to in Form 604, Notice of change of interest of substantial holder
Vicki Clarkson
Company Secretary
Commonwealth Bank of Australia ACN 123 123 124
Dated the 28/10/2026
Commonwealth Bank of Australia will, if requested by the company or responsible entity to whom this form must be given or by the Australian Securities and Investments Commission (ASIC), give a copy of one or more of the following agreements to the company, responsible entity or ASIC (as appropriate). Citigroup Global Markets Limited (Agreement 5) Type of agreement: Parties to agreement:
Australian Master Securities Lending Agreement (1) Citigroup Global Markets Limited; and (2) Colonial First State Investments Limited
Can the parties exercise voting rights attaching to the No securities? If yes, in what circumstances? N/A Date on which the securities were (or are) expected to be The dates indicated in Annexure B on which securities were delivered to the borrower or its nominee (ie borrow date): borrowed. Scheduled date (if any) when the securities are expected to be Any particular day. returned to the lender or its nominee (ie return date): Does the borrower have the right to return the securities early? Yes [Yes/No] If yes, in which circumstances? At any time subject to giving notice. Does the lender have the right to recall the securities early (ie Yes before the scheduled return date)? [Yes/No] If yes, in which circumstances? At any time subject to giving notice. Are there circumstances in which the borrower will not be No required to return the securities on settlement? [Yes/No] If yes, in which circumstances? N/A
13
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
Wednesday, 28 October 2026 2026 ANNUAL GENERAL MEETING RESULTS In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Australian Clinical Labs Limited (ASX:ACL)(Company) announces the outcome of each resolution put to shareholders at its Annual General Meeting, which was held today. The following resolutions were passed on a poll, with full details of the number of votes and the total number of proxy votes appearing at Appendix A to this announcement: 1. 2. 3. 4. 5. 6.
Adoption of 2026 Remuneration Report Re-election of Dr Amandeep Hansra Re-election of Christine Butler Grant of Performance Rights to Group CEO Renewal of the proportional takeover provisions in the constitution Appointment of Deloitte as new auditor
Shareholders who were unable to attend the AGM will find a recording of the Chair’s and CEO’s address on the Company’s website. – ENDS – This announcement was authorised for release to ASX by the Company Secretary of ACL.
605
Page 1 of 2 15 July 2001
Form 605 Corporations Act 2001 Section 671B
Notice of ceasing to be a substantial holder To Company Name/Scheme
Australian Clinical Labs Limited
ACN/ARSN
645 711 128
- Details of substantial holder (1) Name
United Super Pty Ltd
ACN/ARSN (if applicable)
006 261 623
The holder ceased to be a substantial holder on The previous notice was given to the company on
15/10/2026 20/10/2026 20/10/2026
The previous notice was dated
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
See Annexure A
Person whose relevant interest changed
Nature of change (4)
Consideration given in relation to change (5)
Class (6) and number of securities affected
Person's votes affected
United Super Pty Ltd
- Changes in association The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
Not Applicable
- Addresses The addresses of persons named in this form are as follows: Name
Address
United Super Pty Ltd
Level 22, 130 Lonsdale Street, Melbourne
Signature print name
sign here
Maxine Jacona
capacity
Company Secretary
date
21/10/2026
605
Page 2 of 2 15 July 2001
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
(2)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(3)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(4)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (5)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(6)
The voting shares of a company constitute one class unless divided into separate classes.
(7)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
ANNEXURE A Holder of relevant interest
United Super Pty Ltd
Date of Acquisition
Consideration Cash
Opening balance 14/10/2026 15/10/2026 N/A Closing balance 15/10/2026
Non-Cash Collateral Posted
Class of securities
Number of Securities
Ordinary Shares Ordinary Shares
9,779,128 649,625 9,129,503
603
Page 1 of 2 15 July 2001
Form 603 Corporations Act 2001 Section 671B
Notice of initial substantial holder To Company Name/Scheme
Australian Clinical Labs Limited
ACN/ARSN
645 711 128
- Details of substantial holder (1) Name
United Super Pty Ltd
ACN/ARSN (if applicable)
006 261 623
The holder became a substantial holder on
14/10/2026
- Details of voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows: Class of securities (4)
Number of securities
Ordinary Shares
Person's votes (5)
Voting power (6)
9,779,128
9,779,128
5.24%
- Details of relevant interests The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows: Holder of relevant interest
Nature of relevant interest (7)
Class and number of securities
United Super Pty Ltd
Shareholder
Ordinary Shares 9,779,128
- Details of present registered holders The persons registered as holders of the securities referred to in paragraph 3 above are as follows: Holder of relevant interest
Registered holder of securities
JP Morgan Nominees Australia Ltd as United Super Pty Ltd Custodian for United Super Pty Ltd
Person entitled to be registered as holder (8)
JP Morgan Nominees Australia Ltd as Custodian for United Super Pty Ltd
Class and number of securities
Ordinary Shares 9,779,128
- Consideration The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows: Holder of relevant interest
Date of acquisition
Consideration (9) Cash
See Annexure A
Class and number of securities Non-cash
603
Page 2 of 2 15 July 2001
- Associates The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows: Name and ACN/ARSN (if applicable)
Nature of association
N/A 7. Addresses The addresses of persons named in this form are as follows: Name
Address
United Super Pty Ltd
Level 22, 130 Lonsdale Street, Melbourne
JP Morgan Nominees Australia Ltd
Locked Bag 20049, Melbourne VIC 3001
Signature print name
Maxine Jacona
sign here
capacity
Company Secretary
date
20/10/2026
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
(6)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(7)
Include details of: (a)
any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (8)
If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option) write "unknown".
(9)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
ANNEXURE A Holder of relevant interest
United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd United Super Pty Ltd
Date of Acquisition
Consideration Cash Non-Cash Opening balance 12/06/2026 16/06/2026 -20,159 15/07/2026 -28,845 17/07/2026 -15,068 22/07/2026 -78,824 28/07/2026 -22,756 6/08/2026 -55,332 12/08/2026 -19,437 17/08/2026 477,906 19/08/2026 -54,009 26/08/2026 -19,319 3/09/2026 -21,715 9/09/2026 -20,174 17/09/2026 -20,273 24/09/2026 -20,497 30/09/2026 -20,193 14/10/2026 N/A Collateral Received Closing balance 14/10/2026
Class of securities Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares Ordinary Shares
Number of Securities
9,141,971 9,050 12,692 6,382 33,942 9,557 22,835 8,299 177,573 19,160 6,734 7,983 7,220 7,042 7,142 7,067 649,625 9,779,128
Notice of ceasing to be a substantial holder To:
Australian Clinical Labs Ltd (“ACL”, Ordinary Fully Paid)
Details of substantial shareholder
Form 605 Corporations Act Section 671B
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) and each of the related bodies corporate in the Citi group of companies worldwide (for more details please visit www.citigroup.com). The holder ceased being a substantial holder on 14 October 2026. The previous notice had been given to the company on 15 October 2026. 2.
Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change
Person whose relevant interest changed and Person’s votes affected
14 October 2026
Citigroup Global Markets Australia Pty Limited
14 October 2026
Citigroup Global Markets Limited
Nature of Relevant Interest Citigroup Global Markets Australia Pty Limited holds a decreased relevant interest in these shares pursuant to contracts entered into in the ordinary course of business on a stock market of a stock exchange, containing no terms and conditions other than standard terms and conditions. Citigroup Global Markets Australia Pty Limited holds a decreased relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
Class and number of securities affected
-1,281 Ordinary Fully Paid
-3,188,901 Ordinary Fully Paid
Changes in association The persons who have become associates of, ceased to be associates of, or have changed the nature of their association with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable) N/A
Nature of association N/A
Addresses The addresses of persons named in this form are as follows: Name
Address
Citigroup Global Markets Australia Pty Limited
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Limited
Citigroup Centre, Canary Wharf 33 Canada Square London, E14 5LB, United Kingdom
Dated this day, 16 October 2026. Ji Hyun Kim Citigroup Global Markets Australia Pty Limited T: +61 2 8225 2489
Annexure A This is Annexure A of 2 pages referred to in Form 605 ‘Notice of ceasing to be a substantial holder’ Schedule (Loan) Type of Agreement
AMSLA / GMSLA / MSLA
Parties to Agreement
Various
Transfer date
Various
Holder of voting rights
Borrower
Are there any restrictions on voting rights?
No
Scheduled return date
Unknown
Does the borrower have the right to return early? If yes, details
Yes
Does the lender have the right to recall early? If yes, details
Yes
Will the securities be returned on settlement?
n/a
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the AMSLA / GMSLA / MSLA to the company or ASIC.
Standard AMSLA / GMSLA / MSLA terms
Standard AMSLA / GMSLA / MSLA terms
Schedule (Agency Lending Agreement) Type of Agreement
Securities Lending Agency Agreement (SLAA)
Parties to Agreement
Various
Circumstances under which the agent lender can exercise the authorisations in relation to the securities
Agent Lender can only exercise authority, as agent, in relation to the lender’s securities as defined and agreed in the Securities Lending Agency Agreement.
Circumstances under which the agent lender is subject to any restrictions in how it can deal with the securities
Lenders will define the restrictions and/or securities lending parameters in the Securities Lending Agency Agreement entered into with the lending agent. Such restrictions/parameters include specific designated accounts, lendable limits, acceptable collateral and/or cash reinvestment guidelines.
Does the agent lender have the right to recall early?
If yes, details
Statement
Agent Lenders have the right to early recall on behalf of Lender’s instructions. However, the expectation is the Lender and Borrower would have mutually agreed no sales/recall of the securities during the duration of the loan term. Hence, borrowers are not obligated to return the securities early for termed loans. Authorised under the standard Securities Lending Agency Agreement terms. If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the authorisation agreement to the company or ASIC.
Form 603 Corporations Act Section 671B
Notice of initial substantial shareholder To:
Australian Clinical Labs Ltd (“ACL”, Ordinary Fully Paid)
Details of substantial shareholder Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) and each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com). The holder became a substantial holder on 13 October 2026.
Details of voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate had a relevant interest in on the date the substantial holder became a substantial holder are as follows:
Class of securities
Number of securities
Person’s vote
Voting Power
Ordinary Fully Paid
10,634,595
10,634,595
5.7016%
Details of relevant interests Holder of relevant interest
Nature of relevant interest
Class and number of securities
Citibank, N.A. Sydney Branch
Citibank, N.A. Sydney Branch holds a relevant interest in these shares acting as Agent Lender and as the holder of securities subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
2,033,756 Ordinary Fully Paid
Citigroup Global Markets Australia Pty Limited
Citigroup Global Markets Australia Pty Limited holds a relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement and pursuant to contracts entered into in the ordinary course of business on a stock market of a stock exchange, containing no terms and conditions other than standard terms and conditions. Refer to Annexure A.
171,596 Ordinary Fully Paid
Citigroup Global Markets Limited
Citigroup Global Markets Limited holds a relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
8,429,243 Ordinary Fully Paid
Details of present registered holders The persons registered as holders of the securities referred to in paragraph 3 above are as follows: Holder of relevant interest
Registered holder of securities
Class and number of securities 2,033,756 Ordinary Fully Paid
Citibank, N.A. Sydney Branch
Various
Citigroup Global Markets Australia Pty Limited
Citicorp Nominees Pty Limited
171,596 Ordinary Fully Paid
Citigroup Global Markets Limited
Citicorp Nominees Pty Limited
8,429,243 Ordinary Fully Paid
Consideration The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:
Holder of relevant interest
Date of acquisition
Consideration
Class and number of securities
Citibank, N.A. Sydney Branch
Various
Various (Refer Annexure A)
2,033,756 Ordinary Fully Paid
Citigroup Global Markets Australia Pty Limited
Various
Various (Refer Annexure A)
171,596 Ordinary Fully Paid
Citigroup Global Markets Limited
Various
Various (Refer Annexure A)
8,429,243 Ordinary Fully Paid
Associates The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows: Name and ACN/ARSN (if applicable)
Citibank, N.A. Sydney Branch
Nature of association Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Citigroup Global Markets Australia Pty Limited
Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Citigroup Global Markets Limited
Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Addresses The addresses of persons named in this form are as follows: Name
Address
Citibank, N.A. Sydney Branch
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Australia Pty Limited
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Limited
Citigroup Centre, Canary Wharf 33 Canada Square London, E14 5LB, United Kingdom
Dated this day, 15 October 2026. Ji Hyun Kim Citigroup Global Markets Australia Pty Limited T: +61 2 8225 2489
Annexure A This is Annexure A of 2 pages referred to in Form 603 ‘Notice of initial substantial holder’ Schedule (Loan) Type of Agreement
AMSLA / GMSLA / MSLA
Parties to Agreement
Various
Transfer date
Various
Holder of voting rights
Borrower
Are there any restrictions on voting rights?
No
Scheduled return date
Unknown
Does the borrower have the right to return early? If yes, details
Yes
Does the lender have the right to recall early? If yes, details
Yes
Will the securities be returned on settlement?
n/a
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the AMSLA / GMSLA / MSLA to the company or ASIC.
Standard AMSLA / GMSLA / MSLA terms
Standard AMSLA / GMSLA / MSLA terms
Schedule (Agency Lending Agreement) Type of Agreement
Securities Lending Agency Agreement (SLAA)
Parties to Agreement
Various
Circumstances under which the agent lender can exercise the authorisations in relation to the securities
Agent Lender can only exercise authority, as agent, in relation to the lender’s securities as defined and agreed in the Securities Lending Agency Agreement.
Circumstances under which the agent lender is subject to any restrictions in how it can deal with the securities
Lenders will define the restrictions and/or securities lending parameters in the Securities Lending Agency Agreement entered into with the lending agent. Such restrictions/parameters include specific designated accounts, lendable limits, acceptable collateral and/or cash reinvestment guidelines.
Does the agent lender have the right to recall early?
If yes, details
Statement
Agent Lenders have the right to early recall on behalf of Lender’s instructions. However, the expectation is the Lender and Borrower would have mutually agreed no sales/recall of the securities during the duration of the loan term. Hence, borrowers are not obligated to return the securities early for termed loans. Authorised under the standard Securities Lending Agency Agreement terms. If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the authorisation agreement to the company or ASIC.
Australian Clinical Labs Limited (ACL or Company) wishes to notify the market of two typographical errors that appear in the explanatory memorandum to the notice of meeting for the 2026 AGM that was sent to shareholders. ACL advises that:
- In the section headed “Measurement Period” in the table on page 18, the text should read “For each of Tranches 1, 2 and 3 of the Performance Rights, the Measurement Period will be three years from 1 July 2026 to 30 June 2029”;
- In the section headed “Vesting Conditions” on the same page, the % amount of performance rights vesting at the 50th percentile for Tranche 1 rTSR should read 50% and not 100%. An amended notice of meeting is attached and an amended version is also available on our website here.
– ENDS – This announcement was authorised for release to ASX by the Company Secretary of ACL. For further information regarding this announcement, please contact:
Investor Relations Matthew Cordingley Chief Financial Officer Email: [email protected] Phone: +61 (0) 409 287 681
Page 1 of 1 Australian Clinical Labs Limited ABN 94 645 711 128
Governance Eleanor Padman Company Secretary Email: [email protected] Phone: +61 (0) 422 002 918
Australian Clinical Labs Limited ABN 94 645 711 128 clinicallabs.com.au
NOTICE OF ANNUAL GENERAL MEETING 2026 On Wednesday, 28 October 2026 at 2pm AEDT
Dear Shareholders It is my pleasure to invite you to attend the 2026 annual general meeting (AGM) of Australian Clinical Labs Limited (ACL or Company), to be held online as a virtual meeting on Wednesday, 28 October 2026 at 2pm AEDT. This will be the Company’s sixth AGM following its admission to the ASX on 14 May 2021. To facilitate as many Shareholders joining us as possible, the Board has determined that the AGM will be held as a virtual meeting online. This means that there will not be a physical venue for Shareholders to attend in person. Instead, the AGM will be webcast and Shareholders and their proxies, corporate representatives and attorneys will be able to attend and participate virtually through the AGM Online Platform. Full details of how to join the meeting virtually are contained in the Online Platform Guide which has been lodged with ASX and posted on ACL’s website at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/. Registration will take place online and will commence at 1.30pm AEDT on Wednesday, 28 October 2026 at https://meetings.openbriefing.com/ACL26. The items for consideration at this year’s AGM are:
- The consideration of ACL’s financial statements and statutory reports for the financial year ended 30 June 2026;
- The adoption of ACL’s Remuneration Report for the financial year ended 30 June 2026;
- The re-election of Dr Amandeep Hansra as a non-executive Director;
- The re-election of Ms Christine Bartlett as a non-executive Director;
- The approval of the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Executive Director of the Company, as part of his long-term variable remuneration for the period ending 30 June 2027;
- The renewal of the Proportional Takeover Provisions in the Constitution; and
- The appointment of Deloitte as new auditors to the Company. The Board recommends that Shareholders vote in favour of all items of business. Enclosed is a copy of the Notice of Meeting which includes information for Shareholders and explanatory notes. These documents can also be accessed on our website at https://investors.clinicallabs.com.au/investor-information/annual-general-meetings/. If you are unable to attend the AGM online through the AGM Online Platform, you may (and are encouraged to) appoint a proxy to attend and vote on your behalf. Proxy appointments must be received by no later than 2pm AEDT on Monday, 26 October 2026. Proxy appointments can be made either via our share registry – https://au.investorcentre.mpms.mufg.com – or by following the instructions contained in the Notice of Meeting. Even if you plan to attend the AGM online, you may wish to submit a directed proxy vote so that your vote will be counted if for any reason you cannot attend (for example, if you have difficulties with your internet connection on the day of the meeting). We also invite you to submit questions to the Company or auditor in advance of the meeting through our share registry – https://au.investorcentre.mpms.mufg.com – or by emailing us at [email protected] Questions must be received by no later than 5pm AEDT
2
on Wednesday, 21 October 2026. I look forward to welcoming you to the AGM.
Stephen Roche Chair 22 September 2026
3
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the 6th Annual General Meeting of Australian Clinical Labs Limited will be held on: Date:
Wednesday, 28 October 2026
Time:
2pm AEDT
Place:
To be held online (as a virtual annual general meeting)
Webcast:
Shareholders and their proxyholders, corporate representatives and attorneys can register, view and participate in the meeting at https://meetings.openbriefing.com/ACL26. Online registration will open at 1.30pm AEDT on Wednesday, 28 October 2026. Further information on how to join the meeting virtually are set out in the Online Platform Guide which is available at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/
Words that are defined in the Glossary have the same meaning when used in this Notice unless the context requires, or the definitions in the Glossary provide, otherwise.
Ordinary Business Financial statements and reports To receive and consider the financial statements, the Directors’ Report and the Auditor’s Report of the Company for the financial year ended 30 June 2026. Note: No resolution is required for this item of business. Resolution 1: Adoption of the Remuneration Report To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report of the Company for the financial year ended 30 June 2026 as disclosed in the Directors’ Report be adopted.” In accordance with section 250R(3) of the Corporations Act, the vote on Resolution 2 will be advisory only and will not bind the Directors or the Company. Voting exclusion for Resolution 1: In accordance with the Corporations Act, a vote on Resolution 1 must not be cast, and the Company will disregard any votes cast on Resolution 1: (a)
by or on behalf of a member of the KMP, whose remuneration details are included in the Remuneration Report and/or any Closely Related Party of such a member, regardless of the capacity in which the vote is cast; or
4
(b)
as proxy by any person who is a member of the KMP as at the time Resolution 1 is voted on at the meeting or a Closely Related Party of such a member,
unless the vote is cast as proxy for a person otherwise entitled to vote on Resolution 1: (c)
in accordance with the express direction of the appointer; or
(d)
by the Chair where the proxy appointment does not specify the way the proxy is to vote on Resolution 1 and expressly authorises the Chair to exercise the proxy in respect of Resolution 1 even though the resolution is connected directly or indirectly with the remuneration of a member of the KMP.
Resolution 2 : Re-election of Dr Amandeep Hansra as a Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That Dr Amandeep Hansra, having been appointed by the Board as a Director on 1 July 2026 to fill a casual vacancy under rule 6.1(d) of the Company’s Constitution and retiring as a Director of the Company for the purposes of ASX Listing Rule 14.4 and rule 6.1(e) of the Company’s Constitution and who has consented to stand for re-election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.” Resolution 3: Re-election of Ms Christine Bartlett as a Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That Ms Christine Bartlett, retiring as a Director of the Company in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution and who has consented to stand for re- election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.”
Resolution 4: Approval of grant and issue of Performance Rights to Mr Greg Horan To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That approval be given for the purposes of ASX Listing Rule 10.14, and for all other purposes, for the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Executive Director of the Company, in relation to his LTVR for FY27, in accordance with the LTVR Plan and on the terms and conditions described in the explanatory memorandum accompanying this Notice of Meeting.” Voting exclusion for Resolution 4 In accordance with the ASX Listing Rules, the Company will disregard any votes cast on Resolution 4 by or on behalf of Mr Horan (who is a person referred to in ASX Listing Rule 10.14.1 who is eligible to participate in the LTVR Plan) or any of his Associates, regardless of the capacity in which the vote is cast. However, this voting exclusion does not apply to a vote cast in favour of Resolution 4 by: 5
(a)
a person as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with the directions given to the proxy or attorney to vote on Resolution 4 in that way; or
(b)
the Chair as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with a direction given to the Chair to vote on Resolution 4 as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: •
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an Associate of a person excluded from voting, on Resolution 4; and
•
the holder votes on Resolution 4 in accordance with directions given by the beneficiary to the holder to vote in that way.
The Company will also disregard any votes cast on Resolution 4 by or on behalf of any person who is a member of KMP as at the time the resolution is voted on at the meeting, or any of their Closely Related Parties, as a proxy. However, the Company will not disregard the vote of such a person on the resolution if the vote is cast by the person: (a)
as a proxy for a person otherwise entitled to vote on Resolution 4 and the vote is in accordance with the appointor’s express direction; or
(b)
the person is the Chair who has been validly appointed as a proxy for a person otherwise entitled to vote on Resolution 4 and the appointment of the Chair as proxy: •
does not specify the way the proxy is to vote on Resolution 4; and
•
expressly authorises the Chair to exercise the proxy in respect of Resolution 5 even though Resolution 4 is connected directly or indirectly with the remuneration of a member of KMP.
Resolution 5: Reinsertion of the Proportional Takeover Provisions in the Constitution To consider and, if thought fit, to pass the following resolution as a special resolution: “That the Proportional Takeover Provisions contained in rule 14 of the Company’s Constitution, having expired on 22 October 2026, be reinserted for a period of three years commencing on the date this resolution is passed”. Resolution 6: Appointment of Deloitte as new auditor To consider and, if thought fit, to pass the following resolution: “That, for the purposes of sections 327B(1) Corporations Act 2001 and for all other purposes, Deloitte Touche Tohmatsu, having been nominated by a shareholder pursuant to section 328B Corporations Act 2001, and being qualified and having consented in writing to act as to auditor of the Company pursuant to section 328A Corporations Act 2001, be appointed as auditor of the Company to hold office from the
6
conclusion of the Company’s 2026 AGM on 28 October 2026 until the date of its resignation or removal from the office of auditor the Company ” By order of the Board
Eleanor Padman Company Secretary 22 September 2026
7
INFORMATION FOR SHAREHOLDERS
Who may vote?
In accordance with regulation 7.11.37 of the Corporations Regulations 2001 (Cth), the Company has determined that persons whose names are set out in the register of shareholders of the Company as at 7pm AEDT on 26 October 2026 are entitled to vote at the AGM (subject to the applicable voting exclusions set out above).
How will voting be conducted?
In accordance with the Treasury Laws Amendment (2021 Measures No. 1) Act 2021 (Cth), the Chair will put all Resolutions to a poll at the AGM. Voting results on the Resolutions that are put to the meeting (including by proxy votes) will be announced to the ASX as soon as practicable following the conclusion of the AGM.
How can I vote at the meeting?
Shareholders can vote at the meeting by:
casting a live vote during the meeting (through the AGM Online Platform); or
by appointing a proxy (see below).
Shareholders or their attorneys wishing to vote in person should attend the meeting (via the AGM Online Platform) and can vote through the AGM Online Platform. How do I appoint a proxy?
A Shareholder who is entitled to vote at the meeting has a right to appoint up to two proxies to attend and vote for the Shareholder at the AGM. A proxy need not be a Shareholder. A proxy may be an individual or a body corporate. Where a Shareholder appoints two proxies, the appointment should specify the proportion or number of votes which each proxy may exercise. Fractions of votes will be disregarded. If the appointment does not specify the proportion or number of the Shareholders’ votes each proxy may exercise, then each proxy may exercise half those votes. A proxy may decide whether or not to vote on any proposed resolution, except where required by law or the Company’s Constitution to vote, or abstain from voting, in his or her capacity as proxy. If the Shareholder appointing the proxy:
directs the proxy how to vote on a proposed resolution, then the proxy may vote on that resolution only in the way directed; or
does not direct the proxy how to vote on a proposed resolution, then the proxy may vote on that resolution as the proxy thinks fit, subject to any voting exclusions that apply to the proxy; or
8
directs the proxy to abstain, the proxy must not vote on the Shareholder’s behalf and any vote will not be counted.
If you appoint someone as a proxy (other than the Chair) and direct them how to vote, the Chair of the AGM must cast those votes on your behalf on a poll in accordance with your directions if your proxy does not do so. If you appoint the Chair of the AGM as your proxy (or if he is appointed by default) and no direction is provided in relation to a resolution, you will be expressly authorising the Chair to exercise your proxy as the Chair sees fit in relation to that resolution even if the resolution is connected directly or indirectly with the remuneration of the Company’s KMP. If you appoint a Director (other than the Chair) or another member of the Company’s KMP or their Closely Related Parties as your proxy, you must specify how they should vote on Resolutions 1 and 4 by completing the “For”, “Against” or “Abstain” boxes on the proxy form. If you do not, your proxy will not be able to exercise your vote for Resolutions 1 and 4. The Chair intends to vote all available (including undirected) proxies in favour of all Resolutions subject to the voting exclusions described above. In exceptional circumstances, the Chair’s intentions may change. If there is a change to how the Chair intends to vote undirected proxies, the Company will make an immediate announcement to ASX stating that fact and explaining the reasons for the change. The appointment of one or more duly appointed proxies will not preclude a Shareholder from attending this meeting and voting personally. If the Shareholder votes on a Resolution, the proxy must not vote as the member’s proxy on that Resolution. How do I appoint/lodge a proxy?
To be valid, a proxy form must be correctly completed and received, either online, by post or fax or hand delivery (as per the details below), by 2pm AEDT on Monday, 26 October 2026 (noting that hand deliveries will only be accepted during business hours (being Monday to Friday between 9:00am and 5:00pm), including any power of attorney or other authority under which it is signed. Any proxy form received after this time will not be valid. Proxies may be lodged as follows with the Company’s share registry by:
post or facsimile – completed proxy forms may be posted to Australian Clinical Labs Limited C/- MUFG Pension and Market Services Limited Locked Bag A14, SYDNEY SOUTH NSW 1235 or sent by facsimile to +61 2 9287 0309;
9
hand delivery at Australian Clinical Labs Limited C/MUFG Pension and Market Services, Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150 during business hours (being Monday to Friday between 9:00am and 5:00pm); or
lodging the proxy appointment online at https://au.investorcentre.mpms.mufg.com. To use this service, you will need your Securityholder Reference Number (SRN) or Holder Identification Number (HIN), or you can access the service using your postcode and the personalised link sent to you by email if you have registered for electronic communications from the Company.
Given changes to Australia Post’s services which may see mail take longer to arrive, the Company suggests that you allow additional time if you decide to send your completed proxy form by post. How do I appoint a corporate representative?
A Shareholder who is a body corporate and who is entitled to vote at the AGM, or a proxy who is a body corporate and who is appointed by a Shareholder who is entitled to vote at the AGM, may appoint a person to act as its representative at the AGM. The body corporate will need to ensure that it:
appoints an individual as its corporate representative to exercise its powers at meetings, in accordance with section 250D of the Corporations Act; and
provides satisfactory evidence of the appointment of its corporate representative prior to commencement of the meeting.
Body corporate representatives should lodge this documentation with the Company’s share registry by no later than 2pm AEDT on Monday, 26 October 2026, unless it has been previously given to the Company. Corporate Shareholders or proxies wishing to vote by corporate representative should:
I hold my shares jointly with another person. Are we both entitled to vote?
obtain an appointment of corporate representative form from MUFG Pension and Market Services; and
complete and send the form in accordance with the instructions on the form.
When joint holders are named in the register of members, only one joint holder may vote. If more than one of the joint holders is present at the meeting, only the person whose name appears first in the register of members will be entitled to vote. If more than one holder votes at the meeting, only the vote of the first named of the joint holders in the register of members
10
will be counted. How can I ask a question at the AGM?
In accordance with the Corporations Act, a reasonable opportunity will be given to Shareholders to ask questions about or to make comments upon the management of the Company (including in respect of the Remuneration Report) and the Resolutions at the meeting via the AGM Online Platform. Shareholders will have the opportunity to ask questions at the Meeting via the online portal at https://meetings.openbriefing.com/ACL26 More detailed information on how to ask questions during the meeting is provided in the Online Platform Guide available online at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/. The Company strongly encourages Shareholders to submit written questions in advance of the AGM. To submit a written question, please email the Company at [email protected] Alternatively, questions may be submitted by Shareholders logging into their account at https://au.investorcentre.mpms.mufg.com or by completing the question form provided to Shareholders with this Notice of Meeting. Questions must be received by no later than 5pm AEDT on Wednesday, 21 October 2026. Questions should relate to matters that are relevant to the business of the AGM, as outlined in this Notice and the explanatory memorandum. Questions that are relevant to the contents of the Auditor’s Report or the conduct of the audit of the Company’s financial report, may be addressed to the Company’s auditor, Pitcher Partners. Questions will be collated and, during the AGM, the Chair will seek to address as many of the more frequently raised topics as possible and, where appropriate, will give a representative of Pitcher Partners, the Company’s auditor, the opportunity to answer written questions submitted to the auditor. However, there may not be sufficient time available at the AGM to address all topics raised. Please note that individual responses will not be sent to Shareholders.
11
How I participate virtually?
Shareholders and proxyholders can watch, ask questions, make comments and vote in real time during the AGM (for those who are entitled to do so) through the AGM Online Platform at https://meetings.openbriefing.com/ACL26. Registration for attendance at the meeting will be online via the AGM Online Platform and will commence at 1.30pm AEDT on Wednesday, 28 October 2026 for those accessing the AGM Online Platform. To register, Shareholders will need their shareholder number and postcode. Proxyholders will need their proxy number which will be provided by MUFG Pension and Market Services following lodgement of the proxy appointment and no later than 24 hours prior to the meeting. We recommend that you register at least 30 minutes before the AGM and test to see that the AGM Online Platform works on your device before the commencement of the meeting. Further information can be found in the Online Platform Guide which is available at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/.
What happens if there are technical difficulties?
Significant planning and testing has been undertaken and the online technology being used by the Company has been successfully used by other companies. However, unforeseen technical difficulties may still arise during the AGM. The Chair has discretion as to whether and how the meeting should proceed if a technical difficulty arises. In exercising his discretion, the Chair will have regard to the number of Shareholders impacted and the extent to which participation in the business of the meeting is affected. Where he considers it appropriate, the Chair may continue to hold the meeting and transact business, including conducting a poll and voting in accordance with valid proxy instructions. As previously noted, Shareholders are encouraged to lodge a proxy by 2pm AEDT on Monday, 26 October 2026 even if they plan to attend the meeting online via the AGM Online Platform.
What if there are changes to the meeting?
ACL will keep Shareholders informed if there are any changes to the meeting and details will be made available at https://investors.clinicallabs.com.au/, with any changes also notified by an ASX release.
12
ADDITIONAL INFORMATION FOR SHAREHOLDERS – ELECTRONIC COMMUNICATONS Following legislative changes to the Corporations Act in 2023, there are digital new options available to Shareholders for receiving communications from ACL. ACL will no longer be sending physical meeting documents unless you request a copy to be posted. ACL encourages all Shareholders to provide an email address so we can communicate with you electronically when Shareholder notices become available online, for items such as meeting documents and annual reports. Shareholders can still elect to receive some or all their communications in physical or electronic form, or elect not to receive certain documents such as annual reports. To review your communications preferences, or sign up to receive your Shareholder communications via email, please update your details by logging into your shareholding at https://au.investorcentre.mpms.mufg.com If you would like a physical copy of a communication, need further information about the options available to you or have questions about your holding, visit https://au.investorcentre.mpms.mufg.com or contact the Registry as follows: Australian Clinical Labs Limited C/- MUFG Pension and Market Services, Locked Bag A14, SYDNEY SOUTH NSW 1235 Telephone (within Australia): 1300 554 474 Telephone (outside Australia): +61 1300 554 474 Email: [email protected] Website: https://au.investorcentre.mpms.mufg.com
EXPLANATORY MEMORANDUM
This explanatory memorandum accompanies and forms part of, and should be read together with, the Notice. Financial statements and reports The financial report (which includes the financial statements), the Directors’ Report and the Auditor’s Report for the financial year ended 30 June 2026 will be put before the AGM, as required by section 317 of the Corporations Act. The Corporations Act does not require a formal resolution of Shareholders on these reports. These reports are contained in the Annual Report, which is available on the Company’s website at https://investors.clinicallabs.com.au/investor-information/reportspresentations/reports-presentations/ During this item of business, Shareholders will be given a reasonable opportunity to ask questions about, and to make comments on, those reports and the business and management of the Company.
13
Shareholders will also be given an opportunity to ask a representative of the Company’s auditor, Pitcher Partners, questions relevant to the conduct of the audit, the preparation and content of the Auditor’s Report, the accounting policies adopted by the Company in relation to the preparation of the financial reports and the independence of the auditor in relation to the conduct of the audit. Resolution 1: Adoption of the Remuneration Report Section 250R(2) of the Corporations Act requires publicly listed companies to put a resolution to shareholders to adopt the company’s remuneration report for the relevant financial year. Shareholders are asked to adopt the Remuneration Report. The Remuneration Report provides information relating to the details of the remuneration paid to KMP and Directors for the financial year ended 30 June 2026, the Company’s remuneration policy and the relationship between remuneration and the Company’s performance, including information about performance measures applicable to variable incentives. A copy of the Remuneration Report, which sets out remuneration arrangements for ACL can be found in the Company’s Annual Report. Under the Corporations Act, the vote on this resolution is advisory only and does not bind the Board or the Company. However, at its 2025 AGM, the Company received a second ‘strike’ on its remuneration report which provided it with important and consequential Shareholder feedback on its remuneration policy. In the 12 months since the 2025 AGM, the Company has consulted extensively with several Shareholders and other stakeholders to better understand the reasons for the second strike. As outlined in the Company’s Remuneration Report, the Company has responded to that feedback as follows:
the remuneration package of the incoming CEO, Greg Horan, was set in reference to relevant market capitalisation and industry peers, with a total remuneration package set at approximately 43% lower than his predecessor in the role.
in respect of the FY27 LTVR plan:
the 20% Service Right component has been removed and replaced with a new 34% ROIC metric;
the ROIC measure will be assessed against an annual ROIC target that has regard to the Board approved capex budget for each year (over a three year period) which will be disclosed retrospectively at vesting in the Remuneration Report;
the existing metrics of EPS and rTSR have been reweighted to 33% each to accommodate the ROIC metric;
the peer group for the rTSR metric will change from the ASX 300 (ex-financials and resources) to a bespoke index of 12 healthcare service companies with the intention of assessing ACL’s performance against a group of peers from more closely related sectors and with comparably regulated environments, workforce compositions and company models.
A voting exclusion applies to this resolution, as set out in the Notice of Meeting. Noting that each Director has a personal interest in his/her own remuneration from the Company, the Board unanimously recommends that Shareholders vote in favour of Resolution 1.
14
Resolution 2: Re-election of Dr Amandeep Hansra as a Director Dr Amandeep Hansra was appointed as a non-executive Director of ACL on 1 July 2026 to fill a casual vacancy and retires at this meeting in accordance with the casual vacancy rule under ASX Listing Rule 14.4 and rule 6.1(e) of the Company’s Constitution. Being eligible, Dr Hansra stands for re-election under rule 6.1(i) of the Company’s Constitution. Dr Hansra is a General Practitioner with more than 20 years clinical experience whose career has included clinical practice, national digital health leadership, government engagement and a number of board roles. In her executive career, Dr Hansra has held the roles of Chief Medical Officer with Telstra Health, Head of Clinical Innovation at NIB and Deputy Chief Medical Officer at the Department of Home Affairs. Dr Hansra has led national clinical governance frameworks across digital health, telehealth and technology-enabled care, including managing complex incidents and clinician engagement in emerging models of care. Dr Hansra remains committed to her GP practice as a Fellow of the Royal Australian College of General Practitioners and acts a Chief Clinical Advisor to the Australian Digital Health Agency. Dr Hansra is currently a non-executive director of Healthicare, ACHS International, MoleMap New Zealand, Healthengine and the Central and Eastern Sydney Primary Health Network. Dr Hansra also serves as a member of the Industry Growth Committee for the Department of Industry, Science and Resources. Dr Hansra holds a Bachelor of Medicine (Hons) from the University of Newcastle and a Masters of Public Health and Tropical Medicine from James Cook University. Dr Hansra also has a Global Executive MBA from the University of Sydney Business School and is a graduate of the AICD. The Board (with Dr Hansra abstaining) unanimously recommends that Shareholders vote in favour of Resolution 2. Resolution 3: Re-election of Ms Christine Bartlett Ms Christine Bartlett was appointed by Shareholders as a non-executive Director of ACL on 23 October 2023 and retires at this meeting in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution. Being eligible, Ms Bartlett stands for re-election under rule 6.1(i) of the Company’s Constitution. The proposed re-election of Ms Bartlett satisfies the Company’s obligations relating to the election and rotation of Directors under ASX Listing Rules 14.4 and 14.5 and ACL’s Constitution. Ms Bartlett is the Chair of ACL’s People and Culture Committee and is considered to be an independent director. Ms Bartlett is an experienced chief executive officer and senior executive, with extensive executive experience gained through roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Ms Bartlett has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies. Ms Bartlett is currently a non-executive director of Reliance Worldwide Corporation Limited, a non-executive director of Firmus Technologies Pty Ltd and is the Chair of CEDA and NSW Ports. Ms Bartlett is a member of Chief Executive Women and the Australian Institute of Company Directors. Christine holds a Bachelor of Science from the University of Sydney and has completed senior executive management programs at INSEAD.
15
Ms Bartlett has previously held non-executive director roles with Sigma Healthcare Limited (resigned December 2023), Mirvac Limited (resigned April 2026) and TAL Life Limited (resigned April 2026). The Board (with Ms Bartlett abstaining) unanimously recommends that Shareholders vote in favour of Resolution 3. Resolution 4: Approval of grant and issue of Performance Rights to Mr Greg Horan The Company is seeking Shareholder approval for the proposed grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, CEO and Executive Director of the Company, under the LTVR Plan for FY27 (on the basis that Mr Horan is a Director of the Company). Following a review of the efficacy of the LTVR Plan and feedback from investors, a number of changes have been made to the FY27 LTVR Plan from the previous LTVR plan:
a new return on invested capital (ROIC) measure has been introduced as 34% of the total grant to replace the previous 20% Service Right component of the LTVR;
the ROIC measure will be assessed against three cumulative annual ROIC targets approved by the Board (including the approved capex budget for each year). The targets and performance against the targets will be disclosed retrospectively in the appropriate Remuneration Report;
the other two LTVR measures, being earnings per share (EPS) and relative total shareholder return (rTSR) have been reweighted to 33% each to accommodate the new ROIC measure; and
the peer group for the rTSR metric has changed from the ASX 300 (ex-financials and resources) to a bespoke index of 12 healthcare service companies.
ASX Listing Rule 10.14 requires the Company to obtain approval from Shareholders for the issue of securities to a Director under an employee incentive scheme. Mr Horan is CEO and an Executive Director of the Company. Resolution 4 is not seeking approval for the total remuneration of Mr Horan. Rather, it relates to the proposed issue of up to 359,850 Performance Rights to Mr Horan, which represents the FY27 LTVR component of Mr Horan’s remuneration (which is one component of Mr Horan’s total remuneration). If Shareholder approval is not obtained, the Board will consider alternative approaches to rewarding Mr Horan to ensure that the remuneration packages for the Executive Director remains competitive and motivating. The LTVR Plan has been designed to meet the needs of the Company and to reflect modern best-practice remuneration equity structures for executives. A key component of effective remuneration for executives is equity interests, in the form of LTVR to drive shared performance objectives, link remuneration to Company performance and align interests with sustainable value creation for Shareholders. Performance Rights are proposed to be granted to Mr Horan under the FY27 LTVR grant for these reasons. Approval of Resolution 4 under Listing Rule 10.14 will also result in any Rights the subject of this resolution granted to Mr Horan being excepted from ASX Listing Rule 7.1. This means
16
that any Rights the subject of this resolution granted to Mr Horan, and any new shares issued to Mr Horan in satisfaction of those Rights, will be excluded from the calculation of ACL’s annual 15 percent new security issue limit under ASX Listing Rule 7.1. In accordance with ASX Listing Rule 10.15, the features of the proposed FY27 LTVR invitations to apply for Performance Rights proposed to be issued to Mr Horan are summarised below. Capitalised terms used, but not defined in the table below, have the meaning given to them in the LTVR Plan (a copy of which was released to the ASX Market Announcements Platform on 14 May 2021). Aspect Instrument and entitlement
Details If Resolution 4 is approved by Shareholders, Mr Horan will be invited to apply for up to 359,850 Performance Rights. These Rights may vest when performance-based Vesting Conditions are satisfied (or otherwise waived in accordance with the Plan). The Rights are indeterminate Rights issued under the Plan, which are an entitlement to the value of a Share (less any Exercise Price), which may be settled either in cash and/or in Shares (at the Board’s discretion). Generally, it is expected that vested Rights will be settled in Shares (including Restricted Shares, which are Shares subject to a disposal restriction). The value that may be realised is a function of performance against Vesting Conditions and the market value of a Share at the time of sale of any Shares that result from exercising Rights. The type of equity security proposed to be granted to Mr Horan has been selected because the Board believes that it creates a strong link between performance and reward.
Variation of terms and conditions Term
To the extent permitted by the ASX Listing Rules, the Board retains the discretion to vary or amend the terms and conditions of the Plan.
Grant Date
If Shareholder approval is obtained for Resolution 4, the Rights will be granted as soon as practicable after the AGM (and are currently expected to be granted within one month of the AGM), but in any event, within three years of the AGM, and will have an effective grant date of 1 July 2026.
Number of Rights
It is proposed that Mr Horan will be invited to apply for three Tranches of Rights in relation to Resolution 4:
Each Right has a Term of five years from the anniversary of the date of the grant of the Right (Grant Date) and if not exercised within that Term, the Rights will lapse.
Tranche 1 – 118,751 Performance Rights with a relative total shareholder return (rTSR) Vesting Condition (nil Exercise Price);
Tranche 2 –118,751 Performance Rights with an earnings per share return (EPS) Vesting Condition (nil Exercise Price); and
Tranche 3 – 122,348 Performance Rights with a return on invested capital (ROIC) Vesting Condition (nil Exercise Price).
The number of Rights proposed to be granted to Mr Horan for FY27 was determined by dividing the dollar value of Mr Horan’s LTVR opportunity (being
17
100% of Mr Horan’s total fixed remuneration as at 1 July 2026) by the Volume Weighted Average Price (VWAP) of Shares over the 10 business day period from 18 August 2026 to 31 August 2026 (inclusive) being $2.8692 (the Issue Price). When added to the other remuneration elements, the FY27 grant of LTVR for Mr Horan will produce a total remuneration package that the Board believes is market competitive and appropriate given the Company’s circumstances for FY27, based on market benchmarking and the current ACL executive remuneration policy. Achievement at target performance levels will results in partial vesting, increasing up to a maximum of 100% vesting when stretch performance goals are achieved. It is therefore expected that a lesser percentage will actually vest unless exceptional performance outcomes occur. The actual value (if any) that Mr Horan will receive from the proposed FY27 LTVR grant cannot be determined until the end of the Measurement Period, and will depend on the extent to which the Vesting Conditions are achieved, the number of Performance Rights that vest in accordance with the Vesting Conditions and the ACL Share price at the time of vesting. The Board determined the value and form of Mr Horan’s FY27 LTVR award under the Plan in Performance Rights with regard to his overall remuneration package, the nature of his position, the purpose of the LTVR component in ACL’s remuneration strategy and independent benchmarking regarding current market practice. Measurement Period
The Measurement Period is the period over which Vesting Conditions are assessed. For each of Tranches 1, 2 and 3 of the Performance Rights, the Measurement Period will be three years from 1 July 2026 to 30 June 2029.
Gates
There are no gates applicable to the Performance Rights in addition to the metrics set out above.
Vesting Conditions
Vesting Conditions are conditions that are used to determine the extent, if any, of vesting of Performance Rights. For Tranche 1 (rTSR Performance Rights), the Vesting Condition will be based on the ranking of the Relative Total Shareholder Return (rTSR) of ACL over the Measurement Period compared to the TSR peer group (see note 2 below). The vesting scale for this performance vesting metric is as follows: Performance Level Below Target Target Target > Stretch Stretch
rTSR(1) compared to nominated Total Return comparator set(2) <50th Percentile =50th Percentile
50th Percentile and <75th Percentile = 75th Percentile
Vesting % of Tranche Nil 50% Pro-rata 100%
(1) Total Shareholder Return or TSR means the percentage change in the Company’s Share
18
price together with the value of dividends and distributions (assuming that all of those dividends and distributions are re-invested into new Shares as determined by the Board from time to time). Dividends relate to dividends with an ex-dividend date during the performance period. (2) The nominated Total Return comparator set is a bespoke basket of 12 healthcare service companies being Pro Medicus, Sonic Healthcare, Ramsay Health Care, Regis Healthcare, Nanosonics, Integral Diagnostics, Polynovo, Cogstate, Oceania Healthcare, Healius, Monash IVF and Paragon Care. Companies primarily exposed to biotechnology, medical devices, pharmaceuticals or healthcare technology have been excluded on the basis that their valuation drivers, risk profiles and capital intensity are materially different from ACL’s core healthcare services model.
The vesting scale for Tranche 2 (EPS) is as follows: 3Y EPS Growth (CAGR)
% Vesting
Below Threshold
<4%
Nil
Threshold
=4%
25%
Threshold > Stretch
4% and <8%
Pro-rata
Stretch
=8%
100%
The Board reserves the discretion to vary the EPS growth condition should regulatory pricing decisions vary materially from ACL’s forecasts. The vesting scale for the first year of Tranche 3 (ROIC) for FY27 is as follows: Y1 ROIC
% Vesting
Below Threshold
21%
Nil
Threshold
=21%
25%
Threshold > Stretch
21% and <26%
Pro-rata
Stretch
=26%
100%
The ROIC hurdles will be reviewed and set by the Board annually in line with budgets and capex requirements during the performance period, to ensure that the incentive framework delivers value for shareholders and appropriately reflects the investment of capital in the business and the timing of returns for those investments. The targets for FY28 and FY29 and performance against the targets will be disclosed retrospectively in the 2029 Remuneration Report. Acquisition price and Exercise Price
No amount is payable by Mr Horan for the Rights as their value forms a significant portion of the variable remuneration in his total remuneration package for FY27. The Exercise Price for the Rights is nil.
Exercise of vested Rights
Vested Rights may be exercised by the Participant submitting an Exercise Notice at any time between the Vesting Date (or the latter elapsing of Exercise Restrictions, if applicable) and the end of their Term. Otherwise, these Rights will lapse. Rights may not be sold, transferred, mortgaged, charged or otherwise dealt with or encumbered, except by force of law.
Disposal restrictions
Shares acquired from the exercise of vested Rights will be subject to disposal restrictions due to:
19
Termination of Employment
the Company’s securities trading policy; and
the insider trading provisions of the Corporations Act (Division 3 of Part 7.10).
In the case of a termination of employment: (a) unvested Rights will be forfeited, unless and to the extent otherwise determined by the Board in its discretion; (b) vested Rights subject to Exercise Restrictions will cease to be subject to Exercise Restrictions; and (c) vested Rights will lapse if not exercised within 21 days of the date of cessation of employment with the Group.
Change of Control
In the event of a Change of Control, unvested Rights will vest in the proportion that the elapsed portion of the Measurement Period bears to the full Measurement Period. The Board, in its discretion, may determine that none, some or all of the remaining unvested Rights also vest. Any Rights that remain unvested following exercise of the Board’s discretion will lapse.
Major return of capital or demerger
In the event that the Board forms the view that a major part of the Company’s assets or operations will imminently cease to be owned by the Group due to an intention to sell or separately list those assets or operations, or in the event of a major return of capital to Shareholders; (a) unvested Rights will either vest to the extent determined by the Board, with the remainder lapsing, or the Board will adjust the number and vesting conditions of Rights held so that Participants are neither advantaged nor disadvantaged by the return of capital or demerger, and (b) Restricted Rights will cease to be subject to Exercise Restrictions prior to the return of capital or demerger, on the date determined by the Board.
Board discretion to prevent inappropriate benefits, fraud and misconduct
The Board has discretion to adjust the number of Rights that ultimately vest if it forms the view that the unadjusted outcome is not appropriate to the circumstances that prevailed over the Measurement Period and/or to the contribution of a Participant to outcomes over the Measurement Period. The Board has sole discretion to determine that some or all unvested Rights held by a Participant lapse on a specified date, if allowing the Rights to be retained would, in the opinion of the Board, result in an inappropriate benefit to the Participant. Such circumstances include joining a competitor or actions that harm the Company’s stakeholders. In the case of fraud or misconduct, the Participant will forfeit all unvested Rights.
Bonus issues, rights issues, voting and dividend entitlements
In cases of bonus share issues by the Company, the number of Rights held by a Participant shall be increased by the same number as the number of bonus shares that would have been received by the Participant had the Rights been Shares, except in the case that the bonus share issue is in lieu of a dividend payment, in which case no adjustment will apply. Rights do not carry voting or dividend entitlements. Shares (including
20
Restricted Shares) issued when Rights are exercised carry all entitlements of Shares, including voting and dividend entitlements. Quotation
Rights will not be quoted on the ASX. The Company will apply for official quotation of any Shares issued under the Plan, in accordance with the ASX Listing Rules.
Hedging
The Company prohibits the hedging of Rights or Shares subject to disposal restrictions by Mr Horan.
Other details
Further information in accordance with ASX Listing Rule 10.15:
Mr Horan is the only person both subject to ASX Listing Rule 10.14 and entitled to participate in the Plan, as at the date of the preparation of this Notice of Meeting;
No Performance Rights have been previously issued to Mr Horan.
Mr Horan’s current total remuneration package (for FY27) is set out in the Annual Report and is as set out below: o
base remuneration for FY27 of $1,000,000 plus superannuation;
o
a short-term variable incentive which the Board currently values as follows:
o
at Target - $516,250 (being 50% of base remuneration); and
at Stretch - $722,750 (being 70% of base remuneration salary); and
LTVR, which the Board currently values as follows:
at Target – $688,333 (being 239,900 Rights multiplied by the Issue Price); and
at Stretch – $1,032,500 (being 359,850 Rights multiplied by the Issue Price).
Mr Horan’s total remuneration package at LTVR Threshold is therefore currently valued at $2,237,083 at Target and $2,787,750 at Stretch;
no loans have been, or will be, provided by the Company in relation to the grant or exercise of the Performance Rights proposed to be provided to Mr Horan;
details of any securities issued under the Plan will be published in the Company’s annual report relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14;
any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of securities under the Plan after this
21
Resolution 4 is approved and who are not named in this Notice will not participate until approval is obtained under ASX Listing Rule 10.14; and
a voting exclusion applies to Resolution 4, as set out in the Notice of Meeting.
The Directors (with Mr Horan abstaining) unanimously recommend that Shareholders vote in favour of Resolution 4. The Chair of the AGM intends to vote all available proxies in favour or Resolution 4. Resolution 5: Reinsertion of the Proportional Takeover Provisions in the Constitution Rule 14 of the Company’s Constitution contains Proportional Takeover Provisions that prohibit the Company from registering a transfer of its shares under a proportional takeover bid, unless and until the bid is approved via ordinary resolution passed by Shareholders entitled to vote on that resolution in a general meeting (or is otherwise taken to have been passed). Under the Corporations Act, proportional takeover approval provisions expire three years from adoption or renewal. Once the three year period has elapsed, those provisions cease to have effect unless shareholders approve their renewal. The renewal approval must be by special resolution, meaning that at least 75% of the votes cast by Shareholders entitled to vote on the resolution must be in favour of the resolution. If this special resolution is approved and a takeover bid is subsequently made for some but not all of each Shareholder’s shares, the Proportional Takeover Provisions will enable Shareholders entitled to vote on the resolution to vote on whether the proportional bid should be allowed to proceed, independently from their individual decisions as to whether or not to accept the bid. The Proportional Takeover Provisions were contained in the Constitution that was adopted by the Company as part of its admission to the Official List of the ASX on 14 May 2021 and expired on 23 October 2026. Resolution 5 therefore seeks to re-insert the Proportional Takeover Provisions in identical terms for a period of 3 years from the date of the AGM (being 28 October 2026). If the proposed resolution is approved by Shareholders, the Proportional Takeover Provisions will be reinserted into the Constitution and have effect on exactly the same terms as the existing provisions until 28 October 2029. Further detail in relation to Resolution 5 (in accordance with the requirements of the Corporations Act) is set out below. What is a proportional takeover bid and why do we need Proportional Takeover Provisions? A proportional takeover bid (also referred to as a partial takeover bid) involves the bidder offering to buy a proportion only of each Shareholder’s shares in the Company. This means that control of the Company may pass without Shareholders having the chance to sell all their shares to the bidder. It also means that the bidder may take control of the Company without paying an adequate amount for gaining control. In order to deal with this possibility, the Company may provide in its Constitution that:
in the event of a proportional takeover bid being made for shares in the Company, Shareholders are required to vote by ordinary resolution and collectively decide whether to accept or reject the offer; and
the majority decision of the Company’s Shareholders will be binding on all the Shareholders.
22
The Board considers that Shareholders should be able to vote on whether a proportional takeover bid should proceed. Such a bid might otherwise allow control of the Company to change without Shareholders being given the opportunity to dispose of all their shares for a satisfactory control premium. The Board also believes that the right to vote on a proportional takeover bid may avoid Shareholders feeling pressure to accept the bid even if they do not want it to succeed. What is the effect of the Proportional Takeover Provisions? If a proportional takeover bid is made, the Directors must ensure that Shareholders vote on a resolution to approve the bid more than 14 days before the last day of the bid period. The vote is decided on a simple majority. Each person who, as at the end of the day on which the first offer under the bid was made, held bid class securities is entitled to vote on the resolution, except for the bidder and any associates of the bidder (who are not entitled to vote on the resolution). If the resolution is not passed, transfers which would have resulted from the acceptance of the proportional takeover bid will not be registered and the bid will be taken to have been withdrawn. If the bid is approved (or taken to have been approved), the transfers must be registered if they comply with the Corporations Act and the Company’s Constitution. The Directors will breach the Corporations Act if they fail to ensure the approving resolution is voted on before the approving resolution deadline. However, if the resolution is not voted on as at the end of the day before the approving resolution deadline, the bid will be taken to have been approved. The Proportional Takeover Provisions do not apply to full takeover bids and will only apply for three years after the date of adoption or renewal of these provisions. The provisions may be renewed again, but only by a special resolution. Similar provisions are commonly found in the constitutions of publicly listed companies on the ASX and are regularly renewed. Potential advantages and disadvantages The renewal of the Proportional Takeover Provisions will allow the Directors to ascertain Shareholders’ views on a proportional takeover bid. The Proportional Takeover Provisions do not otherwise offer any advantage or disadvantage to the Directors who remain free to make their own recommendation as to whether an offer under a proportional takeover bid should be accepted. The potential advantages of the Proportional Takeover Provisions for Shareholders of the Company include:
Shareholders will have an opportunity to study a proportional takeover bid proposal and decide by majority vote whether an offer under a proportional takeover bid should proceed; the provisions may help Shareholders avoid being locked in as a minority; the provisions may ensure that a potential bidder structures its offer in a way which is attractive to a majority of Shareholders, including appropriate pricing; and knowing the view of the majority of Shareholders may help individual Shareholders assess the likely outcome of the proportional takeover when determining whether to accept or reject the offer.
The potential disadvantages of the Proportional Takeover Provisions for Shareholders of the Company include:
23
the provisions may discourage proportional takeover bids for shares in the Company; the provisions may reduce any speculative element in the market price of the Company's shares arising from the possibility of a takeover offer being made; the provisions may be considered to constitute an unwarranted additional restriction on the ability of Shareholders to freely deal with their shares; and the chance of a proportional takeover bid being successful may be reduced.
The Board considers that the potential advantages for Shareholders of the Proportional Takeover Provisions outweigh the potential disadvantages. There have been no full or proportional takeover bids for the Company in the period during which the Proportional Takeover Provisions have been in effect. Therefore, there has been no example against which to review the advantages or disadvantages of the provisions for the Directors and Shareholders, respectively, during this period. As at the date that this explanatory memorandum was prepared, no Director is aware of a proposal by a person to acquire, or to increase the extent of, a substantial interest in the Company. The Board unanimously recommends that Shareholders vote in favour of Resolution 5. Resolution 6: Appointment of Deloitte as new auditor Pitcher Partners has been the Company’s auditor for more than 10 years. The Company’s Audit and Risk Committee therefore considered that it was good corporate governance to put the Company’s audit services to tender and to seek proposals from a number of providers. As a result of that tender process, the Board resolved to appoint Deloitte as its new auditor. The Board thanks Pitcher Partners for the services they have provided to the Company. Section 328B(1) of the Corporations Act requires that written notice of nomination of a new auditor be received from a member of the Company. The Company has received such a nomination from Mark Haberlin, the Chair of the Audit and Risk Committee, in his capacity as a Shareholder of the Company. A copy of the nomination is set out in Annexure A. Pitcher Partners has tendered a notice of resignation to ASIC under section 329(5) Corporations Act 2001 and Deloitte has given its written consent to act as the new Company auditor. If Resolution 6 is passed, the appointment of Deloitte as the Company’s new auditor will take effect at the close of the AGM. Subject to ASIC’s consent to the resignation of Pitcher Partners, the Board unanimously recommends that Shareholders vote in favour of Resolution 6. If ASIC does not consent to the current auditor’s resignation, Pitcher Partners will continue to the Company’s auditor and Resolution 6 will not be put to the meeting. If Resolution 6 is put to the meeting and is not passed, the Company will need to appoint a new auditor other than Deloitte. The Chair intends to vote undirected proxies in favour of Resolution 6.
24
GLOSSARY AGM or Annual General Meeting means the annual general meeting convened by this Notice. AGM Online Platform means the online platform used to hold the AGM accessible at https://meetings.openbriefing.com/ACL26 Annual Report means the annual report of ACL for the year ended 30 June 2026. ASX means ASX Limited (ACN 008 624 691) or, as the context requires, the financial market operated by it. Auditor’s Report means the auditor’s report for the Company for the year ended 30 June 2026 as contained in the Annual Report. Board means the board of Directors. Chair means the person appointed to chair the Company’s meeting. Closely Related Party has the meaning given to that term in section 9 of the Corporations Act. Company or ACL means Australian Clinical Labs Limited (ACN 645 711 128). Constitution means the constitution of the Company. Corporations Act means the Corporations Act 2001 (Cth). Directors means the directors of the Company and Director means any one of them. Directors’ Report means the directors’ report for the Company for the year ended 30 June 2026 as contained in the Annual Report. EPS means earnings per share. FY26 and FY27 means the financial years ending 30 June 2026 and 30 June 2027 respectively. Glossary means this glossary. KMP means people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) who are identified in the Remuneration Report. KPI means key performance indicator. Listing Rule or ASX Listing Rule means the official listing rules of ASX. LTVR means long-term variable remuneration. LTVR Plan or Plan means the Company’s long-term variable remuneration plan.
25
Notice or Notice of Meeting means this notice of annual general meeting. Remuneration Report means the remuneration report for the Company for the year ended 30 June 2026, as contained in the Annual Report. Resolution means a resolution set out in this Notice. ROIC means return on invested capital. rTSR means relative total shareholder return. Share means a fully paid ordinary share of the Company. Shareholder means a holder of at least one Share. STVR means short term variable remuneration.
26
Annexure A – Letter of Nomination Mr Mark Haberlin c/o Australian Clinical Labs Limited 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
The Company Secretary Australian Clinical Labs Limited ABN 94 645 711 128 1868-1892 Dandenong Road Clayton VIC 3168 Australia 14 September 2026
Dear Eleanor Notice of Nomination of Auditor in accordance with section 328B(1) of the Corporations Act 2001 (Cth) I, Mark Haberlin, being a shareholder of Australian Clinical Labs Limited (Company) nominate Deloitte Touche Tohmatsu of Level 31, 477 Collins Street, Melbourne for appointment to the position of auditor of the Company at the next annual general meeting. I consent to the distribution of this notice of nomination as an attachment to the Notice of Meeting and Explanatory Memorandum for the 2026 annual general meeting for the purposes of section 328B(3) Corporations Act 2001. Yours sincerely
Mark Haberlin Shareholder and non-executive director
Page 1 of 1
Notice of ceasing to be a substantial holder To:
Australian Clinical Labs Ltd (“ACL”, Ordinary Fully Paid)
Details of substantial shareholder
Form 605 Corporations Act Section 671B
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) and each of the related bodies corporate in the Citi group of companies worldwide (for more details please visit www.citigroup.com). The holder ceased being a substantial holder on 8 October 2026. The previous notice had been given to the company on 9 October 2026. 2.
Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change
8 October 2026
8 October 2026
Person whose relevant interest changed and Person’s votes affected
Nature of Relevant Interest
Class and number of securities affected
Citibank, N.A. Sydney Branch
Citibank, N.A. Sydney Branch holds a decreased relevant interest in these shares acting as Agent Lender and as the holder of securities subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
-589,276 Ordinary Fully Paid
Citigroup Global Markets Australia Pty Limited
Citigroup Global Markets Australia Pty Limited holds an increased relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement and pursuant to contracts entered into in the ordinary course of business on a stock market of a stock exchange, containing no terms and conditions other than standard terms and conditions. Refer to Annexure A.
135 Ordinary Fully Paid
Changes in association The persons who have become associates of, ceased to be associates of, or have changed the nature of their association with, the substantial holder in relation to voting interests in the company or scheme are as follows:
Name and ACN/ARSN (if applicable) N/A 4.
Nature of association N/A
Addresses The addresses of persons named in this form are as follows: Name
Address
Citibank, N.A. Sydney Branch
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Australia Pty Limited
Two Park 2 Park St Sydney, NSW 2000 Australia
Dated this day, 12 October 2026. Cynthia Yu Citigroup Global Markets Australia Pty Limited T: +61 2 8225 2489
Annexure A This is Annexure A of 2 pages referred to in Form 605 ‘Notice of ceasing to be a substantial holder’ Schedule (Loan) Type of Agreement
AMSLA / GMSLA / MSLA
Parties to Agreement
Various
Transfer date
Various
Holder of voting rights
Borrower
Are there any restrictions on voting rights?
No
Scheduled return date
Unknown
Does the borrower have the right to return early? If yes, details
Yes
Does the lender have the right to recall early? If yes, details
Yes
Will the securities be returned on settlement?
n/a
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the AMSLA / GMSLA / MSLA to the company or ASIC.
Standard AMSLA / GMSLA / MSLA terms
Standard AMSLA / GMSLA / MSLA terms
Schedule (Agency Lending Agreement) Type of Agreement
Securities Lending Agency Agreement (SLAA)
Parties to Agreement
Various
Circumstances under which the agent lender can exercise the authorisations in relation to the securities
Agent Lender can only exercise authority, as agent, in relation to the lender’s securities as defined and agreed in the Securities Lending Agency Agreement.
Circumstances under which the agent lender is subject to any restrictions in how it can deal with the securities
Lenders will define the restrictions and/or securities lending parameters in the Securities Lending Agency Agreement entered into with the lending agent. Such restrictions/parameters include specific designated accounts, lendable limits, acceptable collateral and/or cash reinvestment guidelines.
Does the agent lender have the right to recall early?
If yes, details
Statement
Agent Lenders have the right to early recall on behalf of Lender’s instructions. However, the expectation is the Lender and Borrower would have mutually agreed no sales/recall of the securities during the duration of the loan term. Hence, borrowers are not obligated to return the securities early for termed loans. Authorised under the standard Securities Lending Agency Agreement terms. If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the authorisation agreement to the company or ASIC.
Form 603 Corporations Act Section 671B
Notice of initial substantial shareholder To:
Australian Clinical Labs Ltd (“ACL”, Ordinary Fully Paid)
Details of substantial shareholder Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) and each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com). The holder became a substantial holder on 7 October 2026.
Details of voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate had a relevant interest in on the date the substantial holder became a substantial holder are as follows:
Class of securities
Number of securities
Ordinary Fully Paid
9,550,565
Person’s vote 9,550,565
Voting Power 5.1204%
Details of relevant interests Holder of relevant interest
Nature of relevant interest
Class and number of securities
Citibank, N.A. Sydney Branch
Citibank, N.A. Sydney Branch holds a relevant interest in these shares acting as Agent Lender and as the holder of securities subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
2,719,726 Ordinary Fully Paid
Citigroup Global Markets Australia Pty Limited
Citigroup Global Markets Australia Pty Limited holds a relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement and pursuant to contracts entered into in the ordinary course of business on a stock market of a stock exchange, containing no terms and conditions other than standard terms and conditions. Refer to Annexure A.
155,334 Ordinary Fully Paid
Citigroup Global Markets Limited
Citigroup Global Markets Limited holds a relevant interest in these shares pursuant to contracts entered into subject to an obligation to return under a securities lending agreement. Refer to Annexure A.
6,675,505 Ordinary Fully Paid
Details of present registered holders The persons registered as holders of the securities referred to in paragraph 3 above are as follows: Holder of relevant interest
Registered holder of securities
Class and number of securities 2,719,726 Ordinary Fully Paid
Citibank, N.A. Sydney Branch
Various
Citigroup Global Markets Australia Pty Limited
Citicorp Nominees Pty Limited
155,334 Ordinary Fully Paid
Citigroup Global Markets Limited
Citicorp Nominees Pty Limited
6,675,505 Ordinary Fully Paid
Consideration The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:
Holder of relevant interest
Date of acquisition
Consideration
Class and number of securities
Citibank, N.A. Sydney Branch
Various
Various (Refer Annexure A)
2,719,726 Ordinary Fully Paid
Citigroup Global Markets Australia Pty Limited
Various
Various (Refer Annexure A)
155,334 Ordinary Fully Paid
Citigroup Global Markets Limited
Various
Various (Refer Annexure A)
6,675,505 Ordinary Fully Paid
Associates The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows: Name and ACN/ARSN (if applicable)
Citibank, N.A. Sydney Branch
Nature of association Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Citigroup Global Markets Australia Pty Limited
Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Citigroup Global Markets Limited
Each of the related bodies corporate in the Citigroup group of companies worldwide (for more details please visit www.citigroup.com).
Addresses The addresses of persons named in this form are as follows: Name
Address
Citibank, N.A. Sydney Branch
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Australia Pty Limited
Two Park 2 Park St Sydney, NSW 2000 Australia
Citigroup Global Markets Limited
Citigroup Centre, Canary Wharf 33 Canada Square London, E14 5LB, United Kingdom
Dated this day, 9 October 2026. Ji Hyun Kim Citigroup Global Markets Australia Pty Limited T: +61 2 8225 2489
Annexure A This is Annexure A of 2 pages referred to in Form 603 ‘Notice of initial substantial holder’ Schedule (Loan) Type of Agreement
AMSLA / GMSLA / MSLA
Parties to Agreement
Various
Transfer date
Various
Holder of voting rights
Borrower
Are there any restrictions on voting rights?
No
Scheduled return date
Unknown
Does the borrower have the right to return early? If yes, details
Yes
Does the lender have the right to recall early? If yes, details
Yes
Will the securities be returned on settlement?
n/a
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the AMSLA / GMSLA / MSLA to the company or ASIC.
Standard AMSLA / GMSLA / MSLA terms
Standard AMSLA / GMSLA / MSLA terms
Schedule (Agency Lending Agreement) Type of Agreement
Securities Lending Agency Agreement (SLAA)
Parties to Agreement
Various
Circumstances under which the agent lender can exercise the authorisations in relation to the securities
Agent Lender can only exercise authority, as agent, in relation to the lender’s securities as defined and agreed in the Securities Lending Agency Agreement.
Circumstances under which the agent lender is subject to any restrictions in how it can deal with the securities
Lenders will define the restrictions and/or securities lending parameters in the Securities Lending Agency Agreement entered into with the lending agent. Such restrictions/parameters include specific designated accounts, lendable limits, acceptable collateral and/or cash reinvestment guidelines.
Does the agent lender have the right to recall early?
If yes, details
Statement
Agent Lenders have the right to early recall on behalf of Lender’s instructions. However, the expectation is the Lender and Borrower would have mutually agreed no sales/recall of the securities during the duration of the loan term. Hence, borrowers are not obligated to return the securities early for termed loans. Authorised under the standard Securities Lending Agency Agreement terms. If requested by the company to whom the prescribed form must be given, or if requested by ASIC, Citi will give a copy of the authorisation agreement to the company or ASIC.
Australia Clinical Labs Limited (ACL or Company) wishes to notify the market in accordance with ASX Listing Rule 3.16.3 that Deloitte Touche Tohmatsu (Deloitte) has been appointed auditor of the Company with effect from 28 October 2026 and the conclusion of the Company’s AGM. This appointment follows the Company receiving notice of the resignation of Pitcher Partners as auditors and the receipt of ASIC’s consent to their resignation. Pitcher Partners has been the Company’s auditor for more than 10 years. The Company’s Audit and Risk Committee therefore considered that it was good corporate governance to put the Company’s audit services to tender and to seek proposals from a number of providers. As a result of that tender process, the Board resolved to appoint Deloitte as its new auditor. The Board sincerely thanks Pitcher Partners for the services they have provided to the Company. In accordance with section 327B(1) Corporations Act 2001, a resolution will be put to shareholders at the AGM to approve the appointment of Deloitte. A notice of meeting has been sent to shareholders and is available on ACL’s website here.
– ENDS – This announcement was authorised for release to ASX by the Company Secretary of ACL. For further information regarding this announcement, please contact:
Investor Relations Matthew Cordingley Chief Financial Officer Email: [email protected] Phone: +61 (0) 409 287 681
Page 1 of 1 Australian Clinical Labs Limited ABN 94 645 711 128
Governance Eleanor Padman Company Secretary Email: [email protected] Phone: +61 (0) 422 002 918
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
Tuesday 22 September 2026 Australian Clinical Labs Limited - 2026 Annual General Meeting
The following announcements to the market are provided: ✓
AGM Notice of Meeting
✓
Proxy Form
✓ Online Guide from Link Market Services Australian Clinical Labs Limited 2026 Annual Report (including the 2026 Corporate Governance Statement and 2026 Sustainability Report) Appendix 4G
– ENDS – This announcement was authorised for release to ASX by the Company Secretary. For further information regarding this announcement, please contact: Company Secretary Eleanor Padman Company Secretary Email: [email protected] Phone: +61 (0) 422 002 918 About Australian Clinical Labs
ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients’ lives.
Page 1 of 1
Australian Clinical Labs Limited ABN 94 645 711 128 clinicallabs.com.au
NOTICE OF ANNUAL GENERAL MEETING 2026 On Wednesday, 28 October 2026 at 2pm AEDT
Dear Shareholders It is my pleasure to invite you to attend the 2026 annual general meeting (AGM) of Australian Clinical Labs Limited (ACL or Company), to be held online as a virtual meeting on Wednesday, 28 October 2026 at 2pm AEDT. This will be the Company’s sixth AGM following its admission to the ASX on 14 May 2021. To facilitate as many Shareholders joining us as possible, the Board has determined that the AGM will be held as a virtual meeting online. This means that there will not be a physical venue for Shareholders to attend in person. Instead, the AGM will be webcast and Shareholders and their proxies, corporate representatives and attorneys will be able to attend and participate virtually through the AGM Online Platform. Full details of how to join the meeting virtually are contained in the Online Platform Guide which has been lodged with ASX and posted on ACL’s website at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/. Registration will take place online and will commence at 1.30pm AEDT on Wednesday, 28 October 2026 at https://meetings.openbriefing.com/ACL26. The items for consideration at this year’s AGM are:
- The consideration of ACL’s financial statements and statutory reports for the financial year ended 30 June 2026;
- The adoption of ACL’s Remuneration Report for the financial year ended 30 June 2026;
- The re-election of Dr Amandeep Hansra as a non-executive Director;
- The re-election of Ms Christine Bartlett as a non-executive Director;
- The approval of the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Executive Director of the Company, as part of his long-term variable remuneration for the period ending 30 June 2027;
- The renewal of the Proportional Takeover Provisions in the Constitution; and
- The appointment of Deloitte as new auditors to the Company. The Board recommends that Shareholders vote in favour of all items of business. Enclosed is a copy of the Notice of Meeting which includes information for Shareholders and explanatory notes. These documents can also be accessed on our website at https://investors.clinicallabs.com.au/investor-information/annual-general-meetings/. If you are unable to attend the AGM online through the AGM Online Platform, you may (and are encouraged to) appoint a proxy to attend and vote on your behalf. Proxy appointments must be received by no later than 2pm AEDT on Monday, 26 October 2026. Proxy appointments can be made either via our share registry – https://au.investorcentre.mpms.mufg.com – or by following the instructions contained in the Notice of Meeting. Even if you plan to attend the AGM online, you may wish to submit a directed proxy vote so that your vote will be counted if for any reason you cannot attend (for example, if you have difficulties with your internet connection on the day of the meeting). We also invite you to submit questions to the Company or auditor in advance of the meeting through our share registry – https://au.investorcentre.mpms.mufg.com – or by emailing us at [email protected] Questions must be received by no later than 5pm AEDT
2
on Wednesday, 21 October 2026. I look forward to welcoming you to the AGM.
Stephen Roche Chair 22 September 2026
3
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the 6th Annual General Meeting of Australian Clinical Labs Limited will be held on: Date:
Wednesday, 28 October 2026
Time:
2pm AEDT
Place:
To be held online (as a virtual annual general meeting)
Webcast:
Shareholders and their proxyholders, corporate representatives and attorneys can register, view and participate in the meeting at https://meetings.openbriefing.com/ACL26. Online registration will open at 1.30pm AEDT on Wednesday, 28 October 2026. Further information on how to join the meeting virtually are set out in the Online Platform Guide which is available at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/
Words that are defined in the Glossary have the same meaning when used in this Notice unless the context requires, or the definitions in the Glossary provide, otherwise.
Ordinary Business Financial statements and reports To receive and consider the financial statements, the Directors’ Report and the Auditor’s Report of the Company for the financial year ended 30 June 2026. Note: No resolution is required for this item of business. Resolution 1: Adoption of the Remuneration Report To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report of the Company for the financial year ended 30 June 2026 as disclosed in the Directors’ Report be adopted.” In accordance with section 250R(3) of the Corporations Act, the vote on Resolution 2 will be advisory only and will not bind the Directors or the Company. Voting exclusion for Resolution 1: In accordance with the Corporations Act, a vote on Resolution 1 must not be cast, and the Company will disregard any votes cast on Resolution 1: (a)
by or on behalf of a member of the KMP, whose remuneration details are included in the Remuneration Report and/or any Closely Related Party of such a member, regardless of the capacity in which the vote is cast; or
4
(b)
as proxy by any person who is a member of the KMP as at the time Resolution 1 is voted on at the meeting or a Closely Related Party of such a member,
unless the vote is cast as proxy for a person otherwise entitled to vote on Resolution 1: (c)
in accordance with the express direction of the appointer; or
(d)
by the Chair where the proxy appointment does not specify the way the proxy is to vote on Resolution 1 and expressly authorises the Chair to exercise the proxy in respect of Resolution 1 even though the resolution is connected directly or indirectly with the remuneration of a member of the KMP.
Resolution 2 : Re-election of Dr Amandeep Hansra as a Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That Dr Amandeep Hansra, having been appointed by the Board as a Director on 1 July 2026 to fill a casual vacancy under rule 6.1(d) of the Company’s Constitution and retiring as a Director of the Company for the purposes of ASX Listing Rule 14.4 and rule 6.1(e) of the Company’s Constitution and who has consented to stand for re-election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.” Resolution 3: Re-election of Ms Christine Bartlett as a Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That Ms Christine Bartlett, retiring as a Director of the Company in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution and who has consented to stand for re- election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.”
Resolution 4: Approval of grant and issue of Performance Rights to Mr Greg Horan To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That approval be given for the purposes of ASX Listing Rule 10.14, and for all other purposes, for the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Executive Director of the Company, in relation to his LTVR for FY27, in accordance with the LTVR Plan and on the terms and conditions described in the explanatory memorandum accompanying this Notice of Meeting.” Voting exclusion for Resolution 4 In accordance with the ASX Listing Rules, the Company will disregard any votes cast on Resolution 4 by or on behalf of Mr Horan (who is a person referred to in ASX Listing Rule 10.14.1 who is eligible to participate in the LTVR Plan) or any of his Associates, regardless of the capacity in which the vote is cast. However, this voting exclusion does not apply to a vote cast in favour of Resolution 4 by: 5
(a)
a person as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with the directions given to the proxy or attorney to vote on Resolution 4 in that way; or
(b)
the Chair as proxy or attorney for a person who is entitled to vote on Resolution 4, in accordance with a direction given to the Chair to vote on Resolution 4 as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: •
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an Associate of a person excluded from voting, on Resolution 4; and
•
the holder votes on Resolution 4 in accordance with directions given by the beneficiary to the holder to vote in that way.
The Company will also disregard any votes cast on Resolution 4 by or on behalf of any person who is a member of KMP as at the time the resolution is voted on at the meeting, or any of their Closely Related Parties, as a proxy. However, the Company will not disregard the vote of such a person on the resolution if the vote is cast by the person: (a)
as a proxy for a person otherwise entitled to vote on Resolution 4 and the vote is in accordance with the appointor’s express direction; or
(b)
the person is the Chair who has been validly appointed as a proxy for a person otherwise entitled to vote on Resolution 4 and the appointment of the Chair as proxy: •
does not specify the way the proxy is to vote on Resolution 4; and
•
expressly authorises the Chair to exercise the proxy in respect of Resolution 5 even though Resolution 4 is connected directly or indirectly with the remuneration of a member of KMP.
Resolution 5: Reinsertion of the Proportional Takeover Provisions in the Constitution To consider and, if thought fit, to pass the following resolution as a special resolution: “That the Proportional Takeover Provisions contained in rule 14 of the Company’s Constitution, having expired on 22 October 2026, be reinserted for a period of three years commencing on the date this resolution is passed”. Resolution 6: Appointment of Deloitte as new auditor To consider and, if thought fit, to pass the following resolution: “That, for the purposes of sections 327B(1) Corporations Act 2001 and for all other purposes, Deloitte Touche Tohmatsu, having been nominated by a shareholder pursuant to section 328B Corporations Act 2001, and being qualified and having consented in writing to act as to auditor of the Company pursuant to section 328A Corporations Act 2001, be appointed as auditor of the Company to hold office from the
6
conclusion of the Company’s 2026 AGM on 28 October 2026 until the date of its resignation or removal from the office of auditor the Company ” By order of the Board
Eleanor Padman Company Secretary 22 September 2026
7
INFORMATION FOR SHAREHOLDERS
Who may vote?
In accordance with regulation 7.11.37 of the Corporations Regulations 2001 (Cth), the Company has determined that persons whose names are set out in the register of shareholders of the Company as at 7pm AEDT on 26 October 2026 are entitled to vote at the AGM (subject to the applicable voting exclusions set out above).
How will voting be conducted?
In accordance with the Treasury Laws Amendment (2021 Measures No. 1) Act 2021 (Cth), the Chair will put all Resolutions to a poll at the AGM. Voting results on the Resolutions that are put to the meeting (including by proxy votes) will be announced to the ASX as soon as practicable following the conclusion of the AGM.
How can I vote at the meeting?
Shareholders can vote at the meeting by:
casting a live vote during the meeting (through the AGM Online Platform); or
by appointing a proxy (see below).
Shareholders or their attorneys wishing to vote in person should attend the meeting (via the AGM Online Platform) and can vote through the AGM Online Platform. How do I appoint a proxy?
A Shareholder who is entitled to vote at the meeting has a right to appoint up to two proxies to attend and vote for the Shareholder at the AGM. A proxy need not be a Shareholder. A proxy may be an individual or a body corporate. Where a Shareholder appoints two proxies, the appointment should specify the proportion or number of votes which each proxy may exercise. Fractions of votes will be disregarded. If the appointment does not specify the proportion or number of the Shareholders’ votes each proxy may exercise, then each proxy may exercise half those votes. A proxy may decide whether or not to vote on any proposed resolution, except where required by law or the Company’s Constitution to vote, or abstain from voting, in his or her capacity as proxy. If the Shareholder appointing the proxy:
directs the proxy how to vote on a proposed resolution, then the proxy may vote on that resolution only in the way directed; or
does not direct the proxy how to vote on a proposed resolution, then the proxy may vote on that resolution as the proxy thinks fit, subject to any voting exclusions that apply to the proxy; or
8
directs the proxy to abstain, the proxy must not vote on the Shareholder’s behalf and any vote will not be counted.
If you appoint someone as a proxy (other than the Chair) and direct them how to vote, the Chair of the AGM must cast those votes on your behalf on a poll in accordance with your directions if your proxy does not do so. If you appoint the Chair of the AGM as your proxy (or if he is appointed by default) and no direction is provided in relation to a resolution, you will be expressly authorising the Chair to exercise your proxy as the Chair sees fit in relation to that resolution even if the resolution is connected directly or indirectly with the remuneration of the Company’s KMP. If you appoint a Director (other than the Chair) or another member of the Company’s KMP or their Closely Related Parties as your proxy, you must specify how they should vote on Resolutions 1 and 4 by completing the “For”, “Against” or “Abstain” boxes on the proxy form. If you do not, your proxy will not be able to exercise your vote for Resolutions 1 and 4. The Chair intends to vote all available (including undirected) proxies in favour of all Resolutions subject to the voting exclusions described above. In exceptional circumstances, the Chair’s intentions may change. If there is a change to how the Chair intends to vote undirected proxies, the Company will make an immediate announcement to ASX stating that fact and explaining the reasons for the change. The appointment of one or more duly appointed proxies will not preclude a Shareholder from attending this meeting and voting personally. If the Shareholder votes on a Resolution, the proxy must not vote as the member’s proxy on that Resolution. How do I appoint/lodge a proxy?
To be valid, a proxy form must be correctly completed and received, either online, by post or fax or hand delivery (as per the details below), by 2pm AEDT on Monday, 26 October 2026 (noting that hand deliveries will only be accepted during business hours (being Monday to Friday between 9:00am and 5:00pm), including any power of attorney or other authority under which it is signed. Any proxy form received after this time will not be valid. Proxies may be lodged as follows with the Company’s share registry by:
post or facsimile – completed proxy forms may be posted to Australian Clinical Labs Limited C/- MUFG Pension and Market Services Limited Locked Bag A14, SYDNEY SOUTH NSW 1235 or sent by facsimile to +61 2 9287 0309;
9
hand delivery at Australian Clinical Labs Limited C/MUFG Pension and Market Services, Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150 during business hours (being Monday to Friday between 9:00am and 5:00pm); or
lodging the proxy appointment online at https://au.investorcentre.mpms.mufg.com. To use this service, you will need your Securityholder Reference Number (SRN) or Holder Identification Number (HIN), or you can access the service using your postcode and the personalised link sent to you by email if you have registered for electronic communications from the Company.
Given changes to Australia Post’s services which may see mail take longer to arrive, the Company suggests that you allow additional time if you decide to send your completed proxy form by post. How do I appoint a corporate representative?
A Shareholder who is a body corporate and who is entitled to vote at the AGM, or a proxy who is a body corporate and who is appointed by a Shareholder who is entitled to vote at the AGM, may appoint a person to act as its representative at the AGM. The body corporate will need to ensure that it:
appoints an individual as its corporate representative to exercise its powers at meetings, in accordance with section 250D of the Corporations Act; and
provides satisfactory evidence of the appointment of its corporate representative prior to commencement of the meeting.
Body corporate representatives should lodge this documentation with the Company’s share registry by no later than 2pm AEDT on Monday, 26 October 2026, unless it has been previously given to the Company. Corporate Shareholders or proxies wishing to vote by corporate representative should:
I hold my shares jointly with another person. Are we both entitled to vote?
obtain an appointment of corporate representative form from MUFG Pension and Market Services; and
complete and send the form in accordance with the instructions on the form.
When joint holders are named in the register of members, only one joint holder may vote. If more than one of the joint holders is present at the meeting, only the person whose name appears first in the register of members will be entitled to vote. If more than one holder votes at the meeting, only the vote of the first named of the joint holders in the register of members
10
will be counted. How can I ask a question at the AGM?
In accordance with the Corporations Act, a reasonable opportunity will be given to Shareholders to ask questions about or to make comments upon the management of the Company (including in respect of the Remuneration Report) and the Resolutions at the meeting via the AGM Online Platform. Shareholders will have the opportunity to ask questions at the Meeting via the online portal at https://meetings.openbriefing.com/ACL26 More detailed information on how to ask questions during the meeting is provided in the Online Platform Guide available online at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/. The Company strongly encourages Shareholders to submit written questions in advance of the AGM. To submit a written question, please email the Company at [email protected] Alternatively, questions may be submitted by Shareholders logging into their account at https://au.investorcentre.mpms.mufg.com or by completing the question form provided to Shareholders with this Notice of Meeting. Questions must be received by no later than 5pm AEDT on Wednesday, 21 October 2026. Questions should relate to matters that are relevant to the business of the AGM, as outlined in this Notice and the explanatory memorandum. Questions that are relevant to the contents of the Auditor’s Report or the conduct of the audit of the Company’s financial report, may be addressed to the Company’s auditor, Pitcher Partners. Questions will be collated and, during the AGM, the Chair will seek to address as many of the more frequently raised topics as possible and, where appropriate, will give a representative of Pitcher Partners, the Company’s auditor, the opportunity to answer written questions submitted to the auditor. However, there may not be sufficient time available at the AGM to address all topics raised. Please note that individual responses will not be sent to Shareholders.
11
How I participate virtually?
Shareholders and proxyholders can watch, ask questions, make comments and vote in real time during the AGM (for those who are entitled to do so) through the AGM Online Platform at https://meetings.openbriefing.com/ACL26. Registration for attendance at the meeting will be online via the AGM Online Platform and will commence at 1.30pm AEDT on Wednesday, 28 October 2026 for those accessing the AGM Online Platform. To register, Shareholders will need their shareholder number and postcode. Proxyholders will need their proxy number which will be provided by MUFG Pension and Market Services following lodgement of the proxy appointment and no later than 24 hours prior to the meeting. We recommend that you register at least 30 minutes before the AGM and test to see that the AGM Online Platform works on your device before the commencement of the meeting. Further information can be found in the Online Platform Guide which is available at https://investors.clinicallabs.com.au/investorinformation/annual-general-meetings/.
What happens if there are technical difficulties?
Significant planning and testing has been undertaken and the online technology being used by the Company has been successfully used by other companies. However, unforeseen technical difficulties may still arise during the AGM. The Chair has discretion as to whether and how the meeting should proceed if a technical difficulty arises. In exercising his discretion, the Chair will have regard to the number of Shareholders impacted and the extent to which participation in the business of the meeting is affected. Where he considers it appropriate, the Chair may continue to hold the meeting and transact business, including conducting a poll and voting in accordance with valid proxy instructions. As previously noted, Shareholders are encouraged to lodge a proxy by 2pm AEDT on Monday, 26 October 2026 even if they plan to attend the meeting online via the AGM Online Platform.
What if there are changes to the meeting?
ACL will keep Shareholders informed if there are any changes to the meeting and details will be made available at https://investors.clinicallabs.com.au/, with any changes also notified by an ASX release.
12
ADDITIONAL INFORMATION FOR SHAREHOLDERS – ELECTRONIC COMMUNICATONS Following legislative changes to the Corporations Act in 2023, there are digital new options available to Shareholders for receiving communications from ACL. ACL will no longer be sending physical meeting documents unless you request a copy to be posted. ACL encourages all Shareholders to provide an email address so we can communicate with you electronically when Shareholder notices become available online, for items such as meeting documents and annual reports. Shareholders can still elect to receive some or all their communications in physical or electronic form, or elect not to receive certain documents such as annual reports. To review your communications preferences, or sign up to receive your Shareholder communications via email, please update your details by logging into your shareholding at https://au.investorcentre.mpms.mufg.com If you would like a physical copy of a communication, need further information about the options available to you or have questions about your holding, visit https://au.investorcentre.mpms.mufg.com or contact the Registry as follows: Australian Clinical Labs Limited C/- MUFG Pension and Market Services, Locked Bag A14, SYDNEY SOUTH NSW 1235 Telephone (within Australia): 1300 554 474 Telephone (outside Australia): +61 1300 554 474 Email: [email protected] Website: https://au.investorcentre.mpms.mufg.com
EXPLANATORY MEMORANDUM
This explanatory memorandum accompanies and forms part of, and should be read together with, the Notice. Financial statements and reports The financial report (which includes the financial statements), the Directors’ Report and the Auditor’s Report for the financial year ended 30 June 2026 will be put before the AGM, as required by section 317 of the Corporations Act. The Corporations Act does not require a formal resolution of Shareholders on these reports. These reports are contained in the Annual Report, which is available on the Company’s website at https://investors.clinicallabs.com.au/investor-information/reportspresentations/reports-presentations/ During this item of business, Shareholders will be given a reasonable opportunity to ask questions about, and to make comments on, those reports and the business and management of the Company.
13
Shareholders will also be given an opportunity to ask a representative of the Company’s auditor, Pitcher Partners, questions relevant to the conduct of the audit, the preparation and content of the Auditor’s Report, the accounting policies adopted by the Company in relation to the preparation of the financial reports and the independence of the auditor in relation to the conduct of the audit. Resolution 1: Adoption of the Remuneration Report Section 250R(2) of the Corporations Act requires publicly listed companies to put a resolution to shareholders to adopt the company’s remuneration report for the relevant financial year. Shareholders are asked to adopt the Remuneration Report. The Remuneration Report provides information relating to the details of the remuneration paid to KMP and Directors for the financial year ended 30 June 2026, the Company’s remuneration policy and the relationship between remuneration and the Company’s performance, including information about performance measures applicable to variable incentives. A copy of the Remuneration Report, which sets out remuneration arrangements for ACL can be found in the Company’s Annual Report. Under the Corporations Act, the vote on this resolution is advisory only and does not bind the Board or the Company. However, at its 2025 AGM, the Company received a second ‘strike’ on its remuneration report which provided it with important and consequential Shareholder feedback on its remuneration policy. In the 12 months since the 2025 AGM, the Company has consulted extensively with several Shareholders and other stakeholders to better understand the reasons for the second strike. As outlined in the Company’s Remuneration Report, the Company has responded to that feedback as follows:
the remuneration package of the incoming CEO, Greg Horan, was set in reference to relevant market capitalisation and industry peers, with a total remuneration package set at approximately 43% lower than his predecessor in the role.
in respect of the FY27 LTVR plan:
the 20% Service Right component has been removed and replaced with a new 34% ROIC metric;
the ROIC measure will be assessed against an annual ROIC target that has regard to the Board approved capex budget for each year (over a three year period) which will be disclosed retrospectively at vesting in the Remuneration Report;
the existing metrics of EPS and rTSR have been reweighted to 33% each to accommodate the ROIC metric;
the peer group for the rTSR metric will change from the ASX 300 (ex-financials and resources) to a bespoke index of 12 healthcare service companies with the intention of assessing ACL’s performance against a group of peers from more closely related sectors and with comparably regulated environments, workforce compositions and company models.
A voting exclusion applies to this resolution, as set out in the Notice of Meeting. Noting that each Director has a personal interest in his/her own remuneration from the Company, the Board unanimously recommends that Shareholders vote in favour of Resolution 1.
14
Resolution 2: Re-election of Dr Amandeep Hansra as a Director Dr Amandeep Hansra was appointed as a non-executive Director of ACL on 1 July 2026 to fill a casual vacancy and retires at this meeting in accordance with the casual vacancy rule under ASX Listing Rule 14.4 and rule 6.1(e) of the Company’s Constitution. Being eligible, Dr Hansra stands for re-election under rule 6.1(i) of the Company’s Constitution. Dr Hansra is a General Practitioner with more than 20 years clinical experience whose career has included clinical practice, national digital health leadership, government engagement and a number of board roles. In her executive career, Dr Hansra has held the roles of Chief Medical Officer with Telstra Health, Head of Clinical Innovation at NIB and Deputy Chief Medical Officer at the Department of Home Affairs. Dr Hansra has led national clinical governance frameworks across digital health, telehealth and technology-enabled care, including managing complex incidents and clinician engagement in emerging models of care. Dr Hansra remains committed to her GP practice as a Fellow of the Royal Australian College of General Practitioners and acts a Chief Clinical Advisor to the Australian Digital Health Agency. Dr Hansra is currently a non-executive director of Healthicare, ACHS International, MoleMap New Zealand, Healthengine and the Central and Eastern Sydney Primary Health Network. Dr Hansra also serves as a member of the Industry Growth Committee for the Department of Industry, Science and Resources. Dr Hansra holds a Bachelor of Medicine (Hons) from the University of Newcastle and a Masters of Public Health and Tropical Medicine from James Cook University. Dr Hansra also has a Global Executive MBA from the University of Sydney Business School and is a graduate of the AICD. The Board (with Dr Hansra abstaining) unanimously recommends that Shareholders vote in favour of Resolution 2. Resolution 3: Re-election of Ms Christine Bartlett Ms Christine Bartlett was appointed by Shareholders as a non-executive Director of ACL on 23 October 2023 and retires at this meeting in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution. Being eligible, Ms Bartlett stands for re-election under rule 6.1(i) of the Company’s Constitution. The proposed re-election of Ms Bartlett satisfies the Company’s obligations relating to the election and rotation of Directors under ASX Listing Rules 14.4 and 14.5 and ACL’s Constitution. Ms Bartlett is the Chair of ACL’s People and Culture Committee and is considered to be an independent director. Ms Bartlett is an experienced chief executive officer and senior executive, with extensive executive experience gained through roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Ms Bartlett has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies. Ms Bartlett is currently a non-executive director of Reliance Worldwide Corporation Limited, a non-executive director of Firmus Technologies Pty Ltd and is the Chair of CEDA and NSW Ports. Ms Bartlett is a member of Chief Executive Women and the Australian Institute of Company Directors. Christine holds a Bachelor of Science from the University of Sydney and has completed senior executive management programs at INSEAD.
15
Ms Bartlett has previously held non-executive director roles with Sigma Healthcare Limited (resigned December 2023), Mirvac Limited (resigned April 2026) and TAL Life Limited (resigned April 2026). The Board (with Ms Bartlett abstaining) unanimously recommends that Shareholders vote in favour of Resolution 3. Resolution 4: Approval of grant and issue of Performance Rights to Mr Greg Horan The Company is seeking Shareholder approval for the proposed grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, CEO and Executive Director of the Company, under the LTVR Plan for FY27 (on the basis that Mr Horan is a Director of the Company). Following a review of the efficacy of the LTVR Plan and feedback from investors, a number of changes have been made to the FY27 LTVR Plan from the previous LTVR plan:
a new return on invested capital (ROIC) measure has been introduced as 34% of the total grant to replace the previous 20% Service Right component of the LTVR;
the ROIC measure will be assessed against three cumulative annual ROIC targets approved by the Board (including the approved capex budget for each year). The targets and performance against the targets will be disclosed retrospectively in the appropriate Remuneration Report;
the other two LTVR measures, being earnings per share (EPS) and relative total shareholder return (rTSR) have been reweighted to 33% each to accommodate the new ROIC measure; and
the peer group for the rTSR metric has changed from the ASX 300 (ex-financials and resources) to a bespoke index of 12 healthcare service companies.
ASX Listing Rule 10.14 requires the Company to obtain approval from Shareholders for the issue of securities to a Director under an employee incentive scheme. Mr Horan is CEO and an Executive Director of the Company. Resolution 4 is not seeking approval for the total remuneration of Mr Horan. Rather, it relates to the proposed issue of up to 359,850 Performance Rights to Mr Horan, which represents the FY27 LTVR component of Mr Horan’s remuneration (which is one component of Mr Horan’s total remuneration). If Shareholder approval is not obtained, the Board will consider alternative approaches to rewarding Mr Horan to ensure that the remuneration packages for the Executive Director remains competitive and motivating. The LTVR Plan has been designed to meet the needs of the Company and to reflect modern best-practice remuneration equity structures for executives. A key component of effective remuneration for executives is equity interests, in the form of LTVR to drive shared performance objectives, link remuneration to Company performance and align interests with sustainable value creation for Shareholders. Performance Rights are proposed to be granted to Mr Horan under the FY27 LTVR grant for these reasons. Approval of Resolution 4 under Listing Rule 10.14 will also result in any Rights the subject of this resolution granted to Mr Horan being excepted from ASX Listing Rule 7.1. This means
16
that any Rights the subject of this resolution granted to Mr Horan, and any new shares issued to Mr Horan in satisfaction of those Rights, will be excluded from the calculation of ACL’s annual 15 percent new security issue limit under ASX Listing Rule 7.1. In accordance with ASX Listing Rule 10.15, the features of the proposed FY27 LTVR invitations to apply for Performance Rights proposed to be issued to Mr Horan are summarised below. Capitalised terms used, but not defined in the table below, have the meaning given to them in the LTVR Plan (a copy of which was released to the ASX Market Announcements Platform on 14 May 2021). Aspect Instrument and entitlement
Details If Resolution 4 is approved by Shareholders, Mr Horan will be invited to apply for up to 359,850 Performance Rights. These Rights may vest when performance-based Vesting Conditions are satisfied (or otherwise waived in accordance with the Plan). The Rights are indeterminate Rights issued under the Plan, which are an entitlement to the value of a Share (less any Exercise Price), which may be settled either in cash and/or in Shares (at the Board’s discretion). Generally, it is expected that vested Rights will be settled in Shares (including Restricted Shares, which are Shares subject to a disposal restriction). The value that may be realised is a function of performance against Vesting Conditions and the market value of a Share at the time of sale of any Shares that result from exercising Rights. The type of equity security proposed to be granted to Mr Horan has been selected because the Board believes that it creates a strong link between performance and reward.
Variation of terms and conditions Term
To the extent permitted by the ASX Listing Rules, the Board retains the discretion to vary or amend the terms and conditions of the Plan.
Grant Date
If Shareholder approval is obtained for Resolution 4, the Rights will be granted as soon as practicable after the AGM (and are currently expected to be granted within one month of the AGM), but in any event, within three years of the AGM, and will have an effective grant date of 1 July 2026.
Number of Rights
It is proposed that Mr Horan will be invited to apply for three Tranches of Rights in relation to Resolution 4:
Each Right has a Term of five years from the anniversary of the date of the grant of the Right (Grant Date) and if not exercised within that Term, the Rights will lapse.
Tranche 1 – 118,751 Performance Rights with a relative total shareholder return (rTSR) Vesting Condition (nil Exercise Price);
Tranche 2 –118,751 Performance Rights with an earnings per share return (EPS) Vesting Condition (nil Exercise Price); and
Tranche 3 – 122,348 Performance Rights with a return on invested capital (ROIC) Vesting Condition (nil Exercise Price).
The number of Rights proposed to be granted to Mr Horan for FY27 was determined by dividing the dollar value of Mr Horan’s LTVR opportunity (being
17
100% of Mr Horan’s total fixed remuneration as at 1 July 2026) by the Volume Weighted Average Price (VWAP) of Shares over the 10 business day period from 18 August 2026 to 31 August 2026 (inclusive) being $2.8692 (the Issue Price). When added to the other remuneration elements, the FY27 grant of LTVR for Mr Horan will produce a total remuneration package that the Board believes is market competitive and appropriate given the Company’s circumstances for FY27, based on market benchmarking and the current ACL executive remuneration policy. Achievement at target performance levels will results in partial vesting, increasing up to a maximum of 100% vesting when stretch performance goals are achieved. It is therefore expected that a lesser percentage will actually vest unless exceptional performance outcomes occur. The actual value (if any) that Mr Horan will receive from the proposed FY27 LTVR grant cannot be determined until the end of the Measurement Period, and will depend on the extent to which the Vesting Conditions are achieved, the number of Performance Rights that vest in accordance with the Vesting Conditions and the ACL Share price at the time of vesting. The Board determined the value and form of Mr Horan’s FY27 LTVR award under the Plan in Performance Rights with regard to his overall remuneration package, the nature of his position, the purpose of the LTVR component in ACL’s remuneration strategy and independent benchmarking regarding current market practice. Measurement Period
The Measurement Period is the period over which Vesting Conditions are assessed. For each of Tranches 1, 2 and 3 of the Performance Rights, the Measurement Period will be three years from 1 July 2027 to 30 June 2029.
Gates
There are no gates applicable to the Performance Rights in addition to the metrics set out above.
Vesting Conditions
Vesting Conditions are conditions that are used to determine the extent, if any, of vesting of Performance Rights. For Tranche 1 (rTSR Performance Rights), the Vesting Condition will be based on the ranking of the Relative Total Shareholder Return (rTSR) of ACL over the Measurement Period compared to the TSR peer group (see note 2 below). The vesting scale for this performance vesting metric is as follows: Performance Level Below Target Target Target > Stretch Stretch
rTSR(1) compared to nominated Total Return comparator set(2) <50th Percentile =50th Percentile
50th Percentile and <75th Percentile = 75th Percentile
Vesting % of Tranche Nil 100% Pro-rata 100%
(1) Total Shareholder Return or TSR means the percentage change in the Company’s Share
18
price together with the value of dividends and distributions (assuming that all of those dividends and distributions are re-invested into new Shares as determined by the Board from time to time). Dividends relate to dividends with an ex-dividend date during the performance period. (2) The nominated Total Return comparator set is a bespoke basket of 12 healthcare service companies being Pro Medicus, Sonic Healthcare, Ramsay Health Care, Regis Healthcare, Nanosonics, Integral Diagnostics, Polynovo, Cogstate, Oceania Healthcare, Healius, Monash IVF and Paragon Care. Companies primarily exposed to biotechnology, medical devices, pharmaceuticals or healthcare technology have been excluded on the basis that their valuation drivers, risk profiles and capital intensity are materially different from ACL’s core healthcare services model.
The vesting scale for Tranche 2 (EPS) is as follows: 3Y EPS Growth (CAGR)
% Vesting
Below Threshold
<4%
Nil
Threshold
=4%
25%
Threshold > Stretch
4% and <8%
Pro-rata
Stretch
=8%
100%
The Board reserves the discretion to vary the EPS growth condition should regulatory pricing decisions vary materially from ACL’s forecasts. The vesting scale for the first year of Tranche 3 (ROIC) for FY27 is as follows: Y1 ROIC
% Vesting
Below Threshold
21%
Nil
Threshold
=21%
25%
Threshold > Stretch
21% and <26%
Pro-rata
Stretch
=26%
100%
The ROIC hurdles will be reviewed and set by the Board annually in line with budgets and capex requirements during the performance period, to ensure that the incentive framework delivers value for shareholders and appropriately reflects the investment of capital in the business and the timing of returns for those investments. The targets for FY28 and FY29 and performance against the targets will be disclosed retrospectively in the 2029 Remuneration Report. Acquisition price and Exercise Price
No amount is payable by Mr Horan for the Rights as their value forms a significant portion of the variable remuneration in his total remuneration package for FY27. The Exercise Price for the Rights is nil.
Exercise of vested Rights
Vested Rights may be exercised by the Participant submitting an Exercise Notice at any time between the Vesting Date (or the latter elapsing of Exercise Restrictions, if applicable) and the end of their Term. Otherwise, these Rights will lapse. Rights may not be sold, transferred, mortgaged, charged or otherwise dealt with or encumbered, except by force of law.
Disposal restrictions
Shares acquired from the exercise of vested Rights will be subject to disposal restrictions due to:
19
Termination of Employment
the Company’s securities trading policy; and
the insider trading provisions of the Corporations Act (Division 3 of Part 7.10).
In the case of a termination of employment: (a) unvested Rights will be forfeited, unless and to the extent otherwise determined by the Board in its discretion; (b) vested Rights subject to Exercise Restrictions will cease to be subject to Exercise Restrictions; and (c) vested Rights will lapse if not exercised within 21 days of the date of cessation of employment with the Group.
Change of Control
In the event of a Change of Control, unvested Rights will vest in the proportion that the elapsed portion of the Measurement Period bears to the full Measurement Period. The Board, in its discretion, may determine that none, some or all of the remaining unvested Rights also vest. Any Rights that remain unvested following exercise of the Board’s discretion will lapse.
Major return of capital or demerger
In the event that the Board forms the view that a major part of the Company’s assets or operations will imminently cease to be owned by the Group due to an intention to sell or separately list those assets or operations, or in the event of a major return of capital to Shareholders; (a) unvested Rights will either vest to the extent determined by the Board, with the remainder lapsing, or the Board will adjust the number and vesting conditions of Rights held so that Participants are neither advantaged nor disadvantaged by the return of capital or demerger, and (b) Restricted Rights will cease to be subject to Exercise Restrictions prior to the return of capital or demerger, on the date determined by the Board.
Board discretion to prevent inappropriate benefits, fraud and misconduct
The Board has discretion to adjust the number of Rights that ultimately vest if it forms the view that the unadjusted outcome is not appropriate to the circumstances that prevailed over the Measurement Period and/or to the contribution of a Participant to outcomes over the Measurement Period. The Board has sole discretion to determine that some or all unvested Rights held by a Participant lapse on a specified date, if allowing the Rights to be retained would, in the opinion of the Board, result in an inappropriate benefit to the Participant. Such circumstances include joining a competitor or actions that harm the Company’s stakeholders. In the case of fraud or misconduct, the Participant will forfeit all unvested Rights.
Bonus issues, rights issues, voting and dividend entitlements
In cases of bonus share issues by the Company, the number of Rights held by a Participant shall be increased by the same number as the number of bonus shares that would have been received by the Participant had the Rights been Shares, except in the case that the bonus share issue is in lieu of a dividend payment, in which case no adjustment will apply. Rights do not carry voting or dividend entitlements. Shares (including
20
Restricted Shares) issued when Rights are exercised carry all entitlements of Shares, including voting and dividend entitlements. Quotation
Rights will not be quoted on the ASX. The Company will apply for official quotation of any Shares issued under the Plan, in accordance with the ASX Listing Rules.
Hedging
The Company prohibits the hedging of Rights or Shares subject to disposal restrictions by Mr Horan.
Other details
Further information in accordance with ASX Listing Rule 10.15:
Mr Horan is the only person both subject to ASX Listing Rule 10.14 and entitled to participate in the Plan, as at the date of the preparation of this Notice of Meeting;
No Performance Rights have been previously issued to Mr Horan.
Mr Horan’s current total remuneration package (for FY27) is set out in the Annual Report and is as set out below: o
base remuneration for FY27 of $1,000,000 plus superannuation;
o
a short-term variable incentive which the Board currently values as follows:
o
at Target - $516,250 (being 50% of base remuneration); and
at Stretch - $722,750 (being 70% of base remuneration salary); and
LTVR, which the Board currently values as follows:
at Target – $688,333 (being 239,900 Rights multiplied by the Issue Price); and
at Stretch – $1,032,500 (being 359,850 Rights multiplied by the Issue Price).
Mr Horan’s total remuneration package at LTVR Threshold is therefore currently valued at $2,237,083 at Target and $2,787,750 at Stretch;
no loans have been, or will be, provided by the Company in relation to the grant or exercise of the Performance Rights proposed to be provided to Mr Horan;
details of any securities issued under the Plan will be published in the Company’s annual report relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14;
any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of securities under the Plan after this
21
Resolution 4 is approved and who are not named in this Notice will not participate until approval is obtained under ASX Listing Rule 10.14; and
a voting exclusion applies to Resolution 4, as set out in the Notice of Meeting.
The Directors (with Mr Horan abstaining) unanimously recommend that Shareholders vote in favour of Resolution 4. The Chair of the AGM intends to vote all available proxies in favour or Resolution 4. Resolution 5: Reinsertion of the Proportional Takeover Provisions in the Constitution Rule 14 of the Company’s Constitution contains Proportional Takeover Provisions that prohibit the Company from registering a transfer of its shares under a proportional takeover bid, unless and until the bid is approved via ordinary resolution passed by Shareholders entitled to vote on that resolution in a general meeting (or is otherwise taken to have been passed). Under the Corporations Act, proportional takeover approval provisions expire three years from adoption or renewal. Once the three year period has elapsed, those provisions cease to have effect unless shareholders approve their renewal. The renewal approval must be by special resolution, meaning that at least 75% of the votes cast by Shareholders entitled to vote on the resolution must be in favour of the resolution. If this special resolution is approved and a takeover bid is subsequently made for some but not all of each Shareholder’s shares, the Proportional Takeover Provisions will enable Shareholders entitled to vote on the resolution to vote on whether the proportional bid should be allowed to proceed, independently from their individual decisions as to whether or not to accept the bid. The Proportional Takeover Provisions were contained in the Constitution that was adopted by the Company as part of its admission to the Official List of the ASX on 14 May 2021 and expired on 23 October 2026. Resolution 5 therefore seeks to re-insert the Proportional Takeover Provisions in identical terms for a period of 3 years from the date of the AGM (being 28 October 2026). If the proposed resolution is approved by Shareholders, the Proportional Takeover Provisions will be reinserted into the Constitution and have effect on exactly the same terms as the existing provisions until 28 October 2029. Further detail in relation to Resolution 5 (in accordance with the requirements of the Corporations Act) is set out below. What is a proportional takeover bid and why do we need Proportional Takeover Provisions? A proportional takeover bid (also referred to as a partial takeover bid) involves the bidder offering to buy a proportion only of each Shareholder’s shares in the Company. This means that control of the Company may pass without Shareholders having the chance to sell all their shares to the bidder. It also means that the bidder may take control of the Company without paying an adequate amount for gaining control. In order to deal with this possibility, the Company may provide in its Constitution that:
in the event of a proportional takeover bid being made for shares in the Company, Shareholders are required to vote by ordinary resolution and collectively decide whether to accept or reject the offer; and
the majority decision of the Company’s Shareholders will be binding on all the Shareholders.
22
The Board considers that Shareholders should be able to vote on whether a proportional takeover bid should proceed. Such a bid might otherwise allow control of the Company to change without Shareholders being given the opportunity to dispose of all their shares for a satisfactory control premium. The Board also believes that the right to vote on a proportional takeover bid may avoid Shareholders feeling pressure to accept the bid even if they do not want it to succeed. What is the effect of the Proportional Takeover Provisions? If a proportional takeover bid is made, the Directors must ensure that Shareholders vote on a resolution to approve the bid more than 14 days before the last day of the bid period. The vote is decided on a simple majority. Each person who, as at the end of the day on which the first offer under the bid was made, held bid class securities is entitled to vote on the resolution, except for the bidder and any associates of the bidder (who are not entitled to vote on the resolution). If the resolution is not passed, transfers which would have resulted from the acceptance of the proportional takeover bid will not be registered and the bid will be taken to have been withdrawn. If the bid is approved (or taken to have been approved), the transfers must be registered if they comply with the Corporations Act and the Company’s Constitution. The Directors will breach the Corporations Act if they fail to ensure the approving resolution is voted on before the approving resolution deadline. However, if the resolution is not voted on as at the end of the day before the approving resolution deadline, the bid will be taken to have been approved. The Proportional Takeover Provisions do not apply to full takeover bids and will only apply for three years after the date of adoption or renewal of these provisions. The provisions may be renewed again, but only by a special resolution. Similar provisions are commonly found in the constitutions of publicly listed companies on the ASX and are regularly renewed. Potential advantages and disadvantages The renewal of the Proportional Takeover Provisions will allow the Directors to ascertain Shareholders’ views on a proportional takeover bid. The Proportional Takeover Provisions do not otherwise offer any advantage or disadvantage to the Directors who remain free to make their own recommendation as to whether an offer under a proportional takeover bid should be accepted. The potential advantages of the Proportional Takeover Provisions for Shareholders of the Company include:
Shareholders will have an opportunity to study a proportional takeover bid proposal and decide by majority vote whether an offer under a proportional takeover bid should proceed; the provisions may help Shareholders avoid being locked in as a minority; the provisions may ensure that a potential bidder structures its offer in a way which is attractive to a majority of Shareholders, including appropriate pricing; and knowing the view of the majority of Shareholders may help individual Shareholders assess the likely outcome of the proportional takeover when determining whether to accept or reject the offer.
The potential disadvantages of the Proportional Takeover Provisions for Shareholders of the Company include:
23
the provisions may discourage proportional takeover bids for shares in the Company; the provisions may reduce any speculative element in the market price of the Company's shares arising from the possibility of a takeover offer being made; the provisions may be considered to constitute an unwarranted additional restriction on the ability of Shareholders to freely deal with their shares; and the chance of a proportional takeover bid being successful may be reduced.
The Board considers that the potential advantages for Shareholders of the Proportional Takeover Provisions outweigh the potential disadvantages. There have been no full or proportional takeover bids for the Company in the period during which the Proportional Takeover Provisions have been in effect. Therefore, there has been no example against which to review the advantages or disadvantages of the provisions for the Directors and Shareholders, respectively, during this period. As at the date that this explanatory memorandum was prepared, no Director is aware of a proposal by a person to acquire, or to increase the extent of, a substantial interest in the Company. The Board unanimously recommends that Shareholders vote in favour of Resolution 5. Resolution 6: Appointment of Deloitte as new auditor Pitcher Partners has been the Company’s auditor for more than 10 years. The Company’s Audit and Risk Committee therefore considered that it was good corporate governance to put the Company’s audit services to tender and to seek proposals from a number of providers. As a result of that tender process, the Board resolved to appoint Deloitte as its new auditor. The Board thanks Pitcher Partners for the services they have provided to the Company. Section 328B(1) of the Corporations Act requires that written notice of nomination of a new auditor be received from a member of the Company. The Company has received such a nomination from Mark Haberlin, the Chair of the Audit and Risk Committee, in his capacity as a Shareholder of the Company. A copy of the nomination is set out in Annexure A. Pitcher Partners has tendered a notice of resignation to ASIC under section 329(5) Corporations Act 2001 and Deloitte has given its written consent to act as the new Company auditor. If Resolution 6 is passed, the appointment of Deloitte as the Company’s new auditor will take effect at the close of the AGM. Subject to ASIC’s consent to the resignation of Pitcher Partners, the Board unanimously recommends that Shareholders vote in favour of Resolution 6. If ASIC does not consent to the current auditor’s resignation, Pitcher Partners will continue to the Company’s auditor and Resolution 6 will not be put to the meeting. If Resolution 6 is put to the meeting and is not passed, the Company will need to appoint a new auditor other than Deloitte. The Chair intends to vote undirected proxies in favour of Resolution 6.
24
GLOSSARY AGM or Annual General Meeting means the annual general meeting convened by this Notice. AGM Online Platform means the online platform used to hold the AGM accessible at https://meetings.openbriefing.com/ACL26 Annual Report means the annual report of ACL for the year ended 30 June 2026. ASX means ASX Limited (ACN 008 624 691) or, as the context requires, the financial market operated by it. Auditor’s Report means the auditor’s report for the Company for the year ended 30 June 2026 as contained in the Annual Report. Board means the board of Directors. Chair means the person appointed to chair the Company’s meeting. Closely Related Party has the meaning given to that term in section 9 of the Corporations Act. Company or ACL means Australian Clinical Labs Limited (ACN 645 711 128). Constitution means the constitution of the Company. Corporations Act means the Corporations Act 2001 (Cth). Directors means the directors of the Company and Director means any one of them. Directors’ Report means the directors’ report for the Company for the year ended 30 June 2026 as contained in the Annual Report. EPS means earnings per share. FY26 and FY27 means the financial years ending 30 June 2026 and 30 June 2027 respectively. Glossary means this glossary. KMP means people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) who are identified in the Remuneration Report. KPI means key performance indicator. Listing Rule or ASX Listing Rule means the official listing rules of ASX. LTVR means long-term variable remuneration. LTVR Plan or Plan means the Company’s long-term variable remuneration plan.
25
Notice or Notice of Meeting means this notice of annual general meeting. Remuneration Report means the remuneration report for the Company for the year ended 30 June 2026, as contained in the Annual Report. Resolution means a resolution set out in this Notice. ROIC means return on invested capital. rTSR means relative total shareholder return. Share means a fully paid ordinary share of the Company. Shareholder means a holder of at least one Share. STVR means short term variable remuneration.
26
Annexure A – Letter of Nomination Mr Mark Haberlin c/o Australian Clinical Labs Limited 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
The Company Secretary Australian Clinical Labs Limited ABN 94 645 711 128 1868-1892 Dandenong Road Clayton VIC 3168 Australia 14 September 2026
Dear Eleanor Notice of Nomination of Auditor in accordance with section 328B(1) of the Corporations Act 2001 (Cth) I, Mark Haberlin, being a shareholder of Australian Clinical Labs Limited (Company) nominate Deloitte Touche Tohmatsu of Level 31, 477 Collins Street, Melbourne for appointment to the position of auditor of the Company at the next annual general meeting. I consent to the distribution of this notice of nomination as an attachment to the Notice of Meeting and Explanatory Memorandum for the 2026 annual general meeting for the purposes of section 328B(3) Corporations Act 2001. Yours sincerely
Mark Haberlin Shareholder and non-executive director
Page 1 of 1
LODGE YOUR VOTE ONLINE https://au.investorcentre.mpms.mufg.com ABN 94 645 711 128
BY MAIL
Australian Clinical Labs Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia
FAX BY +61 2 9287 0309 HAND BY MUFG Corporate Markets (AU) Limited
Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150
ENQUIRIES TO ALL Telephone: 1300 554 474
Overseas: +61 1300 554 474
X99999999999
E
X99999999999
PROXY FORM
L
I/We being a member(s) of Australian Clinical Labs Limited (Company) and entitled to attend, and vote at, the Annual General Meeting of the Company to be held at 2:00pm (AEDT) on Wednesday, 28 October 2026 (the Meeting) hereby appoint:
APPOINT A PROXY
STEP 1
the Chair of the Meeting (mark box)
OR if you are NOT appointing the Chair of the Meeting as your proxy, please write the name and email of the person or body corporate you are appointing as your proxy, and an email will be sent to your appointed proxy with details on how to access the virtual meeting
P
Name Email
or failing the person or body corporate named, or if no person or body corporate is named, the Chair of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Meeting and at any postponement or adjournment of the Meeting. The Meeting will be conducted as a virtual meeting and you can participate by logging in online at https://meetings.openbriefing.com/ACL26 (refer to details in the Virtual Meeting Online Guide). Important for Resolutions 1 and 4: If the Chair of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chair of the Meeting to exercise the proxy in respect of Resolutions 1 and 4, even though the Resolutions are connected directly or indirectly with the remuneration of a member of the Company’s Key Management Personnel (KMP). The Chair of the Meeting intends to vote undirected proxies in favour of all Resolutions.
VOTING DIRECTIONS
S
A
M
Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting. Please read the voting instructions overleaf before marking any boxes with an T
STEP 2
Resolutions
1 Adoption of the Remuneration Report 2 Re-election of Dr Amandeep Hansra as a Director
For Against Abstain*
For Against Abstain* 5 Reinsertion of the Proportional Takeover Provisions in the Constitution 6 Appointment of Deloitte as new auditor
3 Re-election of Ms Christine Bartlett as a Director
f you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your * Ivotes will not be counted in computing the required majority on a poll.
STEP 3
SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED Shareholder 1 (Individual)
Joint Shareholder 2 (Individual)
Joint Shareholder 3 (Individual)
Sole Director and Sole Company Secretary
Director/Company Secretary (Delete one)
Director
This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder’s attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company’s constitution and the Corporations Act 2001 (Cth).
ACL PRX2601N
ACL PRX2601N
4 Approval of grant and issue of Performance Rights to Mr Greg Horan
HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM YOUR NAME AND ADDRESS This is your name and address as it appears on the Company’s share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. Please note: you cannot change ownership of your shares using this form.
APPOINTMENT OF PROXY If you wish to appoint the Chair of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company. If you return a Proxy Form without identifying a proxy at Step 1, you will be taken to have appointed the Chair of the Meeting as your proxy to vote on your behalf on all resolutions at the Meeting.
LODGEMENT OF A PROXY FORM This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by 2:00pm (AEDT) on Monday, 26 October 2026, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting. Proxy Forms may be lodged using the reply paid envelope or:
Login to the Investor Centre using the holding details as shown on the Voting/Proxy Form. Select ‘Voting’ and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their “Holder Identifier” - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).
DEFAULT TO CHAIR OF THE MEETING Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Resolutions are connected directly or indirectly with the remuneration of KMP.
BY MOBILE DEVICE Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link https://au.investorcentre.mpms.mufg.com into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.
VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as they choose. If you mark more than one box on an item your vote on that item will be invalid.
APPOINTMENT OF A SECOND PROXY
A
To appoint a second proxy you must: (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and (b) return both forms together; and (c) clearly indicate on the second Proxy Form that it is a second proxy and not a revocation of the first proxy.
SIGNING INSTRUCTIONS
S
You must sign this form as follows in the spaces provided: Individual: where the holding is in one name, the holder must sign. Joint Holding: where the holding is in more than one name, either shareholder may sign. Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it. Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.
CORPORATE REPRESENTATIVES If a representative of the corporation is to attend the Meeting the appropriate “Certificate of Appointment of Corporate Representative” must be received at [email protected] prior to admission in accordance with the Notice of Meeting. A form of the certificate may be obtained from the Company’s share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.
L
QR Code
E
To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.
P
BY MAIL
M
You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company’s share registry or you may copy this form and return them both together.
ONLINE https://au.investorcentre.mpms.mufg.com
Australian Clinical Labs Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia
BY FAX +61 2 9287 0309
BY HAND delivering it to MUFG Corporate Markets (AU) Limited* Parramatta Square Level 22, Tower 6 10 Darcy Street Parramatta NSW 2150 *During business hours Monday to Friday (9:00am - 5:00pm)
Online Meeting Guide Before you begin Ensure your browser is compatible. Check your current browser by going to the website: whatismybrowser.com Supported browsers are: • Chrome – Version 44 & 45 and after • Edge – 92.0 and up To attend and vote you must have your shareholder number and postcode. Appointed Proxy: Your proxy number will be provided by MUFG before the meeting. Please make sure you have this information before proceeding.
Corporate Markets
Online Meeting Guide
- Get a Voting Card To register to vote – click on the ‘Get a Voting Card’ button. This will bring up a box which looks like this.
Step 1 Open your web browser and go to https://meetings.openbriefing.com/ACL26
Step 2 Log in to the portal using your full name, mobile number and email address, and participant type Please read and accept the terms and conditions before clicking on the ‘Register and Watch Meeting’ button. • On the left – a live webcast of the Meeting starts automatically once the meeting has commenced. If the webcast does not start automatically please press the play button and ensure the audio on your computer or device is turned on. • On the right – the presentation slides that will be addressed during the Meeting • At the bottom – buttons for ‘Get a Voting Card’, ‘Ask a Question’ and a list of company documents to download Note: If you close your browser, your session will expire and you will need to re-register. If using the same email address, you can request a link to be emailed to you to log back in. 2 • Online Meeting Guide
If you are an individual or joint shareholder you will need to register and provide validation by entering your shareholder number and postcode. If you are an appointed Proxy, please enter the Proxy Number issued by MUFG in the PROXY DETAILS section. Then click the ‘SUBMIT DETAILS AND VOTE’ button. Once you have registered, your voting card will appear with all of the resolutions to be voted on by shareholders at the Meeting (as set out in the Notice of Meeting). You may need to use the scroll bar on the right hand side of the voting card to view all resolutions. Shareholders and proxies can submit either a Full Vote or Partial Vote.
Full Votes To submit a full vote on a resolution ensure you are in the ‘Full Vote’ tab. Place your vote by clicking on the ‘For’, ‘Against’, or ‘Abstain’ voting buttons.
Partial Votes To submit a partial vote on a resolution ensure you are in the ‘Partial Vote’ tab. You can enter the number of votes (for any or all) resolution/s. The total amount of votes that you are entitled to vote for will be listed under each resolution. When you enter the number of votes it will automatically tally how many votes you have left. Note: If you are submitting a partial vote and do not use all of your entitled votes, the un‑voted portion will be submitted as No Instruction and therefore will not be counted.
Once you have finished voting on the resolutions scroll down to the bottom of the box and click on the ‘Submit Vote’ or ‘Submit Partial Vote’ button. Note: You can close your voting card without submitting your vote at any time while voting remains open. Any votes you have already made will be saved for the next time you open up the voting card. The voting card will appear on the bottom left corner of the webpage. The message ‘Not yet submitted’ will appear at the bottom of the page. You can edit your voting card at any point while voting is open by clicking on ‘Edit Card’. This will reopen the voting card with any previous votes made. Online Meeting Guide • 3
Online Meeting Guide 2. How to ask a question Note: Only verified Shareholders, Proxyholders and Corporate Representatives are eligible to ask questions.
If you have yet to obtain a voting card, you will be prompted to enter your shareholder number and postcode or proxy details before you can ask a question. To ask a question, click on the ‘Ask a Question’ button either at the top or bottom of the webpage.
continued
A ‘View Questions’ box will appear where you can view your questions at any point. Only you can see the questions you have asked. If your question has been answered and you would like to exercise your right of reply, you can submit another question. Note, the company will do their best to address all questions.
The ‘Ask a Question’ box will pop up and you have the option to type in a written question of ask an audio question over the phone line.
-
Downloads View relevant documentation in the Downloads section.
-
Voting closing Voting will end 5 minutes after the close of the Meeting.
In the ‘Regarding’ section click on the drop down arrow and select the category/resolution for your question. Click in the ‘Question’ section and type your question and click on ‘Submit’.
At the conclusion of the Meeting a red bar with a countdown timer will appear at the top of the Webcast and Slide screens advising the remaining voting time. If you have not submitted your vote, you should do so now. Once voting has been closed all submitted voting cards cannot be changed.
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au
Tuesday 22 September 2026 Australian Clinical Labs Limited - 2026 Annual General Meeting
The following announcements to the market are provided: AGM Notice of Meeting Proxy Form Online Guide from Link Market Services ✓
Australian Clinical Labs Limited 2026 Annual Report (including the 2026 Corporate Governance Statement and 2026 Sustainability Report) Appendix 4G
– ENDS – This announcement was authorised for release to ASX by the Company Secretary. For further information regarding this announcement, please contact: Company Secretary Eleanor Padman Company Secretary Email: [email protected] Phone: +61 (0) 422 002 918 About Australian Clinical Labs
ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients’ lives.
Page 1 of 1
Annual Report 2026
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. ACL has laboratories and pathology collection centres in all Australian States and Territories (except Tasmania) and is one of the largest private hospital pathology businesses nationally.
ii
Australian Clinical Labs
Contents Our Mission and Values
02
FY26 Highlights
04
Letter from the Chair and CEO
06
ACL National Footprint
10
Social Responsibility
12
Financial Report
16
Directors’ Report
18
Auditor’s Independence Declaration
29
Remuneration Report
31
Corporate Governance Statement 2026
51
Financial Statements 2026
68
Consolidated Entity Disclosure Statement
115
Directors’ Declaration
118
Independent Auditor’s Report
119
Shareholder Information
124
Sustainability Report
127
Corporate Directory
147 Annual Report 2026
1
Mission and Values Our Mission and Values were developed by our people and embody who we are, what we stand for, and the positive impact we strive to make as a healthcare organisation. They guide our decisions, shape our culture, and underpin our commitment to delivering exceptional care and service. Across our teams nationwide, our employees demonstrate these principles every day. Their dedication, professionalism and pride in our organisation are reflected in countless examples of individuals and teams going above and beyond to bring our Mission and Values to life.
Our Mission
Our Values
We combine talented people, medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients’ lives.
Our values and behaviours serve to shape the culture within the workplace; set and manage expectations for staff, patients and the community; and strengthen and further define our organisational culture. We have formal methods of promulgating our values to ensure they are felt and seen in the way we behave. The fundamental strength of our values is that they are driven by us at all levels, due to employee engagement, passion and commitment to our mission.
2
Australian Clinical Labs
ACL’s values are: •
Patient Focus and Medical Excellence
•
Passion and Enthusiasm
•
Entrepreneurship and Agility
•
Efficiency and Effectiveness
•
Respect and Integrity
Annual Report 2026
3
FY26 Highlights
$735.8m
25.2%
Annual Revenue
Return on Invested Capital1 Through a combination of earnings growth and disciplined capital allocation.
$64.7m
$69.2m
Free Cash Flow2
Underlying EBIT3
Strong operating cash flow generation. Supported investment in strategic initiatives.
18.3cps
9.4%
Underlying EPS3
Underlying EBIT margin3
Earnings per Share increased year-on-year, reflecting continued margin discipline and strong cash generation.
$47.1m Returned to our shareholders
- ROIC measured as Underlying EBIT*(1 – 30%) / Average opening and closing invested capital (after adding back $4.2m prepayment write-off in FY26).
- Free cash flow before interest, tax and financing excluding AIC settlement of $6.2m.
4
Australian Clinical Labs
- Underlying results exclude certain non-recurring revenue and expenses.
- Increase in dividend compared to prior year FY25 includes both the interim and final dividend
9.25cps
+80
Final dividend4
Net Promoter Score
+0.5cps vs FY25.
From 440,007 responses.
50:50
189
Gender-balanced Board
Hybrid vehicles across Australia
2%
+150,00km
Reduction in carbon emissions per pathology episode
per month saved on courier routes
Continued roll-out of automation, artificial intelligence and digital workflow initiatives to improve productivity and service delivery.
Annual Report 2026
5
Letter from the Chair and CEO Dear Shareholders, FY2026 was a year of significant change for Australian Clinical Labs. Against a backdrop of industry funding reductions, inflationary cost pressures and subdued pathology market growth, ACL delivered a resilient financial result while continuing to strengthen the foundations of the business for the future. Throughout the year, our focus remained clear: maintain financial discipline, improve operational efficiency, invest in long-term capabilities and allocate capital in a manner that enhances shareholder value. As a result, ACL delivered underlying EBIT growth, increased earnings per share, improved return on invested capital and returned significant capital to shareholders through dividends and share buy-backs. These outcomes demonstrate the strength of our operating model and the commitment of our people in a challenging environment.
Stephen Roche, Chair
6
Australian Clinical Labs
Resilience in a Challenging Operating Environment A defining feature of FY2026 was ACL’s disciplined response to significant structural and funding pressures across the pathology sector. Medicare fee reductions for vitamin B12 and urine testing, subdued GP consultation volumes, lower respiratory and HPV testing, and broader inflationary pressures weighed on industry growth. The result also absorbed $1.8 million of costs arising from the initial implementation of the Fair Work Commission’s gender undervaluation decision, together with the 3.5% annual increase to modern award wages and the 0.5% increase in superannuation. ACL supports fair remuneration for its people; however, the scale of these additional labour costs, when combined with constrained industry funding, reinforces the need for sustainable funding settings that protect patient access and service availability. Through labour productivity, laboratory efficiency, procurement discipline and portfolio optimisation, ACL more than offset these cost pressures while improving underlying EBIT and margin.
Greg Horan, Group CEO and Managing Director
Our strategy is designed to create disciplined value from ACL’s resilient national platform, without relying on a rapid recovery in market volumes. The single national Laboratory Information System is the foundation of this strategy, enabling ACL to build once and deploy nationally across billing, automation, artificial intelligence, workflow quality, laboratory productivity and future integration. This structural advantage reduces duplication, supports consistent clinical and operational standards, and provides operating leverage as activity improves.
OUR CORPORATE ADVANTAGE
ACL’s Growth Strategy Our growth agenda is focused on five connected priorities: •
Expand our collection centre network and contracts only where appropriate returns can be achieved.
•
Grow strategic new business in commercial pathology, research partnerships, genetics, specialised diagnostics and melanoma-related opportunities.
•
Assess pathology and adjacent acquisitions, including opportunities associated with SunDoctors.
•
Improve revenue quality through digitised billing, upfront payment processes, recovery of non-Medicare and unfunded tests, contract pricing and continued funding advocacy.
•
Drive further operational improvement through Lab of the Future, the National Skin Laboratory, AI, automation, procurement and route optimisation.
SINGLE LABORATORY INFORMATION SYSTEM
OUR STRATEGIC PILLARS
Disciplined network expansion
OUR INITIATIVES
VALUE CREATION
Strategic New Business
Strategic Aquisitions
Revenue Initiatives
Operational improvement
Lab of the Future
Network and hospital services
Commercial pathology
AU pathology acquisitions
Digitised nonMedicare billing
Complementary non-Medicare testing
Research program partnerships
SunDoctors GP clinics
Unfunded MBS test recovery
International
Specialists
Genetics
Funding advocacy
Increased profitability and margins
Other strategic Melanoma test investments commercialisation
Revenue diversification
Scale and synergies
National Skin Laboratory AI and Automation Procurement
Pricing for non-MBS tests
Revenue growth, reduced bad debts
Lower costs and higher efficiency
Annual Report 2026
7
Letter from the Chair and CEO
Strengthening Our Social and Environmental Impact As a provider of essential healthcare services, we recognise that sustainable success is measured not only by financial performance, but also by the outcomes we deliver for patients, healthcare providers, our people and the communities we serve. Throughout FY2026, ACL continued to make meaningful progress across its Environmental, Social and Governance (ESG) priorities, delivering improvements in environmental efficiency, workplace safety, diversity and customer experience. Carbon emissions per pathology episode reduced by 2%, supported by logistics optimisation initiatives and the continued expansion of our hybrid vehicle fleet. The adoption of digital ordering solutions also continued to grow, improving the experience for referrers while reducing administrative complexity and paper consumption. Our commitment to quality patient care remained central to everything we do. Every day, ACL’s diagnostic services support clinical decision making for patients across Australia, helping to enable timely diagnosis, treatment and ongoing management of health conditions. During FY2026, customer advocacy remained exceptionally strong, reflected in a Net Promoter Score of +80. We also continued to invest in the health, safety and development of our workforce, achieving a Lost Time Injury Frequency Rate of 4.3, below relevant industry benchmarks. In parallel, ACL strengthened its governance framework through the continued development of its internal audit capability, maintained gender balance across the Board and advanced leadership and inclusion initiatives to support a diverse and high-performing workforce. These achievements reinforce our commitment to creating long‑term value for shareholders while maintaining the highest standards of care, integrity and operational excellence.
8
Australian Clinical Labs
Update From the Board The Board and management team remain committed to disciplined capital management. ACL generated strong cash flow, maintained a conservative balance sheet and continued to deliver shareholder returns while preserving flexibility to invest in future growth opportunities. We believe this balance of capital discipline and strategic investment will continue to support sustainable long-term value creation. FY2026 also marks an important leadership transition for ACL. After over a decade of outstanding service, Melinda McGrath concluded her tenure as Group Chief Executive Officer/ Executive Director, and we were delighted to announce the appointment of Greg Horan as her successor. Under Melinda’s leadership, ACL successfully integrated multiple pathology businesses, established a national operating platform, completed its ASX listing and navigated the challenges of the pandemic and subsequent market adjustments. On behalf of the Board and our shareholders, we thank Melinda for her vision, leadership and significant contribution to ACL’s success. Greg brings extensive operational and healthcare leadership experience and joins ACL at a time when the business is well positioned to build on its strengths. His focus on disciplined execution, profitable growth, operational excellence and accountability aligns strongly with the strategy that has guided ACL’s success to date. The Board is confident that Greg’s experience and leadership will support ACL’s continued growth and strategic ambitions.
Outlook and FY27 Guidance Looking ahead, we remain confident in the long‑term fundamentals of pathology. Demand for diagnostic services continues to be supported by an ageing population, rising chronic disease and the growing role of diagnostics in clinical decision making. Our investment case does not depend on a rapid market recovery. We are focused on the levers within ACL’s control: service reliability, referrer engagement, disciplined account management, improved billing and revenue capture, labour and laboratory productivity, and rigorous capital allocation. Under Greg’s leadership, the strategic direction remains consistent, with greater intensity of execution, clearer accountability and a continued focus on earnings quality, cash generation and sustainable shareholder returns. For FY2027, ACL is targeting revenue of $745 million to $765 million and underlying EBIT of $67 million to $73 million, representing an implied EBIT margin of 9.0% to 9.5%. This guidance reflects a measured view of the market and does not assume a rapid recovery in pathology volumes. It incorporates expected modest market growth, continued wage pressure and known industry funding settings, except for the final stage of the gender undervaluation outcome for pathology collectors, which remains subject to further assessment. It also reflects the anticipated benefits of initiatives already underway, including upfront episode billing, pricing changes for non-MBS funded tests, Lab of the Future, artificial intelligence initiatives and closer alignment of workforce capacity to activity.
Share buy-backs will continue subject to funding requirements, strategic investment opportunities and ongoing capital expenditure. The FY2027 focus is therefore clear: maintain margin stability through known headwinds, execute the initiatives within our control and pursue sustainable, returns-focused growth. Finally, we would like to thank our pathologists, scientists, collectors, couriers and support teams across Australia. Their professionalism, dedication and commitment to patient care underpin everything we achieve. We also thank our shareholders for your ongoing support and confidence in ACL. We look forward to delivering on the significant opportunities ahead and creating sustainable value for all stakeholders. Yours sincerely,
Stephen Roche
Greg Horan
Chair
Group CEO and Managing Director
About ACL’s new CEO, Greg Horan Greg brings significant executive leadership experience across healthcare, infrastructure, private equity and industrial sectors, with a strong track record of leading complex organisations through periods of change and positioning them for long-term growth. Most recently, Greg served as Chief Executive Officer of Healthscope, where he led one of Australia’s largest private hospital operators through a challenging post-pandemic operating environment, with responsibility for business performance, strategic direction and a large national workforce.
Annual Report 2026
9
Our footprint As one of Australia’s largest private hospital pathology businesses, ACL has developed a significant unified network across Western Australia, Victoria, New South Wales, Queensland, South Australia, the Northern Territory and the Australian Capital Territory. The Company maintains a strong position in community pathology services and continues to grow its operations, enhancing its reach and accessibility for patients and healthcare providers.
4,500+
28
43
Employees
Specialist skin cancer clinics
NATA accredited laboratories
90+
1,273
1
Public and private hospitals serviced
Approved collection centres
Unified laboratory network
10
Australian Clinical Labs
Darwin Lab
NT QLD
WA
Queensland Murrarie Lab
SA
NSW
Perth Osborne Park Lab Adelaide Adelaide Airport Lab
ACT
Sydney Bella Vista Lab
VIC Melbourne Clayton Lab
Approved Collection Centres Western Australia . . ........................................ 148
Queensland..................................................... 34
Northern Territory........................................... 10
Australian Capital Territory.............................. 15
South Australia .............................................. 131
New South Wales. . ........................................ 445 Victoria ......................................................... 490
Annual Report 2026
11
Social Responsibility At ACL, social responsibility is integral to our purpose and the way we create value for the communities we serve. Through initiatives that promote reconciliation, support healthcare education, and strengthen clinical capability, we strive to make a positive and lasting contribution to the health and wellbeing of Australians.
12
Australian Clinical Labs
Reconciliation Action Plan Our commitment to reconciliation continued to advance throughout FY26, reflecting our ongoing efforts to foster meaningful relationships with Aboriginal and Torres Strait Islander peoples and communities. A highlight of the year was a special ceremony held during National Reconciliation Week, led by Bunurong Elder Uncle Shane Clarke. Uncle Shane welcomed employees to Country, acknowledging the Bunurong people as the Traditional Custodians of the land and sharing the enduring connection that First Nations peoples have maintained with Country for thousands of years. Employees also witnessed a Traditional Smoking Ceremony involving the burning of native plants, a Cultural practice that promotes cleansing, wellbeing, respect and renewal.
Our Continued Commitment Reconciliation is an important part of building a more inclusive and equitable Australia. It is founded on strengthening relationships, deepening understanding, and creating opportunities for Aboriginal and Torres Strait Islander peoples. Through our Reconciliation Action Plan, we remain committed to fostering a workplace culture that values diversity, promotes inclusion, and encourages open and respectful dialogue. By continuing to listen, learn, and take meaningful action, we aim to contribute to positive outcomes for our employees, patients, communities, and the broader Australian society.
Bunurong Elder Uncle Shane Clarke Annual Report 2026
13
Dr Sowmya Sharma – NSW Lead Cytopathologist and Senior Anatomical Pathologist (MBBS, FRCPA, FIAC) 14
Australian Clinical Labs
Social Responsibility
Advancing Knowledge and Improving Patient Care ACL is committed to supporting the ongoing development of Australia’s healthcare professionals and contributing to improved health outcomes across the communities we serve. Continuing Professional Development
Through our continuing professional development (CPD) programs, more than 5,000 general practitioners engage with educational resources designed to enhance clinical practice and support high-quality patient care. Our RACGPregistered clinical audits enable participants to evaluate outcomes, reflect on performance, and undertake targeted learning activities that drive continuous improvement. Key areas of focus include diabetes management, skin cancer diagnosis and cervical screening, helping clinicians deliver effective care. These programs consistently receive outstanding feedback from participants, consistently achieving Net Promoter Scores of +80 or higher, reflecting their value and relevance to the medical community. Sharing Expertise with the Medical Community
ACL’s specialist pathologists continue to make a meaningful contribution to medical education by sharing their expertise with healthcare professionals across Australia. Through presentations at industry events, conferences, and educational forums, our experts help advance clinical knowledge and support evidence-based practice. During the year, ACL pathologists delivered presentations on a range of important healthcare topics, including women’s health, iron deficiency, interpretation of common laboratory tests, cervical screening and histopathology. These engagements also reinforced the vital role that general practitioners play in delivering coordinated, patient-centred care. By sharing knowledge, encouraging professional development and fostering clinical excellence, ACL continues to play an important role in strengthening healthcare capability and improving patient outcomes across Australia.
Annual Report 2026
15
Financial Report 2026 For the year ended 30 June 2026
16
Australian Clinical Labs
Contents
Directors’ Report
18
Auditor’s Independence Declaration
29
Remuneration Report
31
Corporate Governance Statement 2026
51
Financial Statements
68
Consolidated Entity Disclosure Statement
115
Directors’ Declaration
118
Independent Auditor’s Report
119
Shareholder Information
124
Corporate Directory
147
Annual Report 2026
17
Directors’ Report for the year ended 30 June 2026
The Directors of Australian Clinical Labs Limited (referred to as ‘the Company’) present their Report for the financial year ended 30 June 2026 (referred to as ‘the year’ or ‘FY26’) accompanied by the Financial Report of Australian Clinical Labs Limited and the entities it controlled (referred to as ‘Clinical Labs’, ‘ACL’ or ‘the Group’) from time to time during the year. Pursuant to the requirements of the Corporations Act 2001 (Cth) (Corporations Act), the Directors’ Report is as follows:
- Directors The following persons were Directors of the Company during the year (or, where indicated, during part of the year) and/or up to the date of this Report: Directors
Position
Date Appointed/Resigned
Chair Independent Non-Executive Director
Appointed Chair 26 August 2025
Melinda McGrath
Chief Executive Officer and Executive Director
Resignation effective 30 August 2026
Mark Haberlin
Interim Chair Independent Non-Executive Director
Interim Chair – 1 May 2025 to 25 August 2025
Christine Bartlett
Independent Non-Executive Director
Sarah Butler
Independent Non-Executive Director
Dr Amandeep Hansra
Independent Non-Executive Director
Appointed 1 July 2026
Dr Leanne Rowe AM
Independent Non-Executive Director
Resigned 22 October 2025
Grant Jeffery
Independent Non-Executive Director
Resigned 7 April 2026
Current Stephen Roche
Former
18
Australian Clinical Labs
- Directors cont.
Stephen Roche
Melinda McGrath
Chair (from 26 August 2025)
Chief Executive Officer and Executive Director
Independent Non-Executive Director Chair – Nominations and Governance Committee (from 4 December 2025) Stephen has been a Non-Executive Director since 20 June 2025 and became the Chair of the Board on 26 August 2025. Stephen has a wealth of strategic and operational experience across several industry sectors including healthcare, retail, building materials and fast-moving consumer goods. Stephen has over 20 years’ experience as a director of public companies, not-for-profits and private family offices, having held executive roles as the Managing Director and CEO of Australian Pharmaceutical Industries Limited and Bridgestone Australia & New Zealand. Stephen is currently the Chair of Baby Bunting Group Limited (ASX: BBN) and a Director of the Adelaide Football Club. Stephen was formerly a NonExecutive Director of Myer Family Investments Ltd, the Blackmores Group Ltd (ASX: BKL) and GWA Group Limited (ASX: GWA). He also established and was Chair of the Priceline Sisterhood Foundation from 2015, before retiring in 2018. The foundation, with its mission of creating positive health outcomes and support for women, became the official charity for all Wesfarmers Health businesses from 2025.
Melinda has been the Chief Executive Officer and Executive Director of ACL’s predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Melinda was appointed an Executive Director of ACL on 19 December 2020. Melinda has more than 30 years’ experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation’s restructure and transformation, building ACL’s scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope’s Australian pathology business, St John of God Health Care’s pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system.
Melinda was Chief Executive Officer of QML Pathology (part of Healius/ Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held various transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew’s War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super. Melinda holds a Bachelor of Human Movement Studies Degree and a Bachelor of Arts Degree from the University of Queensland, a Master of Business Administration from the University of Central Queensland, and a Certificate in Governance Practice from the Governance Institute of Australia.
Annual Report 2026
19
Directors’ Report for the year ended 30 June 2026
- Directors cont.
Mark Haberlin
Christine Bartlett
Sarah Butler
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Interim Chair (from 1 May 2025 to 25 August 2025)
Chair – People and Culture Committee
Member – People and Culture Committee
Chair – Audit and Risk Committee Member – People and Culture Committee (from 10 November 2025) Member – Nominations and Governance Committee (from 4 December 2025) Mark has been a Non-Executive Director of ACL since 28 April 2021. Mark has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Chair of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC’s Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. Mark holds a Bachelor of Science (Civil Engineering) (Honours) from Imperial College London and qualified as a Chartered Accountant in the United Kingdom.
20
Australian Clinical Labs
Member – Audit and Risk Committee Member – Nominations and Governance Committee (from 4 December 2025) Christine was appointed as a NonExecutive Director on 23 August 2023. Christine is an experienced Non-Executive Director, with extensive executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies. Christine is currently the Chair of CEDA, the Chair of NSW Ports and a Non-Executive Director of Reliance Worldwide Corporation Limited and Firmus Technologies Pty Ltd. Christine is a member of Chief Executive Women and the Australian Institute of Company Directors. Christine holds a Bachelor of Science from the University of Sydney and has completed senior executive management programs at INSEAD. Christine has previously held NonExecutive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family, Sigma Healthcare Limited, Mirvac Limited and TAL Life Limited.
Member – Nominations and Governance Committee (from 4 December 2025) Sarah was appointed a Non-Executive Director on 1 February 2025 and has extensive experience in health, insurance, government, consumer and technology industries with a long career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including five years spent living and working in China and Asia. She led PwC’s Global Health Services and NSW Government practices through COVID-19, and previously led Booz & Company’s Greater China business and Global Insurance. Sarah is currently a Non-Executive Director of Nanosonics Limited (ASX: NAN), Lumonus (global cancer healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee. Sarah is an adjunct professor of the UNSW Medicine faculty office. Sarah is an FAICD, a graduate of the Australian Institute of Company Directors, and a member of Chief Executive Women. Sarah holds a MA & BA (Hons) in Natural Sciences (Chemistry) from the University of Cambridge.
Dr Amandeep Hansra Independent Non-Executive Director (from 1 July 2026) Member – Nominations and Governance Committee (from 1 July 2026) Dr Amandeep Hansra joined the Board as a Non-Executive Director on 1 July 2026. Dr Hansra is a General Practitioner with more than 20 years clinical experience and whose career has included clinical practice, national digital health leadership, government engagement and a number of board roles. In her executive career, Dr Hansra has held the roles of Chief Medical Officer with Telstra Health, Head of Clinical Innovation at NIB and Deputy Chief Medical Officer at the Department of Home Affairs.
Dr Hansra has led national clinical governance frameworks across digital health, telehealth and technologyenabled care, including managing complex incidents and clinician engagement in emerging models of care. Dr Hansra remains committed to her GP practice as a Fellow of the Royal Australian College of General Practitioners and acts a Chief Clinical Advisor to the Australian Digital Health Agency.
Dr Hansra also serves as a member of the Industry Growth Committee for the Department of Industry, Science and Resources. Dr Hansra holds a Bachelor of Medicine (Hons) from the University of Newcastle and a Masters of Public Health and Tropical Medicine from James Cook University. Dr Hansra also has a Global Executive MBA from the University of Sydney Business School and is a graduate of the AICD.
Dr Hansra is currently a nonexecutive director of Healthicare, ACHS International, MoleMap New Zealand, Healthengine and the Central and Eastern Sydney Primary Health Network.
Former Directors Dr Leanne Rowe AM Independent Non-Executive Director (resigned 22 October 2025) Member – People and Culture Committee (resigned 22 October 2025)
Grant Jeffery Independent Non-Executive Director (resigned 7 April 2026) Member – Audit and Risk Committee (resigned 7 April 2026)
Annual Report 2026
21
Directors’ Report for the year ended 30 June 2026
- Directorships of Other Listed Companies The following table shows, for each Director, all directorships of companies that were listed on the ASX, other than the Company, from 30 June 2020, and the period for which each directorship has been held: Director
Listed Entity
Period Directorship Held
Stephen Roche
Baby Bunting Group Limited GWA Group Limited Blackmores Group Limited
September 2021 – present October 2022 – August 2025 September 2021 – August 2023
Melinda McGrath
–
–
Mark Haberlin
Abacus Property Group
November 2018 – present
Christine Bartlett
Reliance Worldwide Corporation Limited Mirvac Limited Sigma Healthcare Limited
November 2019 – present December 2014 – April 2026 March 2016 – December 2023
Sarah Butler
Nanosonics Limited
January 2026 – present
Dr Amandeep Hansra
–
–
- Meetings of Directors and Board Committees The number of meetings of the Board and each of the Board Committees held during the year ended 30 June 2026, and the number of meetings attended by each Director are shown below. From time to time, Directors attend meetings of Committees of which they are not currently members; however, only attendances by Directors who are members of the relevant Committee are shown below:
Directors
Board of Directors
Audit and Risk Committee
People and Culture Committee
Nominations and Governance Committee
Eligible Attended
Eligible Attended
Eligible Attended
Eligible
Attended
Current Stephen Roche
16
16
–
–
–
–
1
1
Melinda McGrath
16
15
–
–
–
–
–
–
Mark Haberlin
16
16
5
5
3
3
1
1
Christine Bartlett
16
15
5
5
4
4
1
1
Sarah Butler
16
16
–
–
4
4
1
1
Dr Leanne Rowe AM
4
4
–
–
1
1
–
–
Grant Jeffery
9
8
4
4
–
–
–
–
Former
Further meetings occurred during the year on specific issues, including meetings of the Chair with the CEO and meetings of Non-Executive Directors with management.
22
Australian Clinical Labs
- Directors’ Relevant Interests in Shares The following table sets out the relevant interests that each Director and their immediate family has in the Company’s ordinary shares as at the date of this report: Ordinary Shares
Performance Rights
Stephen Roche
70,000
–
Melinda McGrath
2,923,331
395,490
Mark Haberlin
47,500
–
Christine Bartlett
20,000
–
Sarah Butler
22,617
–
–
–
Director
Dr Amandeep Hansra
-
Company Secretary Eleanor Padman was appointed Company Secretary on 28 April 2021. Eleanor is a corporate lawyer, governance and sustainability expert with more than 25 years’ experience gained in the UK and Australia. Having held the roles of General Counsel, Company Secretary and Head of Risk and Compliance at various ASX listed companies for 10 years, in 2019, Eleanor established her own boutique advisory business and provides corporate governance services to ACL, as well as acting as Company Secretary to the Board and its Committees. Eleanor combines multi-disciplinary technical abilities with a strong commercial approach and a focus on promoting good corporate governance. Eleanor is a Fellow of the Governance Institute of Australia, a Graduate of the Australian Institute of Company Directors and also holds Company Secretary and Non-Executive Director positions for various private companies. Eleanor holds a Masters in Sustainability (USyd) and a Bachelor of Modern Languages (First Class Honours) from the University of Oxford, a Graduate Diploma in Law and Postgraduate Diploma in Legal Practice from the University of Law, London (formerly the College of Law) and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.
-
Principal Activities During the year the principal continuing activity of the Group was the provision of pathology diagnostic services.
-
Operating and Financial Review Key financial highlights in the financial year ended 30 June 2026 compared to the financial year ended 30 June 2025 include: •
Total Revenue of $735.8m down $5.5m (-0.7%) on FY25.
•
Underlying Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA1) of $204.5m up 0.2% on FY25.
•
Underlying Earnings Before Interest and Tax (EBIT1) of $69.2m up 1.7% on FY25.
•
Underlying EBIT1 Margin of 9.4%, up 20 basis points on FY25.
•
Statutory EBIT of $55.5m down $10.6m on FY25.
•
Underlying Net Profit After Tax (NPAT1) of $35.5m up 4.3% on FY25.
•
Statutory NPAT of $24.0m down $8.8m on FY25.
•
Free cash flow before interest, tax and financing of $64.7m2 down 8.7% on FY25.
•
Declared a final fully franked dividend of 9.25 cps (9 cps for FY25).
1
Underlying figures are calculated excluding certain non-recurring revenue and expenses (AIC settlement – EBITDA/EBIT/NPAT $6.2m, Medlab contract - EBITDA/EBIT $4.2m and NPAT $2.9m, Labour – prior periods - EBITDA/EBIT $1.4m and NPAT $1.0m and Other - EBITDA/EBIT $1.9m and NPAT $1.3m). Free cash flow before interest, tax and financing excludes the AIC settlement of $6.2m.
2
Annual Report 2026
23
Directors’ Report for the year ended 30 June 2026
- Operating and Financial Review cont. Underlying EBIT was $69.2m, representing an underlying EBIT margin of 9.4% and growth of 1.7% compared with FY25. The second half of the year showed stronger operating leverage, with an underlying EBIT margin of approximately 11.1%. The improved underlying earnings was achieved in a challenging operating environment characterised by subdued pathology market volumes and changes to Medicare funding arrangements. This performance also reflected the benefits of portfolio optimisation, improved operational efficiency, disciplined contract management and the early contribution from revenue initiatives, partly offset by award wage increases, gender undervaluation costs, higher superannuation costs and other inflationary pressures. Revenue for the year was $735.8m, representing a decline of 0.7% on the prior corresponding period. The reduction in revenue reflected a low-growth pathology market, lower general practitioner attendances, the impact of Medicare fee changes including reductions to certain testing items. These headwinds were partially offset by revenue enhancement initiatives, including the progressive implementation of digitalised upfront patient billing and improved recovery of fees that are not reimbursed by Medicare. ACL also effected the deliberate rationalisation of parts of our collection centre and contract portfolio where acceptable commercial returns and terms could not be achieved. Underlying NPAT was $35.5m, an increase of 4.3% on FY25. Reported NPAT was $24.0m, a decrease of 26.8% on FY25, reflecting specific items and other matters separately addressed in the financial statements. Underlying earnings per share increased by 8.5% to 18.3 cents per share, supported by improved underlying profitability and the benefit of the onmarket share buy-back program. Free cash flow was $64.7m1, representing a decrease of 8.7% compared with FY25. ACL maintained a strong balance sheet and continued to apply a disciplined capital allocation policy, balancing investment in strategic initiatives with shareholder returns. $47.1m was returned to shareholders through dividends and the on-market share buy-back program. A fully franked final dividend of 9.25 cents per share for FY26 was declared.
FY26 Operations ACL is one of the largest providers of pathology services in Australia by revenue, with operations in Victoria, New South Wales, Western Australia, South Australia, Queensland and the Northern Territory with a heritage of hospital-based pathology and the skills to deliver time-critical and complex hospital pathology, as well as the scale to efficiently provide community pathology. The network at 30 June 2026 comprises: •
Over 4,500 scientists, collectors and support staff
•
Over 40 accredited laboratories
•
Over 1,270 collection centres
•
28 specialist skin cancer clinics
ACL continued to benefit from its national operating model and single national Laboratory Information System. This platform remains a key strategic advantage, reducing duplication, supporting consistent processes, enabling national implementation of technology and billing initiatives, and improving the scalability of operational improvements across the network. Several of these factors contributed to the improvement in laboratory efficiency of 10.4% on a panels per FTE basis this year. This effort was supported by an enhanced procurement program that delivered a reduction in our consumables spend as a percentage of revenue over FY25. Continual improvement in operational efficiency is a core element of business-as-usual activities, driven by a targeted KPI enhancement program. On top of this, ACL has also progressed a number of automation, artificial intelligence and digitalisation initiatives across billing, laboratory workflows and back-office functions. These initiatives support further efficiency improvements, improve billing accuracy, reduce manual processing and enhance the scalability of the business. This focus has enabled ACL to increase its underlying EBIT margin in FY26.
1
Free cash flow before interest, tax and financing excludes the AIC settlement of $6.2m.
24
Australian Clinical Labs
-
Significant Changes in State of Affairs There was no other significant change in the state of affairs of the Group during the year.
-
Business Strategies and Future Developments The Board and the Executive Management Team are focused on delivering against a growth strategy that will drive expansion in ACL’s core community and hospital pathology market, entry into strategic adjacencies and continue to improve operating efficiency. ACL’s growth and strategic development is focused on the following five initiatives to drive increased shareholders returns:
-
Disciplined network expansion •
ACL will continue to invest in sustainable and profitable collection centre network expansion and hospital services growth, with a focus on high value specialist inpatient and outpatient services.
•
Look to add complementary non-Medicare additions to the network including Clinical Trials and Skin Cancer Clinics.
- Strategic new business •
ACL is focused on developing a pipeline of new tests and service opportunities through investments in partnerships to support growth.
•
Prosecution of opportunities in specialised diagnostics and genetics testing, including oncological genomics and recently accredited tests for melanoma, reproductive health testing and specialist outpatient referrals. These areas provide potential for revenue diversification and growth in higher-value testing categories over time.
- Strategic acquisitions •
ACL continues to actively explore strategic acquisition opportunities for the business with key targets including domestic pathology, SunDoctor clinics, strategical investments aligned to competitive advantage as well as international and adjacent pathology.
- Revenue initiatives •
ACL continues to focus on the improvement and digitisation of billing processes to recover unpaid patient testing.
•
Various initiatives to support the growth of non-MBS tests.
•
Application of AI to manual billing practices.
- Operational improvement and restructuring •
The Lab of the Future program is progressing and is expected to leverage ACL’s national operating platform to increase automation and improve laboratory efficiency. The program is designed to enable a significant proportion of routine work to be processed through highly automated, extended-hours laboratory workflows, supported by robotics, artificial intelligence and machine learning.
•
Continuing to refine the national skin cancer strategy, including the development of a more automated skin laboratory model and the integration of clinical and operational capability across SunDoctors, Southern Sun Pathology and ACL.
•
AI automation of operations and diagnostics/clinical practice.
- Key Risks and Uncertainties ACL is subject to risks both specific to ACL and ACL’s business activities, as well as general risks.
Government policy and regulation may change ACL seeks to provide affordable pathology services to its patients. This is facilitated through bulk-billing the vast majority of its services to patients and receiving reimbursements through the Australian Government’s Medicare Benefits Schedule (MBS). The MBS is subject to continual review and change, with the included services and prices being determined by the Federal Government. Any changes to the MBS or any other Government funding initiatives, including a reduction in fees or tests that will be covered by the MBS, could lead to a reduction in revenue for ACL and may adversely affect ACL’s ability to provide testing and demand for ACL’s services. Annual Report 2026
25
Directors’ Report for the year ended 30 June 2026
- Key Risks and Uncertainties cont. The nature, timing and impact of future changes to laws, government policies and regulations are not predictable and are beyond ACL’s control. Failure by ACL to comply with applicable laws, regulations and other professional standards and accreditation may lead to enforcement actions that disrupt ACL’s operations and result in it being subject to fines, penalties, damages and disruption to its operations. ACL monitors legislative and regulatory developments and engages proactively with key stakeholders to manage this risk.
A failure of technical, process or people controls may contribute to a significant Cyber Security or Data related incident ACL is heavily dependent on technology for the delivery of the services it provides its customers. Any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet and data network failures, and natural disasters. ACL is committed to preventing and reducing cyber security risks. ACL has information security and data protection policies and standards frameworks established in accordance with the National Institute of Standards and Technology (NIST). ACL implements and operates IT security in-house with the assistance of partners and common IT security technologies to protect, detect and respond to security concerns. ACL conducts routine testing of systems and works closely with third-party security specialists to implement its security roadmap.
Clinical care and patient safety ACL acknowledges the inherent risks associated with its practice in the healthcare space that could lead to an adverse impact on quality of clinical care and/or patient safety in the course of ACL providing pathology and associated services. The organisation manages this risk with a detailed clinical governance framework that includes quality assurance procedures, annual credentialing and qualification review, clinical review processes and professional development for all disciplines. ACL’s laboratories are all accredited by the National Association of Testing Authorities (NATA) and our pathologists are Fellows of the Royal College of Pathologists Australasia and registered with the Australian Health Practitioner Regulation Agency (AHPRA). ACL maintains a zero appetite for critical safety incidents, emphasising its commitment to patient safety and is dedicated to maintaining high levels of patient satisfaction.
ACL may be unable to recruit and retain key personnel The successful operation of ACL’s business relies on its ability to recruit and retain experienced and high-performing management, pathologists, scientists, and IT and operating staff. Relationships with certain referrers may be heavily reliant on particular ACL personnel (especially pathologists and scientists), such that their departure from the business could have an adverse impact on ACL’s relationship with the referrer. There is significant competition to recruit these personnel, which can lead to increased labour costs. ACL’s focus on diagnostic excellence through its centres of excellence and commitment to continuing professional education for staff and referrers, including training the next generation of pathologists and scientists, help to attract and retain a professional workforce. ACL’s unified pathology system also provides flexibility to its national workplace.
ACL is subject to labour agreement negotiations and Fair Work Commission (FWC) determinations The majority of ACL’s employees have terms and conditions of employment governed by enterprise agreements or modern awards which periodically require classification assessment, renegotiation or renewal. Any such classification assessment, renegotiation or renewal may result in increased direct and indirect labour costs for ACL, and issues may also arise during the processes which lead to strikes or other forms of industrial action that could disrupt ACL’s operations. This could adversely impact on the financial performance and reputation of ACL. The FWC is currently reviewing gender-based undervaluation in modern awards, including awards that cover ACL employees. This review aims to address historical gender-based assumptions that have led to lower pay in female-dominated industries.
26
Australian Clinical Labs
In addition, any deterioration in the relationship with employees or unions could potentially lead to reputational damage, loss of key employees, increased direct and indirect labour costs or the inability for ACL to undertake the level of services it anticipates in the future. ACL is currently in negotiations relating to two enterprise agreements. ACL has managers and staff dedicated to negotiating workplace agreements and ensuring staff engagement.
Pay and Entitlements Paying employees correctly and ensuring they are paid correct entitlements is essential to maintaining trust and the Company’s reputation. ACL regularly reviews and enhances baseline controls across the end-to-end pay process. Where possible, automated procedures are utilised to reduce the risk of manual errors. Industrial instruments are proactively reviewed, and management are responsible for staying abreast of changes to industrial relations legislation and ensuring all leaders understand and comply.
ACL’s exposure to international developments may impact its operations ACL sources testing supplies such as reagents and equipment from international markets. Prices of these supplies and equipment are subject to change driven by, among other factors, foreign exchange rates, market demand and supply, supply chain interference due to global geopolitical issues, and scientific and technological advancements. ACL is unable to pass on cost increases as a substantial portion of ACL’s revenue is derived from the MBS with almost all community pathology being bulk-billed under the MBS and some private hospital contracts linked to services in the MBS. Any adverse movements in testing supplies and equipment may increase ACL’s costs of business and may have a material adverse impact on ACL’s performance. ACL manages supply price risk by entering into long-term fixed price arrangements with major suppliers for consumable products and by sourcing consumables locally in Australia. ACL remains vigilant in actively monitoring international developments, and managing supply costs and disruptions. For example, ACL successfully managed the surge in demand for COVID-19 testing with no material operational disruptions.
Another pandemic may impact ACL’s business Pandemic risks, such as COVID-19, pose business continuity risk to ACL. There is the risk from lockdowns across communities in response to a pandemic that the volume of routine pathology testing may be adversely impacted. There is a risk that staff and laboratories are adversely impacted by a pandemic which limits ACL’s ability to provide testing facilities. ACL staff may be front-line personnel providing collection services to customers potentially infected. Notwithstanding policies and procedures in place to mitigate such risks, there is a risk that staff in key operational roles are infected, impacting ACL’s operations.
-
Matters Subsequent to the End of the Financial Year Since the end of the financial year, the Directors are not aware of any matter or circumstance not otherwise dealt with in these financial statements that has significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in subsequent financial years.
-
Dividends In respect of the full year ended 30 June 2026, a final dividend of 9.25 cents per share (100% franked) has been declared with a record date of 3 September 2026 and payable 23 September 2026, bringing total dividends for FY26 to 13 cents per share (100% franked). This represented a dividend payout ratio of 69% of FY26 Underlying NPAT, which is consistent with ACL’s policy of paying out 50% to 70% of Underlying NPAT as a dividend. The dividend reinvestment plan will remain suspended for the FY2026 final dividend.
-
Share Rights and Options Information on Australian Clinical Labs Performance Rights and Service Rights is disclosed in Note 21 – Share-Based Payments.
Annual Report 2026
27
Directors’ Report for the year ended 30 June 2026
-
Remuneration Report The Remuneration Report which forms part of this Directors’ Report is presented separately from page 31.
-
Indemnification and Insurance of Directors and Officers The Company’s Constitution provides that the Company may indemnify current and former Directors, alternate Directors, Executive Officers, Officers and auditors of the Company on a full indemnity basis and to the extent permitted by the law against all liabilities and losses incurred as an officer of the Group, except to the extent covered by insurance. Further, the Company’s Constitution permits the Company to maintain and pay insurance premiums for director and officer liability insurance, to the extent permitted by law. Consistent with (and in addition to) the provisions in the Company’s Constitution outlined above, the Company has also entered into deeds of access, indemnity and insurance with all Directors and certain Officers of the Company which provide indemnities against losses incurred in their role, subject to certain exclusions, including to the extent that such indemnity is prohibited by the Corporations Act 2001 (Cth) or any other applicable law. During the financial period, the Company paid insurance premiums for a directors’ and officers’ liability insurance contract that provides cover for the current and former Directors, alternate Directors, Secretaries, Executive Officers and Officers of the Company and its subsidiaries. The Directors have not included details of the nature of the liabilities covered in this contract or the amount of the premium paid, as disclosure is prohibited under the terms of the contract. The Group’s auditor is Pitcher Partners (Melbourne) (Pitcher Partners). No payment has been made to indemnify Pitcher Partners during or up to the date of this report. No premium has been paid by the Group in respect of any insurance for Pitcher Partners. No Officers of the Group were Partners or Directors of Pitcher Partners whilst Pitcher Partners conducted audits of the Group.
-
Proceedings on behalf of the Company In April 2026, ACL was served with a representative proceeding filed in the Supreme Court of Victoria by a Ms Michelle RaabIvanov, which is expressed to be on behalf of persons who were customers of Medlab Pathology and/or ACL prior to 15 July 2022, and whose personal information was affected by a cyberattack on Medlab Pathology in February 2022 (Claim). The Claim seeks damages in respect of a number of allegations relating to the cyber attack. ACL denies the allegations in the Claim and intends to vigorously defend it. There are no other proceedings brought or intervened in, or applications to bring or intervene in proceedings, on behalf of the Group by a member or other person entitled to do so under section 237 of the Corporations Act.
-
Environmental Regulation The operations of the Group are not subject to any site‑specific environmental licences or permits which would constitute particular or significant environmental regulation under the laws of the Australian Government or an Australian Territory. ACL, through its internal policy and processes, is committed to managing operations in an environmentally sustainable manner to maximise resource efficiency in relation to the consumption of energy and natural resources and minimise waste.
-
Non-Audit Services There is no person who has acted as an officer of the Group during the year who has previously been a partner at Pitcher Partners when that firm conducted the Group’s audit. During the year Pitcher Partners did not provide any non-audit services.
28
Australian Clinical Labs
- Auditor’s Independence Declaration
AUSTRALIAN CLINICAL LABS LIMITED ABN: 94 645 711 128 AUDITOR’S INDEPENDENCE DECLARATION TO THE DIRECTORS OF AUSTRALIAN CLINICAL LABS LIMITED
In accordance with section 307C of the Corporations Act 2001, I declare to the best of my knowledge and belief in relation to the audit of the financial report of Australian Clinical Labs Limited for the year ended 30 June 2026, there have been: (i)
No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation the audit; and
(ii)
No contraventions of APES 110 Code of Ethics for Professional Accountants (including Independence Standards) in relation the audit.
This declaration is in respect of Australian Clinical Labs Limited and the entities it controlled during the year.
B POWERS Partner
PITCHER PARTNERS Melbourne
Date: 14 August 2026
Pitcher Partners. An independent Victorian Partnership ABN 27 975 255 196. Level 13, 664 Collins Street, Docklands, VIC 3008 Pitcher Partners is an association of independent firms. Liability limited by a scheme approved under Professional Standards Legislation. Pitcher Partners is a member of the global network of Baker Tilly International Limited, the members of which are separate and independent legal entities
Adelaide Brisbane Melbourne Newcastle Sydney Perth
pitcher.com.au
Annual Report 2026
29
Directors’ Report for the year ended 30 June 2026
-
Rounding Amounts The Company is an entity of a kind referred to in ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2026/183, dated 27 March 2026, and in accordance with that Instrument, amounts in this report and the Financial Report are rounded off to the nearest thousand dollars or, in certain cases, to the nearest dollar. Some numerical figures included in this report have been subject to rounding adjustments. Any differences between totals and sums of components in tables or figures contained in this report are due to rounding.
-
Annual General Meeting ACL will be holding its AGM on 28 October 2026.
Signing of Directors’ Report Signed in accordance with a resolution of the Directors made pursuant to section 298(2) of the Corporations Act 2001. On behalf of the Directors.
Stephen Roche Chair 14 August 2026
30
Australian Clinical Labs
Remuneration Report For the year ended 30 June 2026
Annual Report 2026
31
Directors’ Report / Remuneration Report for the year ended 30 June 2026
Letter from the Chair of the People and Culture Committee In FY26, ACL continued to demonstrate medical excellence and has strived for operational discipline in a challenging pathology market which has been persistently subdued as MBS outlay growth trends below long-term averages. The business has remained committed to optimising factors within its control which included closing unprofitable collection centres, achieving workforce productivity gains and deploying AI-enabled efficiencies across our portfolio in order to grow margins despite softer revenue in FY26.
Dear Shareholders, On behalf of the Board of Australian Clinical Labs (ACL), I am pleased to present the 2026 Remuneration Report. ACL is one of the largest providers of pathology services in Australia by revenue with a heritage of hospitalbased pathology and the skills to deliver time-critical and complex hospital pathology, as well as the scale to efficiently provide community pathology. ACL also operates the SunDoctors business with 28 Medical Centres.
Our strategy remains focused on delivering sustainable profitable growth through optimising our footprint and cost structure, capturing new revenue streams and disciplined capital allocation. We continue to progress a strong pipeline of efficiency initiatives that are expected to deliver material earnings benefits in FY27.
Our strategy remains focused on delivering sustainable profitable growth through optimising our footprint and cost structure, capturing new revenue streams and disciplined capital allocation.
32
Australian Clinical Labs
FY26 performance ACL’s business performed to expectations this year, improving margins notwithstanding continuing industry cost pressures. As in FY25, ACL has continued to apply a disciplined approach to optimising its ACC portfolio and bidding for commercial contracts to focus on accretive margins. Operationally, we have begun to see the positive impact of our AI and automation projects on our operational management, leveraging our unique competitive advantage of a single national laboratory information system. ACL continues to embed operational efficiency as a core element of its business-as-usual activities, and this approach has enabled ACL to again slightly improve its margin in FY26 despite challenging inflationary and labour cost pressures including the Fair Work Commission’s determination on gender-based undervaluation in the Health Professionals and Support Services Award, which will provide for phased wage increases for pathology and health professionals in the coming years. We met our revised FY26 revenue guidance and exceeded our underlying EBIT guidance. ACL achieved a conversion of EBITDA to operating cash flow of 119.2% underscoring ACL’s continued ability to generate cash for shareholders. This efficient cash flow management has allowed ACL to return $21.8m to shareholders by way of an on-market share buy-back and pay $25.3m in dividends. During FY26, ACL outperformed the S&P/ASX 200 Healthcare Index’s return of -36% by 21%.
FY26 remuneration outcomes The FY26 STVR program met its gateway requirement by recording an Underlying EBITDA Margin (pre AASB 16) of 9.2%. As the gate opened, based on performance against financial and strategic measures, the CEO’s STVR outcome was assessed at 99% of target and the CFO’s STVR outcome was assessed at 94% of target. The FY24 LTVR grant was tested against the sole indexed total shareholder return (iTSR) measure against the ASX 300 Industrials (excl. Financials and Resources) index, which was assessed as below the threshold level of performance for the period, resulting in nil LTVR rights vesting in FY26. Further detail on our STVR and LTVR outcomes can be found in Section 4.
Remuneration framework and changes for FY26 and FY27 At the 2025 AGM, ACL received a ‘second strike’ against its 2025 Remuneration Report. The Board has continued to engage with key investors and external stakeholders following this vote. The concerns expressed in FY25 were very similar to those raised in FY24 and related to a number of historic arrangements.
Key changes to our remuneration framework for FY27 include: •
•
Removal of the 20% service-rights component, for the FY27 LTVR grant, and introducing a ROIC measure (34%) with the existing EPS (33%) and rTSR measures (33%) reweighted to accommodate the new measure. This means that 100% of LTVR will be linked to performance for all KMPs. Changing our rTSR peer group from the ASX 300 (ex-financials and resources) index to a bespoke index comprised of a group of comparable ASX-listed healthcare services peers with sufficient market capitalisation, comparable operating models, and exposure to the same external industry forces and dynamics as ACL which the Board believes is more appropriate when assessing our comparative TSR performance.
Following a rigorous search, Greg Horan joined ACL on 1 June 2026 as CEO-elect and will assume the Group CEO and Executive Director role on 31 August 2026. We look forward to working with Greg to further progress ACL’s growth. As previously announced to the market, we welcomed Stephen Roche, our new Chair of the Board, on 26 August 2025, and Dr Amandeep Hansra was appointed as an additional Independent NonExecutive Director on 1 July 2026. Amandeep will stand for election at the forthcoming AGM. During the year, Dr Leanne Rowe AM and Grant Jeffery retired from the Board; I would like to take this opportunity to also thank Leanne and Grant for their contributions to ACL during their tenure. On behalf of the Board, I thank shareholders for their ongoing support of the Company.
Our detailed response to the concerns raised in relation to our 2025 remuneration report and for proposed changes for FY26/FY27 are outlined in Section 5 below.
KMP changes during the year As announced to the ASX, after leading ACL for 10 years, Melinda McGrath has indicated that she wishes to step down from the role of Group CEO and Executive Director on 30 August 2026. Melinda has been an exceptional leader through not only the transformation of ACL’s business model, but also during the COVID-19 pandemic. Melinda has driven the operational performance of ACL over the past decade. On behalf of the Board, I would like to thank Melinda for her enormous contributions to ACL.
Christine Bartlett Chair, People and Culture Committee
Annual Report 2026
33
Directors’ Report / Remuneration Report for the year ended 30 June 2026
Report Structure The remuneration report is divided into the following sections:
34
Section
Overview
- Key Management Personnel for FY26
Details of the Directors and Executives who are subject to the disclosure requirements of this report including Key Management Personnel (KMP).
- Remuneration Overview
An overview of remuneration structures for FY26.
- FY26 Remuneration Outcomes
A summary of the FY26 outcomes including both the STVR and LTVR programs for KMP.
- The Australian Clinical Labs Remuneration Strategy, Policy and Framework
This section provides details of the elements of the remuneration framework, including market positioning, variable remuneration principles, and terms of variable remuneration.
- Response to ‘Second Strike’ and FY27 Remuneration Framework
This section includes a summary of the key concerns of our external stakeholders regarding our FY25 remuneration report, and the proposed changes for the FY27 remuneration framework.
- Statutory Disclosures
This section provides the statutory disclosures not addressed by preceding sections of the report, including statutory remuneration tables, changes in equity, KMP service agreements, related party loans/ transactions, and the engagement of external remuneration consultants.
Australian Clinical Labs
- Key Management Personnel for FY26 This Report covers KMP of ACL, which are defined as those who have the authority and responsibility for planning, directing and controlling the activities of ACL. Name
Position
Date Appointed/Resigned
Stephen Roche
Board Chair Independent Non-Executive Director
Chair appointment 26 August 2025
Mark Haberlin
Interim Board Chair Independent Non-Executive Director
Chair until 25 August 2025
Christine Bartlett
Independent Non-Executive Director
Sarah Butler
Independent Non-Executive Director
Dr Amandeep Hansra
Independent Non-Executive Director
Appointed 1 July 2026
Dr Leanne Rowe AM
Independent Non-Executive Director
Resigned 22 October 2025
Grant Jeffery
Independent Non-Executive Director
Resigned 7 April 2026
Melinda McGrath
Chief Executive Officer and Executive Director
Resignation effective 30 August 2026
Greg Horan
Chief Executive Officer-elect
Appointed 1 June 2026
Matthew Cordingley
Chief Financial Officer
Non-Executive KMP Current
Former
Executive KMP Current
Annual Report 2026
35
Directors’ Report / Remuneration Report for the year ended 30 June 2026
- Remuneration Overview FY26 Executive KMP remuneration structure The following diagram outlines the Executive KMP structure for FY26. Component
Fixed
100% Cash
FY26
FY27
FY28
FY29
FY30
Base salary, superannuation and other benefits 40% EBITDA(i)
Short-Term
Long-Term
(i)
100% Cash
40% EBITDA(i) Margin
Payment in FY27
20% Strategic Objectives 30% rTSR
100% Rights
Exercisable within two years of vesting date
50% EPG CAGR 20% Service
EBITDA refers to Underlying EBITDA pre AASB 16.
The table above represents the components of the FY26 remuneration framework, being: – Fixed component payable during the year; – Short-term variable remuneration payable in FY27 based on achievement of EBITDA (40% weighted), EBITDA Margin (40% weighted) and strategic objectives (20% weighted); and – Long-term variable remuneration exercisable in FY29 based on relative TSR (30% weighted), Earnings Per Share Compound Annual Growth Rate (50% weighted) and retention (20% weighted), all measured from FY26 to FY28. Melinda McGrath did not participate in the FY26 LTVR grant. Under the terms of her fixed term contract she was granted a one-off LTVR cash retention award in FY25, which becomes payable when her employment ceases in August 2026. Greg Horan commenced at the Company as CEO-elect in June 2026. Greg did not participate in the STVR program or LTVR program in FY26. The FY26 pay mix opportunity at maximum/stretch for our KMP is shown below:
FY26 KMP Pay Mix Melinda McGrath (CEO & ED) Matthew Cordingley (CFO)
40%
46% Fixed Pay (FP)
36
Australian Clinical Labs
60%
27% Cash STVR
LTVR
27%
- FY26 Remuneration Outcomes The Board views the outcomes of remuneration for FY26 performance as appropriately aligned with stakeholders’ interests generally, given the performance against annual objectives and progress towards strategic objectives made by the executive team. The table below highlights some of our key financial results over the past five financial years, overlayed with some of our KMP remuneration outcomes. 2022
2023
2024
2025
2026
Share Price as at 30 June ($)
4.59
3.44
2.51
2.78
2.24
Total full-year dividends (cents)
53.00
14.00
12.00
12.50
13.00
LTVR vesting outcome (% max)
n/a
0%
0%
0%
0%
FY26 Short-Term Variable Remuneration (STVR) outcome The STVR plan is designed to reward executives for the achievement against annual performance objectives set by the Board at the beginning of the performance period. The payment of the STVR is dependent on delivery of performance against a range of metrics. The metrics and outcomes of assessment against those metrics are summarised below: Metric/Measure
Actual
Gate
Achieved/Failed
9.2%
8.0%
Achieved
Weight
STVR opportunity $ (target)
STVR opportunity as a % of Fixed Remuneration (target)
STVR achieved $
% STVR target achieved
% STVR target forfeited
40%
600,000
40%
529,500
88%1
12%
40%
600,000
40%
661,547
110%1
-10%
20%
300,000
20%
300,000
100%
0%
1,500,000
100%
1,491,047
99%
1%
Gate Underlying EBITDA Margin (pre AASB 16)
Chief Executive Officer
Metric/Measure Underlying EBITDA (pre AASB 16) This metric is viewed as one of the primary financial drivers of shareholder value creation under the current strategy.
Underlying EBITDA Margin (pre AASB 16) This metric is viewed as one of the primary financial drivers of shareholder value creation under the current strategy. Strategic objectives Strategic objectives are specific to the employee and are determined and approved by the Remuneration and Nomination Committee to align with Company goals and strategy. For FY26 these goals were: Objectives for FY26 were set on leadership and development, enhancing stakeholder management and strategic growth goals. TOTAL 1
CEO target is per fixed term contract, where targets are different to other KMP.
Annual Report 2026
37
Directors’ Report / Remuneration Report for the year ended 30 June 2026
- FY26 Remuneration Outcomes cont. Chief Financial Officer
Metric/Measure
Weight
STVR opportunity $ (target)
STVR opportunity as a % of Fixed Remuneration (target)
STVR achieved $
% STVR target achieved
% STVR target forfeited
40%
83,691
16%
86,352
103%
-3%
40%
83,691
16%
100,073
120%
-20%
20%
41,845
8%
10,462
25%
75%
209,227
40%
196,887
94%
6%
Underlying EBITDA (pre AASB 16) This metric is viewed as one of the primary financial drivers of shareholder value creation under the current strategy. Underlying EBITDA Margin (pre AASB 16) This metric is viewed as one of the primary financial drivers of shareholder value creation under the current strategy. Strategic objectives Strategic objectives are specific to the employee and are determined and approved by the Remuneration and Nomination Committee to align with Company goals and strategy. For FY26 these goals were: Objectives for FY26 were set on enhancing stakeholder management, capital management and strategic and long term growth goals. TOTAL
FY24 Long-Term Variable Remuneration (LTVR) outcome The FY24 LTVR grant was tested over a three-year measurement period from FY24 to FY26. Over the measurement period our indexed total shareholder return (iTSR) was below the threshold level of performance, and as a result none of the FY24 LTVR Rights will vest.
38
Australian Clinical Labs
FY26 Total Remuneration Outcomes The following outlines ‘achieved’ total remuneration, including the portions of maximum variable remuneration that were awarded or vested, and portions that were forfeited or lapsed as the result of performance assessments:
Name
Role
Year
Fixed Pay (incl. Super)
STVR Awarded
LTVR Vested
Achieved Total Remuneration Package ($)
Total Remuneration Package vs max (%)
Melinda McGrath
CEO and Executive Director
FY26
$1,512,874
$1,491,047
$0
$3,003,921
65%
FY25
$1,512,874
$1,271,749
$0
$2,784,623
63%
Greg Horan
CEO-elect and Executive Director
FY26
$90,833
$0
$0
$90,833
100%
Matthew Cordingley
CFO
FY26
$634,355
$196,887
$0
$831,242
99%
FY25
$740,250
$0
$0
$740,250
100%
Note: The CFO Fixed Pay in FY25 includes the sign-on bonus of $523,000 to compensate him for the possibility of foregone incentives with his previous employer and provide a compelling incentive to join our organisation.
- The Australian Clinical Labs Remuneration Strategy, Policy and Framework Executive remuneration – Fixed Pay, Total Remuneration Package (TRP) and the variable remuneration framework
Fixed Pay Fixed Pay comprises base salary plus any other fixed elements such as superannuation, allowances, benefits and fringe benefits tax for example. In general, Fixed Pay is intended to be targeted at P50 of market benchmarks for comparably designed roles, with consideration for level of experience and performance in the role. Our CEO-elect, Greg Horan, joined ACL in June 2026, and will commence his role as Group CEO with effect from 31 August 2026, with a fixed annual remuneration of $1,000,000 plus superannuation. Full details of his remuneration package are contained in Section 4.
Total Remuneration Package (TRP) Total Remuneration Package is intended to be composed of an appropriate mix of remuneration elements including Fixed Pay, Short-Term Variable Remuneration and Long-Term Variable Remuneration. The Target TRP (TTRP), being the TRP value at target/expected performance, is generally intended to fall between P50 and P75 of market benchmarks, with flexibility applied based on role criticality, performance, scarcity of skillset, and industry talent demand.
Annual Report 2026
39
Directors’ Report / Remuneration Report for the year ended 30 June 2026
- The Australian Clinical Labs Remuneration Strategy, Policy and Framework cont. Short-Term Variable Remuneration (STVR) plan A description of the STVR structure for FY26 is set out below, noting that the CEO-elect didn’t participate in the plan for FY26. Description
Overview
Purpose
To provide at-risk remuneration and incentives that rewards executives for performance against annual objectives set by the Board at the beginning of the financial year. Objectives selected are designed to support long-term value creation for shareholders, and link to the long-term strategy on an annual basis.
Measurement Period
The financial year of the Company.
Opportunity
The target value is 100% of Fixed Pay for the CEO, with a maximum/Stretch of 150% of Fixed Pay. The target value is 40% of Fixed Pay for the CFO, with a maximum/Stretch of 60% of Fixed Pay.
Gateway
STVR is subject to a gate of 8% Underlying EBITDA Margin (pre AASB 16) to ensure the plan is only payable where acceptable returns are delivered recognising market context.
Outcome Metrics and Weightings
Subject to the achievement of the financial gateway, the STVR outcome is dependent on meeting Group performance objectives. The metrics for FY26 are: • Underlying EBITDA (pre AASB 16) (40% weighting); • Underlying EBITDA margin (pre AASB 16) (40% weighting); and • Strategic goals (20% weighting). These metrics were selected because they are viewed by the Board as the primary drivers of value creation for the business, they measure the core operating and financial performance having reflected all operating costs.
Settlement
Awards are determined following auditing of accounts after the end of the financial year.
Service condition
STVR is subject to the participant remaining employed on the last day of the financial year unless otherwise determined by the Board.
Malus and Clawback
The STVR plan includes malus and clawback clauses which may apply in a range of circumstances, including material misstatements resulting in overpayment, the participant joining a competitor or being involved in actions that are deemed to have harmed other stakeholders.
Board Discretions
The Board has discretion to modify the awards payable to participants regardless of any performance outcome or gate, to ensure that outcomes are appropriate to the circumstances that prevailed over the Measurement Period.
Corporate Actions
The Board has discretion to determine the treatment of unpaid STVR in the case of major corporate actions such as a change in control, delisting, major return of capital or demerger.
40
Australian Clinical Labs
Long-Term Variable Remuneration (LTVR) plan A description of the LTVR structure for FY26 is set out below, noting that the CEO and CEO-elect didn’t participate in the grant for FY26. Description
Overview
Purpose
To provide at-risk remuneration and incentives that reward executives for performance against long-term value creation objectives set by the Board at the beginning of the financial year and to align the interests of executives with the interests of shareholders.
Measurement Period
Three financial years including the financial year of grant (i.e. FY26 to FY28).
Opportunity
The target value is 40% of Fixed Pay for the CFO, with a maximum/stretch of 60% of Fixed Pay.
Instrument
The Awards that may be offered under the LTVR Plan consist of Performance and Service Rights.
Price and Exercise Price
The Price is nil, because it forms part of the remuneration of the participant. The Exercise Price is nil.
Allocation Method
The number of Rights issued was determined by dividing the maximum value of LTVR by the Volume Weighted 20-day Average Market Price for ACL shares preceding the date of grant.
Gateway
rTSR Performance Rights are subject to a positive TSR gateway during the Measurement Period to ensure the grant does not vest when shareholders are losing value. There are no gates in place for EPS CAGR and Service Rights.
Performance Metrics and Weightings
The LTVR is broken into three difference tranches of rights being: • 30% Relative Total Shareholder Return (rTSR) • 50% Earnings Per Share Compounding Annual Growth Rate (EPS CAGR) • 20% Service Rights rTSR Performance Rights The vesting of such Performance Rights will be determined by comparing the Company’s TSR over the Measurement Period with the TSR of the ASX 300 Ex-Financials and Resources Index. TSR is calculated as a percentage growth in shareholder value based on share price growth and dividends, assuming that they are reinvested into Shares. During periods of nil dividends being declared, TSR is equal to change in share price. The vesting scale for this performance vesting metric is as follows:
Performance Level
Company’s TSR compared to ASX 300 Ex- Financials and Resources
% of Tranche Vesting
Stretch
= 75th Percentile
100%
Target
= 50 Percentile
50%
Below Target
< 50 Percentile
Nil
th
th
Outcomes between Target and Stretch performance are pro-rated on a straight-line basis between 50% and 100% vesting. This metric was selected as it provides a direct link between executive remuneration and shareholder return relative to relevant peer originations. Equity grants are tested against the performance measures set. If the performance hurdles are not met at the vesting date, Performance Rights lapse.
Annual Report 2026
41
Directors’ Report / Remuneration Report for the year ended 30 June 2026
- The Australian Clinical Labs Remuneration Strategy, Policy and Framework cont. Description
Overview EPS CAGR Performance Rights The vesting of such Performance Rights will be determined by comparing the Company’s EPS movement over the Measurement Period. EPS is calculated as the net income divided by the weighted average number of shares. It is calculated over a specific period which for the purpose of this Invitation is the Measurement Period and based on weighted average number of shares in line with financial statements, which will be annualised and expressed as a Compound Annual Growth Rate (CAGR). EPS growth will be measured by the difference between the EPS of FY26 and the EPS of FY28. The vesting scale for this performance vesting metric is as follows: Performance Level
EPS Growth (CAGR)
% of Tranche Vesting
Stretch
= 10% CAGR
100%
Target
= 4% CAGR
50%
Below Target
< 4% CAGR
Nil
Outcomes between Target and Stretch performance are pro-rated on a straight-line basis between 50% and 100% vesting. This metric was selected as it’s the broadest measure of earnings growth and a standard measure on Company performance. Equity grants are tested against the performance measures set. If the performance hurdles are not met at the vesting date, Performance Rights lapse. Service Rights The vesting of Service Rights will be determined by the continued service over the Measurement Period. This metric was selected to encourage stability with the recent changes to the Board and planned CEO transition. Equity grants convert to shares following completion of the Measurement Period. Service Condition
In addition to the performance conditions, continued service during the full Measurement Period is a requirement in order for any Rights to become eligible to vest.
Settlement
The Rights are ‘Indeterminate’ which may be settled in the form of a Company Share (including a Restricted Share), or cash equivalent, upon valid exercise.
Term
Rights must be exercised within five years of the Grant Date, otherwise they lapse.
Malus and Clawback
The LTVR plan includes malus and clawback clauses which will result in forfeiture of unvested Rights in a range of circumstances, including material misstatements resulting in overpayment, the participant joining a competitor or being involved in actions that are deemed to have harmed other stakeholders.
Board Discretions
The Board has discretion to modify vesting to participants regardless of any performance outcome or gate, to ensure that outcomes are appropriate to the circumstances that prevailed
– ENDS – This announcement was authorised for release to ASX by the Company Secretary. For further information regarding this announcement, please contact: Company Secretary Eleanor Padman Company Secretary Email: [email protected] Phone: +61 (0) 422 002 918 About Australian Clinical Labs
ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients’ lives.
Page 1 of 1
Rules 4.7.3 and 4.10.3
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity
Australian Clinical Labs Limited
ABN/ARBN
Financial year ended:
ABN 94 645 711 128
30 June 2026
Our corporate governance statement1 for the period above can be found at:2
☒
These pages of our annual report:
☐
This URL on our website:
Pages 51 to 67
The Corporate Governance Statement is accurate and up to date as at 25 August 2026 and has been approved by the Board. The annexure includes a key to where our corporate governance disclosures can be located. 3 Date: 22 September 2026 Name of authorised officer authorising lodgement:
Eleanor Padman, Company Secretary
1 “Corporate governance statement” is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which
discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period. Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period. Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3. Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council’s recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3. The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately. 2 Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where
your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable. 3 Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not
applicable and just retain the option that is applicable. If you select an option that includes “OR” at the end of the selection and you delete the other options, you can also, if you wish, delete the “OR” at the end of the selection. See notes 4 and 5 below for further instructions on how to complete this form. ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 1
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations
ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT 1.1
1.2
1.3
1.4
A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.
✓ and we have disclosed a copy of our board charter at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.
✓
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.
✓
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.
✓
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
4
Tick the box in this column only if you have followed the relevant recommendation in full for the whole of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with “insert location” underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert “our corporate governance statement”. If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg “pages 10-12 of our annual report”). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg “www.entityname.com.au/corporate governance/charters/”). 5
If you have followed all of the Council’s recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 2
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.5
✓ and we have disclosed a copy of our diversity policy at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/
☐
A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period: (1) the measurable objectives set for that period to achieve gender diversity; (2) the entity’s progress towards achieving those objectives; and (3) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined “senior executive” for these purposes); or (B) if the entity is a “relevant employer” under the Workplace Gender Equality Act, the entity’s most recent “Gender Equality Indicators”, as defined in and published under that Act. If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
and we have disclosed the information referred to in paragraph (c) as follows: (1) Our gender diversity target for the Board and the number of women in senior executive and management roles is set out in our 2021 - 2025 ESG statements which can be found here: https://investors.clinicallabs.com.au/corporateresponsibility/sustainability/ (2) Our progress toward achieving this gender diversity target is set out on page 56 of our Annual Report for the financial year ended 30 June 2026 (which includes our 2026 Corporate Governance Statement)(2026 Annual Report). (3) We are a relevant employer under the Workplace Gender Equality Act and remain compliant with our reporting obligations under that legislation. The company has been in the S&P / ASX 300 during the reporting period. Since 2022, our measurable objective for achieving gender diversity in the composition of our board is 40 : 40 : 20 (being 40% female, 40% male and 20% any gender). As at the date of this document, the composition of the board is 50% female and 50% male.
Page 3
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.6
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed the evaluation process referred to in paragraph (a) at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed the evaluation process referred to in paragraph (a) at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
page 57 of our 2026 Annual Report. and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: page 57 of our 2026 Annual Report.
1.7
A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
page 57 of our 2026 Annual Report. and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: page 57 of our 2026 Annual Report.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 4
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE 2.1
2.2
The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.
✓
A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed our board skills matrix at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
and we have disclosed a copy of the charter of the committee at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/ and the information referred to in paragraphs (4) and (5) at: page 57 of our 2026 Annual Report.
pages 58 to 59 of our 2026 Annual Report.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 5
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
2.3
✓
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.
and we have disclosed the names of the directors considered by the board to be independent directors at: page 60 of the 2026 Annual Report. and, where applicable, the information referred to in paragraph (b) at: page 60 of the 2026 Annual Report. and the length of service of each director at: page 60 of the 2026 Annual Report.
2.4
2.5
2.6
A majority of the board of a listed entity should be independent directors.
✓
The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.
✓
✓
set out in our Corporate Governance Statement OR
During the reporting period, Mr Mark Haberlin, who is considered independent, acted as Interim Chair from 1 July to 25 August 2025. Mr Stephen Roche, who is also considered to be independent, was appointed as Chair with effect from 26 August 2025.
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.
✓
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 6
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY 3.1
A listed entity should articulate and disclose its values.
✓
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
and we have disclosed our values at: pages 61 of the 2026 Annual Report 3.2
3.3
3.4
A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.
✓
A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.
✓
A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or committee of the board is informed of any material breaches of that policy.
✓
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed our code of conduct at:
https://investors.clinicallabs.com.au/companyinformation/corporate-governance/policies/
and we have disclosed our whistleblower policy at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/
and we have disclosed our anti-bribery and corruption policy at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/
Page 7
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS 4.1
The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are nonexecutive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.
✓
4.2
The board of a listed entity should, before it approves the entity’s financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
4.3
A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐
set out in our Corporate Governance Statement
✓
☐
set out in our Corporate Governance Statement
✓
☐
set out in our Corporate Governance Statement
and we have disclosed a copy of the charter of the committee at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/ and the information referred to in paragraphs (4) and (5) at: pages 62 to 63 of the 2026 Annual Report
Page 8
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
✓
☐
set out in our Corporate Governance Statement
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE 5.1
A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.
and we have disclosed our continuous disclosure compliance policy at:
https://investors.clinicallabs.com.au/companyinformation/corporate-governance/policies/ 5.2
A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.
✓
☐
set out in our Corporate Governance Statement
5.3
A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.
✓
☐
set out in our Corporate Governance Statement
✓
☐
set out in our Corporate Governance Statement
PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS 6.1
A listed entity should provide information about itself and its governance to investors via its website.
and we have disclosed information about us and our governance on our website at:
https://investors.clinicallabs.com.au/companyinformation/corporate-governance/policies/ 6.2
A listed entity should have an investor relations program that facilitates effective two-way communication with investors.
✓
☐
set out in our Corporate Governance Statement
6.3
A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.
✓
☐
set out in our Corporate Governance Statement
and we have disclosed how we facilitate and encourage participation at meetings of security holders at: page 64 of the 2026 Annual Report
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 9
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
6.4
A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.
✓
☐
set out in our Corporate Governance Statement
6.5
A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.
✓
☐
set out in our Corporate Governance Statement
The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity’s risk management framework.
✓
☐
set out in our Corporate Governance Statement
The board or a committee of the board should: (a) review the entity’s risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.
✓
☐
set out in our Corporate Governance Statement
PRINCIPLE 7 – RECOGNISE AND MANAGE RISK 7.1
7.2
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed a copy of the charter of the committee at: https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/ and the information referred to in paragraphs (4) and (5) at: pages 62 to 63 and page 65 of the 2026 Annual Report
and we have disclosed whether a review of the entity’s risk management framework was undertaken during the reporting period at: page 65 of the 2026 Annual Report
Page 10
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
7.3
A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.
✓
☐
set out in our Corporate Governance Statement
A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.
✓
☐
set out in our Corporate Governance Statement
7.4
and we have disclosed how our internal audit function is structured and what role it performs at: page 65 of the 2026 Annual Report
and we have disclosed whether we have any material exposure to environmental and social risks in our sustainability report at pages 127 to 141 of the 2026 Annual report and in our 2021 - 2025 ESG Statements which are available on our website at: https://investors.clinicallabs.com.au/corporateresponsibility/sustainability/ and, if we do, how we manage or intend to manage those risks in our sustainability report at pages 127 to 141 of the 2026 Annual report and in our 2021 - 2025 ESG Statements which are available on our website at: https://investors.clinicallabs.com.au/corporateresponsibility/sustainability/
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 11
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of the charter of the committee at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at:
☐
we are an externally managed entity and this recommendation is therefore not applicable
✓
☐
set out in our Corporate Governance Statement OR
and we have disclosed our policy on this issue or a summary of it at: Page 67 of the 2026 Annual Report
☐
we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY 8.1
8.2
https://investors.clinicallabs.com.au/company-information/corporategovernance/policies/ and the information referred to in paragraphs (4) and (5) at: pages 66 to 67 of the 2026 Annual Report
pages 31 to 50 and page 67 of the 2026 Annual Report
8.3
A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 12
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
ADDITIONAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CASES 9.1
9.2
9.3
A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.
☐
☐
set out in our Corporate Governance Statement OR
and we have disclosed information about the processes in place at: ……………………………………………………………………… [insert location]
☐
we do not have a director in this position and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.
☐
☐
set out in our Corporate Governance Statement OR
☐
we are established in Australia and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement OR
☐
we are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable
☐
we are an externally managed entity that does not hold an AGM and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement
A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.
☐
ADDITIONAL DISCLOSURES APPLICABLE TO EXTERNALLY MANAGED LISTED ENTITIES
Alternative to Recommendation 1.1 for externally managed listed entities: The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; and (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐ and we have disclosed the information referred to in paragraphs (a) and (b) at: …………………………………………………………………………….. [insert location]
Page 13
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
☐
☐
Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities: An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
set out in our Corporate Governance Statement
and we have disclosed the terms governing our remuneration as manager of the entity at: …………………………………………………………………………….. [insert location]
Page 14
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To Company Name/Scheme
AUSTRALIAN CLINICAL LABS LTD
ACN/ARSN
645 711 128
- Details of substantial holder (1)
PINNACLE INVESTMENT MANAGEMENT GROUP LIMITED (AND ITS SUBSIDIARIES LISTED IN ANNEXURE A)
Name ACN/ARSN (if applicable)
100 325 184
There was a change in the interests of the substantial holder on
15/09/2026
The previous notice was given to the company on
23/04/2026
The previous notice was dated
20/04/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows: Class of securities (4)
ORDINARY FULLY PAID
Previous notice
Present notice
Person’s votes
Voting power (5)
14,476,487
7.70%
Person’s votes
Voting power (5)
16,330,094
8.76%
REFER TO ANNEXURE A PART 1 AND PART 2
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
REFER TO ANNEXURE B
Person whose relevant interest changed
Nature of change (6)
Consideration given in relation to change (7)
Class and number of securities affected
Person's votes affected
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
REFER TO ANNEXURE C
Registered holder of securities
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
Person's votes
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
NO CHANGES - REFER TO ANNEXURE D FOR PRESENT ASSOCIATIONS
- Addresses The addresses of persons named in this form are as follows: Name
Address
REFER TO ANNEXURE E
Signature print name
TERENCE KWONG
sign here
capacity
COMPANY SECRETARY
date
18/09/2026
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write
"unknown". (9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
AUSTRALIAN CLINICAL LABS LTD Annexure A - Part 1 Holder of relevant interest
Nature of relevant interest
Number of securities
Class of securities
Pinnacle Investment Management Group Limited (ACN 100 325 184) Pinnacle Investment Management Limited (ACN 109 659 109) Ariano Pty Limited (ACN 605 250 799) Next Financial Holding Company Pty Limited (ACN 081 722 894) Next Financial Nominees Pty Ltd (ACN 093 252 576) Next Financial Nominees No. 2 Pty Ltd (ACN 132 819 115) Investment Solutions Client Services Pty Ltd (ACN 117 898 334) Priority Funds Management Pty Ltd (ACN 120 826 575) Priority Investment Management Pty Ltd (ACN 116 943 456 PNI Option Plan Managers Pty Ltd (ACN 125 030 766) Pinnacle RE Services Limited (ACN 130 508 379) Pinnacle Services Administration Pty Ltd (ACN 126 175 148) Pinnacle Investment Management (UK) Limited (Company Number 11026111) POSH Nominees Pty Limited (ACN 620 094 251) Pinnacle Investment Management Holdings Pty Ltd (ACN 682 412 871) Pingroup IM Limited (US) (EIN 85-0920129) PAM Summit Limited (Company number 16995883) PAM Asset Management Holdings Limited (Company number 11289259) HJB Capital Asset Management Limited (Company number 10421506) Pacific Asset Management LLP (Company number OC421757) Pacific Capital Partners Limited (Company number 02849777) Pacific Asset Management Services LLP (Company number OC401436) Parallel Investment Management Limited (Company number 02996795) Enlighten ESG Limited (Company number 13598052) Tourbillon LLP (Company Number OC457067)
Relevant interest by virtue of section 608(3)(a) of the Corporations Act as it has above 20% voting power in the affiliated investment managers set out in Annexure A – Part 2 and Pinnacle Fund Services Limited, who in turn have relevant interests in certain of the FPOs set out in Annexure B by virtue of sections 608(1)(b) and (c) of the Corporations Act (as the relevant affiliated investment manager or Pinnacle Funds Services Limited (as applicable) has the power to control the exercise of the rights to vote attached to, and the power to dispose of, those FPOs).
16,330,094 Ordinary fully paid
Pinnacle Fund Services Limited (ACN 082 494 362)
Relevant interest by virtue of sections 608(1)(b) and (c) of the Corporations Act (as it has the power to control the exercise of the rights to vote attached to, and the power to dispose of, certain of the FPOs set out in Annexure B (in its capacity as responsible entity or trustee of registered or unregistered schemes) and a relevant interest by virtue of section 608(1)(a) of the Corporations Act as it has above 20% voting power in the affiliated investment managers set out in Annexure A – Part 2 who in turn have relevant interests in certain of the FPOs set out in Annexure B by virtue of sections 608(1)(b) and (c) of the Corporations Act (as the relevant affiliated investment manager has the power to control the exercise of the rights to vote attached to, and the power to dispose of, those FPOs).
16,330,094 Ordinary fully paid
This is Annexure "A - Part 1" as mentioned in form 604 Notice of change of interests of substantial holder
Terence Kwong Company Secretary Date: 18/09/2026
AUSTRALIAN CLINICAL LABS LTD Annexure A - Part 2 Affiliated Investment Managers in which PNI and each PNI Controlled Entity has over 20% voting power Aikya Investment Management Limited (UK) (Company Number 12329682) Antipodes Partners Limited (ACN 602 042 035) Coolabah Capital Investments Pty Limited (ACN 153 327 872) Five V Capital Pty Limited (ACN 162 193 928) Hyperion Asset Management Limited (ACN 080 135 897) Langdon Equity Partners Limited (CA) (NRD 73210) Life Cycle Investment Partners Limited (UK) (Company Number 15633723) Metrics Credit Partners Pty Limited (ACN 150 646 996) Palisade Investment Partners Limited (ACN 124 326 361) Plato Investment Management Limited (ACN 120 730 136) Resolution Capital Limited (ACN 108 584 167) Solaris Investment Management Limited (ACN 128 512 621) Riparian Capital Partners Pty Ltd (ACN 630 179 752) North of South Capital LLP (Company number OC309016) North of South Capital DIFC Limited (Company number 8600)
This is Annexure "A - Part 2" as mentioned in form 604 Notice of change of interests of substantial
Terence Kwong Company Secretary Date: 18/09/2026
AUSTRALIAN CLINICAL LABS LTD Annexure B
Date of change Person whose relevant interest changed
Nature of change
21/04/2026
Purchase
22/04/2026
Pinnacle Investment Management Group Limited (and each PNI Controlled Entity listed in Annexure A) As above
23/04/2026
Consideration
Cash $
65,114.74
Purchase
$
29,720.43
As above
Purchase
$
9,054.94
28/04/2026
As above
Purchase
$
25,304.58
29/04/2026
As above
Purchase
$
28,496.78
14/05/2026
As above
Sale
-$
128,138.05
26/05/2026
As above
Purchase
$
160,105.20
02/06/2026
As above
Purchase
$
24,432.77
22/06/2026
As above
Purchase
$
235,692.08
23/06/2026
As above
Sale
-$
115,597.48
24/06/2026
As above
Sale
-$
64,293.75
29/06/2026
As above
Purchase
$
8,143.61
06/07/2026
As above
Purchase
$
26,499.00
09/07/2026
As above
Purchase
$
100,019.13
Non-cash
Class of Securities
Number of securities
Person's votes affected
ORDINARY FULLY PAID
31,423
31,423
ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID
14,663
14,663
4,635
4,635
13,135
13,135
14,822
14,822
69,830 -
69,830
79,260
79,260
12,192
12,192
106,648
106,648
52,664 -
52,664
29,886 -
29,886
3,637
3,637
11,601
11,601
44,906
44,906
10/07/2026
As above
Purchase
$
190,954.22
15/07/2026
As above
Purchase
$
740,176.12
15/07/2026
As above
Sale
-$
544,488.89
16/07/2026
As above
Purchase
$
174,400.86
22/07/2026
As above
Purchase
$
393,154.88
28/07/2026
As above
Purchase
$
208,390.83
03/08/2026
As above
Purchase
$
11,587.24
04/08/2026
As above
Purchase
$
13,494.62
07/08/2026
As above
Purchase
$
141,753.14
19/08/2026
As above
Purchase
$
214,683.91
20/08/2026
As above
Purchase
$
162,427.08
21/08/2026
As above
Purchase
$
37,109.52
24/08/2026
As above
Purchase
$
1,130,878.62
24/08/2026
As above
Sale
-$
675,527.71
25/08/2026
As above
Purchase
$
604,793.69
26/08/2026
As above
Purchase
$
424,347.47
27/08/2026
As above
Purchase
$
77,517.88
08/09/2026
As above
Purchase
$
10,052.33
09/09/2026
As above
Purchase
$
114,967.89
ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID
86,432
86,432
312,287
312,287
225,929 -
225,929
73,210
73,210
168,736
168,736
87,493
87,493
4,932
4,932
5,720
5,720
59,399
59,399
75,561
75,561
57,633
57,633
12,537
12,537
377,743
377,743
225,929 -
225,929
203,957
203,957
147,122
147,122
27,513
27,513
3,629
3,629
41,129
41,129
10/09/2026
As above
Purchase
$
46,945.30
14/09/2026
As above
Purchase
$
72,519.87
15/09/2026
As above
Purchase
$
935,925.62
ORDINARY FULLY PAID ORDINARY FULLY PAID ORDINARY FULLY PAID
This is Annexure "B" as mentioned in form 604 Notice of change of interests of substantial holder
Terence Kwong Company Secretary Date: 18/09/2026
17,032
17,032
26,566
26,566
332,292
332,292
AUSTRALIAN CLINICAL LABS LTD Annexure C Holder of relevant interest
Registered holder of securities
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
BNP Paribas
Person entitled to be registered as holder BNP Paribas
Number of securities 664,424
Class of securities Ordinary fully paid
664,424
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
Citicorp Nominees Pty Ltd
Citicorp Nominees Pty Ltd
11,221,663
Ordinary fully paid
11,221,663
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
HSBC
HSBC
87,493
Ordinary fully paid
87,493
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
JP Morgan Chase Bank
JP Morgan Chase Bank
224,316
Ordinary fully paid
224,316
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
Northern Trust
Northern Trust
988,961
Ordinary fully paid
988,961
Pinnacle Investment Management Group Limited (and its subsidiaries listed in Annexure A)
State Street - AUS
State Street - AUS
3,143,237
Ordinary fully paid
3,143,237
This is Annexure "C" of 1 page as mentioned in form 604 Notice of change of interests of substantial holder
Terence Kwong Company Secretary Date: 18/09/2026
Person's votes
`
AUSTRALIAN CLINICAL LABS LTD Annexure D Name ACN Pinnacle Investment Management Group Limited (PNI) 100 325 184 Pinnacle Investment Management Limited
109 659 109
Pinnacle Fund Services Limited
082 494 362
Ariano Pty Limited
605 250 799
Next Financial Holding Company Pty Limited
081 722 894
Next Financial Nominees Pty Ltd
093 252 576
Next Financial Nominees No. 2 Pty Ltd
132 819 115
Investment Solutions Client Services Pty Ltd
117 898 334
Priority Funds Management Pty Ltd
120 826 575
Priority Investment Management Pty Ltd
116 943 456
PNI Option Plan Managers Pty Ltd
125 030 766
Nature of Association Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities.
Pinnacle RE Services Limited
130 508 379
Pinnacle Services Administration Pty Ltd
126 175 148
Pinnacle Investment Management (UK) Limited
Company Number 11026111
POSH Nominees Pty Limited
620 094 251
Pinnacle Investment Management Holdings Pty Ltd
682 412 871
Pingroup IM Limited (US)
EIN 85-0920129
PAM Summit Limited
Company number 16995883
PAM Asset Management Holdings Limited
Company number 11289259
HJB Capital Asset Management Limited
Company number 10421506
Pacific Asset Management LLP
Company number OC421757
Pacific Capital Partners Limited
Company number 02849777
Pacific Asset Management Services LLP
Company number OC401436
Parallel Investment Management Limited
Company number 02996795
Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities.
Enlighten ESG Limited
Company number 13598052
Tourbillon LLP
Company Number OC457067
Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities. Associate of each other entity listed in this Annexure D by virtue of section 12(2)(a) of the Corporations Act as it controls each of those entities.
This is Annexure "D" as mentioned in form 604 Notice of change of interests of substantial holder
Terence Kwong Company Secretary Date: 18/09/2026
AUSTRALIAN CLINICAL LABS LTD Annexure E Name Pinnacle Investment Management Group Limited Pinnacle Fund Services Limited Pinnacle Investment Management Limited Ariano Pty Limited Next Financial Limited Next Financial Nominees Pty Ltd Next Financial Nominees No. 2 Pty Ltd Investment Solutions Client Services Pty Ltd Priority Funds Management Pty Ltd Priority Investment Management Pty Ltd PNI Option Plan Managers Pty Ltd Pinnacle Investment Management (UK) Limited Pinnacle RE Services Limited Pinnacle Services Administration Pty Ltd POSH Nominees Pty Limited Pinnacle Investment Management Holdings Pty Ltd Pingroup IM Limited (US) PAM Summit Limited PAM Asset Management Holdings Limited HJB Capital Asset Management Limited Pacific Asset Management LLP Pacific Capital Partners Limited Pacific Asset Management Services LLP Pacific Wealth Management Limited Enlighten ESG Limited Tourbillon LLP
Address Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia 7th Floor, Dashwood House, 69 Old Broad Street, London EC2M 1QS, United Kingdom Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia Level 19, 307 Queen St, Brisbane QLD 4000, Australia c/o TMF Group New York, LLC, 48 Wall Street, 27th Floor, New York NY 10005 5th Floor One New Change, London, England, EC4M 9AF 5th Floor One New Change, London, England, EC4M 9AF 5th Floor One New Change, London, England, EC4M 9AF 74 Wigmore Street, London, England, W1U 2SQ 74 Wigmore Street, London, England, W1U 2SQ 74 Wigmore Street, London, England, W1U 2SQ 74 Wigmore Street, London, England, W1U 2SQ 74 Wigmore Street, London, England, W1U 2SQ 55 Sleaford Road, Ruskington, Sleaford, Lincolnshire, England, NG34 9BL
This is Annexure "E" as mentioned in form 604 Notice of change of interests of substantial holder
Terence Kwong Company Secretary Date: 18/09/2026
Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2
Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11
Name of entity
Australian Clinical Labs Limited
ABN
94 645 711 128
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director
Sarah Butler
Date of last notice
20 February 2026
Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest
Indirect interest
Nature of indirect interest (including registered holder)
Date of change
Indirect interest via Beausoleil Investments Pty Limited as trustee for the Muskoka Trust. Sarah Butler is a director of Beausoleil Investments Pty Ltd and a beneficiary of the Muskoka Trust. 10 September 2026
No. of securities held prior to change
22,617
Class
Ordinary shares
Number acquired
18,000
Number disposed
0
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
18,000 shares at an average consideration of $2.77 per share
No. of securities held after change
40,617
Note: Provide details of the circumstances giving rise to the relevant interest.
- See chapter 19 for defined terms. 01/01/2011
Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice On market trade
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback
Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder (if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
N/A
Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?
- See chapter 19 for defined terms. Appendix 3Y Page 2
01/01/2011
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Australian Clinical Labs Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVDS | 0.02% | 32,827 | $ 73.739K | Nov 16, 2026 |
| DFIS | 0.01% | 348,876 | $ 791.156K | Nov 12, 2026 |
| DXIV | 0.01% | 10,669 | $ 24.194K | Nov 12, 2026 |
| DFSI | 0.01% | 28,118 | $ 63.764K | Nov 12, 2026 |
| DFIC | 0.00% | 235,205 | $ 533.381K | Nov 12, 2026 |
| DFAX | 0.00% | 143,919 | $ 326.369K | Nov 12, 2026 |
| DFAI | 0.00% | 175,542 | $ 398.082K | Nov 12, 2026 |
| AVDE | 0.00% | 331,599 | $ 744.871K | Nov 16, 2026 |
| AVSD | 0.00% | 4,498 | $ 10.104K | Nov 16, 2026 |